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Chapter 1
Introduction
The term molecular imaging implies the convergence of multiple image-capture tech-
niques, basic cell/molecular biology, chemistry, medicine, pharmacology, medical
physics, biomathematics, and bioinformatics into a new imaging paradigm. More-
over, molecular imaging has its roots in nuclear medicine and in many ways is a
direct extension of this existing discipline [1].
The origins of nuclear medicine can be traced back to the last years of the 19th
century and the discovery of radioactivity by Henry Becquerel (1896) and of radium
by Marie Curie (1898).
The biologic foundations for nuclear medicine were laid down between 1910 and
1945. In 1913, Georg de Hevesy developed the principles of the tracer approach
and then was the ﬁrst to apply them to a biologic system in 1923, studying the
absorption and translocation of radioactive lead nitrate in plants. The ﬁrst human
study employing radioactive tracers was probably that of Blumgart and Weiss (1927),
who injected an aqueous solution of radon intravenously and measured the transit
time of the blood from one arm to the other using a cloud chamber as radiation
detector.
In 1951, the use of positron emitters and the advantageous imaging properties of
these radionuclides were described by Wrenn and coworkers.
In 1958 Hal Anger developed the forerunner of all the modern nuclear medicine
single-photon system.
In 1968 Paul Harper and colleagues started to use 99mTc as imaging tracer. 99mTc
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also proved to be very ﬂexible for labeling a wide variety of compounds that could
be used to study virtually every organ in the body. Today, 99mTc is the most widely
used radionuclide in nuclear medicine.
The ﬁnal important development was the mathematics to reconstruct tomographic
images from a set of angular views around the patient. This revolutionized the
whole ﬁeld of medical imaging leading to CT, PET, SPECT and MRI. In fact, it
was possible to replace the two dimensional representation of the three dimensional
radioactivity distribution, with a true three-dimensional representation. This allowed
the development of PET by Phelps and coworkers and SPECT by Kuhl and colleagues
during the 1970s, and marked the start of modern era of nuclear medicine [2].
By the mid-1990's, a number of groups dedicated to the development of PET
technology has realized that the ﬁeld of small animal PET could provide a fertile
area for technological innovation. It was possible to justify the building of PET
systems in miniature, in the name of a small animal scanning, at considerably lower
cost than would have been incurred by a full-sized tomography [3].
In 2007, Mario Capecchi, Oliver Smithies and Martin Evans received Nobel Lau-
reates in Physiology or Medicine for their discoveries made in the 1980's on Making
Model Mice The elevation of the humble mouse to become many scientists' exper-
imental animal of choice has been one of the scientiﬁc phenomena of the last two
decades. Today, genetically-altered mice are an essential component of the experi-
mental toolkit, with thousands of varieties contributing to research in laboratories
around the world.
The YAP-(S)PET small animal scanner is part of this environment. It is a
speciﬁcally built scanner able to perform both PET and SPECT and simultaneous
PET/SPECT acquisitions. The scanner was originally developed at the Department
of Physics of the Universities of Ferrara and Pisa, Italy. From 2003, fully engineered
version of the scanner have been produced and commercialized by the small italian
company I.S.E. Ingegneria dei Sistemi Elettronici s.r.l., Pisa, Italy.
This thesis deals with the physical calibration and characterization and with pre-
clinical applications of a new version the YAP-(S)PET originally developed.
Chapter 2 presents an overview of the main characteristics of the emerging molec-
3
ular imaging and of the small animal systems and its applications in the ﬁeld.
In chapter 3 the main hardware and software characteristics of the YAP-(S)PET
scanner are described in detail. The YAP-(S)PET User Friendly interface and the
reconstruction algorithms are widely reported.
Chapter 4 deals with the hardware and software calibration procedures that are
necessary periodically and every time a new scanner has been realized. Both PET
and SPECT calibration procedures are presented for various head-to-head distances:
100, 125 and 150 mm.
In chapter 5 the performance of the scanner in PET and SPECT modalities are
reported. The performance evaluation were performed at various head-to head dis-
tances (100, 125 and 150 mm) in order to evaluate the best working point of the
YAP-(S)PET scanner.
Chapter 6 illustrates how we were able to implement the possibility to perform
simultaneous PET/SPECT acquisitions. The combination of PET and SPECT tech-
niques for small animal studies could oﬀer the unique possibility of developing new
and interesting protocols for the investigation of many biological phenomena more
eﬀectively than with PET or SPECT modality alone.
Finally, chapter 7 describes some of the imaging studies performed in collabora-
tions with diﬀerent research groups. The experiments were performed in both PET
and SPECT modalities, with diﬀerent tracers either with mice or rats. All the exper-
iment can be grouped in three main areas corresponding to diﬀerent medicine branch:
oncology, cardiology and neuroscience.
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Chapter 2
Molecular imaging and small animals
When Watson and Crick elucidated the double-helical structure of DNA in 1958,
they made the greatest discovery of the XX century in the biological sciences. This
discovery initiated a time in biology in which biological and physical scientists would
strive to unravel the genetic code and its regulated expression, which determines
the genotypic basis for the phenotypes of all the cells within the organism. Today,
intense exploration is taking place in the biological sciences to determine the patterns
of gene expression that encode for normal biological processes, such as replication,
migration, signal transduction of cell communication, and the many other functions
that cells perform. In addition, belief is growing that most diseases result from altered
patterns of gene expression that transition cells to the phenotypes of disease. These
alterations in gene expression can result from interactions with the environment,
hereditary defects, developmental errors, and aging. As a result, biology is coming
together with medicine to design ways to identify these fundamental molecular errors
of disease and develop molecular corrections for them. The general name given to
this emerging ﬁeld is molecular medicine [4].
As biology and medicine come together, it is important that imaging also merges
with biology to form the technologies referred to as biological or molecular imaging.
Many scientists state that molecular imaging is not a new discipline: nuclear
imaging approaches such as positron emission tomography (PET) and single-photon
emission computed tomography (SPECT) have been using molecular imaging con-
cepts for more than a decade to visualize the biodistribution of labeled compounds
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including analyses of receptor occupancy. In these studies image contrast is not gov-
erned by the anatomical features of the sample but rather by the local concentration
of the radio-labeled reporter compound, i.e., by a molecular property.
Other scientists claim that molecular imaging is a new scientiﬁc area merging
concepts of molecular biology with noninvasive imaging technologies. This allows the
study of biological processes in a noninvasive manner. These concepts go beyond
labeling of reporter ligands. They involve the development of a great number of
reporter assays that are used to probe speciﬁc biological questions. Is the expression
of a receptor modiﬁed under speciﬁc pathological conditions? Does the receptor exert
its biological activity. Does it activate its associated signaling cascade? Can these
molecular markers be used as early indicators of a pathological transformation? [5]
A precise deﬁnition of molecular imaging is an elusive and perhaps not particularly
important goal [6]. Rather the term reﬂects a shift in emphasis and a shift in atti-
tude, moving from the undeniably useful, but largely non-speciﬁc, diagnostic imaging
approaches that are currently employed in the clinic, to targeting speciﬁc genes and
proteins that are known to be linked directly or indirectly to human disease.
The emergence of molecular imaging strategies is largely due to recent unprece-
dented advances in molecular and cell biology techniques, the use of transgenic animal
models, availability of newer imaging drugs and probes that are highly speciﬁc, and
successful development of small-animal imaging instrumentation [1]. This creates the
possibility of achieving several important goals in biomedical research:
• to develop noninvasive in vivo imaging methods that reﬂect speciﬁc cellular and
molecular processes, for example, gene expression, or more complex molecular
interactions such as protein-protein interactions.
• to monitor multiple molecular events near-simultaneously.
• to follow traﬃcking and targeting of cells.
• to optimize drug and gene therapy.
• to image drug eﬀects at a molecular and cellular level
• to assess disease progression at a molecular pathological level.
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• to create the possibility of achieving all of the above goals of imaging in a
rapid, reproducible and quantitative manner, so as to be able to monitor time-
dependent experimental, developmental, environmental, and therapeutic inﬂu-
ences on gene products in the same animal or patient.
2.1 The importance of small animal models in molec-
ular imaging
Molecular imaging in living subjects oﬀers distinct advantages when compared with
conventional in vitro and cell culture research techniques in biology.
In contrast to cell and tissue culture, in vivo animal models allow the assessment
of phenomena such as tolerances, complementation, and redundancy in biological
pathways. Molecular imaging permits both the temporal and the spatial biodistribu-
tion of a molecular probe and related biological processes to be determined in a more
meaningful manner throughout an intact living subject [1].
Imaging technologies are playing a growing role in animal research, enabling large,
expensive laboratory animals to be studied noninvasively and providing the possibil-
ity of reducing the number of small laboratory animals required in typical longitudinal
studies. As each animal serves as its own individual control, the reproducibility of
data from imaging studies may actually be better than that obtained from tradi-
tional invasive techniques, although this improvement has yet to be demonstrated
unequivocally. Finally, imaging provides a bridge from animal research to human
research.
Since the mid 1980s, the eﬀort to understand mammalian biology and the study
of disease models have caused the mouse to become the animal of choice. More than
90% of all mammals used worldwide in research in the year 2000 were mice [7]. The
rapid rate of reproducibility and short life span of mice aid in keeping down the cost
of maintaining colonies and favor them as a molecular biology research vehicle. In
addition, most human genes have a related mouse gene, allowing mice to be used as
a platform for mimicking many human disease [8]. Furthermore, modern molecular
biology contains the technology to knock-out or disable genes, and to insert or
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knock-in new ones in order to create many types of transgenic mice. The mouse
genome has been the second mammalian genome to be sequenced after the human
genome [9].
Molecular imaging of living mice oﬀers distinct advantages when investigating
phenotypic abnormalities [1]:
• it eliminates the need to kill such mice as part of their phenotype determination.
• by repetitive imaging it is possible to investigate mutants that are otherwise
diﬃcult to interpret with data taken at a single time point.
• it allows concomitant visual and analytical biological phenotyping of animals.
• it allows the researcher to exercise options of multiple imaging strategies (e.g.,
by using diﬀerent imaging reporter probes or modalities) in cases in which
simple genetic manipulations could result in a very complex phenotype involving
a large number of pathways and organs.
Moreover, in vivo mouse imaging as an alternative to killing many animals for
histological processing at diﬀerent time points is also convenient in terms of money.
With each transgenic mouse valued in the 200-300 dollars range, the overall costs of
conventional post mortem biological assays on many animals can mount substantially.
The use of fewer animals in biological assays with molecular imaging would also be
more appealing on ethical grounds. In theory, approval for research projects requiring
large numbers or many separate cohorts of experimental animals could be obtained
more easily [1].
Molecular imaging assays in intact living animals could be of further beneﬁt in
resolving biological questions raised by pharmaceutical scientists. Transgenic animals
are useful in guiding early drug discovery validating the target protein, evaluating test
compounds, determining whether the target is involved in any toxicological eﬀects of
test compounds, and testing the eﬃcacy of compounds to ensure that the compounds
will act as expected in man [1].
In some disciplines, particularly in neuroscience, the rat also remains an important
experimental animal, partly due to the ease of surgical manipulation of the rat brain
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versus the mouse brain (2 g as opposed to 0.45 g). In addition, there is a large
historical knowledge base of both the anatomy and the function of the rat brain,
deriving from many decades during which it was the preferred model [10].
2.2 Molecular imaging instrumentation and techniques
Biological discovery has moved at an accelerated pace in recent years, with consider-
able focus on the transition from in vitro to in vivo models. As such, there has been a
greater need to adapt clinical imaging methods for noninvasive assays of biochemical
processes. Considerable eﬀorts have been directed in recent years toward the develop-
ment of noninvasive, high-resolution, small animal in vivo imaging technologies (see
ﬁgure 2.1). The widespread availability and use of miniaturized imaging systems for
rodents are invaluable resources for basic science laboratories. Nonetheless, signiﬁ-
cant challenges remain to be overcome when attempting to image a 30-g mouse as
compared with a 70-kg human, including the size of the subject, the total volume
that must be evaluated, the spatial resolution necessary for obtaining meaningful
anatomical and/or functional data, and the total time spent on acquiring a set of
images [11]. A comparison between human and small animal size can be obtained by
ﬁgure 2.2.
In small animal research, the primary goal is to obtain as high a signal as possible
and to localize the signal as accurately as possible with high temporal resolution and
with minimal amount of molecular probe. The ultimate goal is to provide a device
that produces a three-dimensional image of anatomical and biological information
fused together. The various existing imaging technologies diﬀer for the following
main aspects [1]:
• spatial and temporal resolution.
• depth penetration.
• energy used for image generation (ionizing or nonionizing, depending on which
component of the electromagnetic radiation spectrum is exploited for image
generation).
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Figure 2.1: Illustrative examples of the variety of images that can be obtained with diﬀerent
imaging modalities. (A) microPET whole-body coronal image of a rat injected with 18FDG,
showing uptake of tracer in tissues including muscles, heart, brain, and accumulation in
bladder owing to renal clearance. (B) microCT coronal image of a mouse abdomen after
injection of intravenous iodinated contrast medium. (C) microSPECT coronal image of
a mouse abdomen and pelvis regions after injection of 99mTc methylene diphosphonate,
showing spine, pelvis, tail vertebrae, femurs, and knee joints owing to accumulation of tracer
in bone. (D) Optical reﬂectance ﬂuorescence image of a mouse showing GFP ﬂuorescence
from the liver, abdomen, spine, and brain. The mouse contains GFP-expressing tumor cells
that have spread to various sites. Images are courtesy of Dr. Hoﬀman, Anticancer Inc. (E)
microMRI coronal T2-weighted image of a mouse brain. (F) Optical bioluminescence image
of a mouse with a subcutaneous xenograft expressing Renilla luciferase in the left shoulder
region, after tail-vein injection of the substrate coelenterazine. Images were obtained using
a cooled CCD camera. The color image of visible light is superimposed on a photographic
image of the mouse with a scale in photons per second per square centimeter per steradian
(sr) [1].
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Figure 2.2: Relative size of a human, rat and mouse brain [12].
• availability of injectable/biocompatible molecular probes
• the respective detection threshold of probes for a given technology.
Table 2.1 outlines some of the general characteristics of the imaging modalities
available.
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2.2.1 Radionuclide imaging
The primary advantage of radioactive assays (whether in vivo, ex vivo or in vitro) is
their exquisite sensitivity and the ability, with appropriate care, of radiation detection
systems to provide quantitative measurements of radioactivity concentrations deep
inside tissue. Radiolabelled tracers have a long history of being used to elucidate
physiology, metabolic pathways and molecular targets [13], and to provide a high
sensitivity tool for molecular imaging studies. A very large number of radiolabelled
tracers have been developed to probe speciﬁc biological targets and functions [14],
and a growing number are moving into clinical use. An important strength is the
availability of radionuclides of biologically relevant elements, particularly carbon, al-
lowing contrast agents to be labelled by direct isotopic substitution. This allows small
biomolecules (many drugs, receptor ligands etc ) to be labelled without changing their
biochemical properties. Another powerful approach is to create analog radiotracers,
in which deliberate chemical changes are made to a biologically active molecule to
isolate speciﬁc pathways or cause speciﬁc trapping of a radiotracer in cells expressing
the target of choice. Analog radiotracers are also designed to allow the use of iso-
topes of elements that are not found within the molecule of interest, but that have
good imaging properties. Larger biomolecules (peptides, antibodies, RNA, synthetic
macromolecules) are also readily labelled with a wide range of radionuclides that have
excellent properties for imaging. A list of the major radionuclides that are currently
being used for in vivo nuclear imaging is provided in table 2.2. A further advantage
is that nuclear imaging approaches are readily translated to the clinic, as the major-
ity of the listed radionuclides produce photons with suﬃcient tissue penetration for
studies in man. Disadvantages of nuclear imaging approaches include obvious factors
such as the involvement of ionizing radiation, and more subtle factors such as the
fact that radioactive decay cannot be controlled, hence there is always non-speciﬁc
background signal present in an image due to non-speciﬁc binding of radiotracers,
residual radiotracer in the circulation and routes of excretion [6].
Nuclear imaging techniques include high resolution (<100 µm) ex vivo autoradio-
graphic techniques using ﬁlm, phosphor storage plates or real time autoradiographic
systems [15] and in vivo methods using radionuclides that produce appropriate energy
14 Chapter 2. Molecular imaging and small animals
photons (gamma-rays, annihilation photons or characteristic x-rays with energies in
the range of 25-511 keV) during decay. The in vivo methods are further broken up into
single photon imaging that utilize radionuclides with single or multiple uncorrelated
gamma ray emissions and PET in which radionuclides decay by positron emission
resulting in two simultaneous annihilation photons emitted back-to-back [2].
The development of higher resolution and higher sensitivity animal PET and
SPECT systems is allowing molecular and genomic imaging approaches, tradition-
ally approached by ex vivo autoradiographic methods, to be translated in vivo into
animal models of disease [16,17]. Dramatic improvements in image quality have been
achieved by using novel detector and collimation approaches, and by exploiting the
more favourable environment found in small-animal imaging.
One of the advantages of nuclear imaging, say as, compared to optical imaging,
is that the radiation involved is highly penetrating, and so the dependence of the
detected signal on the depth at which it is emitted is fairly small. Even without cor-
rection for scatter and attenuation, nuclear images within small animals can exhibit
fairly high quantitative accuracy in speciﬁc circumstances and with the appropriate
calibration object [6].
Radionuclide Half life Energy of principle Imaging modalityphotons (keV)
11C 20.4 mins 511 PET
18F 110 mins 511 PET
64Cu 12.7 h 511 PET
99mTc 6.02 h 140 SPECT
111In 2.83 days 171, 245 SPECT
123I 13.2 h 159 SPECT
124I 4.18 days 511, 603, 723, 1690 PET
125I 60.1 days 27, 31, 35 SPECT
131I 8.04 days 354 SPECT
Table 2.2: Radionuclides commonly used for in vivo nuclear imaging.
2.2.2 Optical imaging
There has been tremendous growth in the use of optical approaches for in vivo imag-
ing of small laboratory animals. This is in part due to the accessibility of optical
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approaches, and also in part because of their extremely high sensitivity. Light is
both scattered and absorbed in tissues, but there is an absorption minimum cor-
responding to wavelengths in the approximate range of 700-950 nm [18]. At these
wavelengths, the light is still readily scattered but the absorption length is on the
order of several centimetres. Thus, light emitted from deep inside a small animal
has a reasonable probability of reaching the surface for external detection. Although
this light has in general scattered many times when it reaches the surface, some posi-
tional information is retained based on the intensity, spatial distribution and spectral
distribution of the emitted light [19]. This region of the electromagnetic spectrum
is known as the optical window because of the more favourable characteristics for
imaging through tissue.
At the present time, most studies are based on imaging the intensity of the emitted
light at the surface of the animal with straightforward detector systems that are
amenable for use in biology labs and have the capability of relatively high throughput.
Two distinct contrast mechanisms are being used for molecular and genomic imaging
studies: one involving ﬂuorescence [20], and the other involving bioluminescence [21].
In ﬂuorescence imaging, an external light source, either a laser, or a broadband
source (e.g., a mercury lamp) with an appropriate low-pass ﬁlter, is used to excite
ﬂuorescent molecules inside the subject. These ﬂuorescent molecules may be geneti-
cally engineered into a mouse, for example by incorporating the gene for a ﬂuorescent
protein as a reporter gene. Green Fluorescent Protein (GFP) has been widely used
in this manner for cell culture and tissue slice experiments, but is less well suited for
in vivo use because of the relatively short excitation (peak ∼ 470-490 nm) and emis-
sion (peak ∼ 510 nm) wavelengths that place it outside the optical window and in a
part of the spectrum where there is signiﬁcant autoﬂuorescence of tissue components.
Despite these diﬃculties, GFP has been used successfully for some in vivo imaging
studies [22]. Subsequently, GFP mutants and other ﬂuorescent proteins have been
discovered that have excitation and emission spectra better suited to in vivo imag-
ing [2325]. Another approach to introducing ﬂuorescent molecules into an animal is
to use ﬂuorophores (or more recently, ﬂuorescent particles known as quantum dots)
as labels on biologically interesting molecules [26]. This is analogous to radionuclide
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labelling for nuclear imaging, although the approach generally is limited to the la-
belling of larger biomolecules where the size of the ﬂuorophore does not interfere with
the biological activity of the agent. Again, ﬂuorophores that are excited and emit
in or close to the optical window are preferred for good penetration depth and large
amplitude signals [6]. Table 2.3 provides data on a number of ﬂuorophores that are
being used for in vivo studies and an example of a study carried out with a near
infrared ﬂuorescence probe is shown in ﬁgure 2.3.
Name Type of agent
Excitation Emission Extinction coeﬃcient Quantum
max (nm) max (nm) (cm−1 M−1) yield
Cy 5 Fluorophore 649 670 250000 0.28
Cy 5.5 Fluorophore 675 694 190000 0.23
Cy 7 Fluorophore 743 767 200000 0.29
Alexa Fluor 700 Fluorophore 702 723 192000
Alexa Fluor 750 Fluorophore 749 775 240000
EGFP Fluorescent protein 489 508 55000 0.60
DsRed Fluorescent protein 558 583 57000 0.79
mRFP1 Fluorescent protein 584 607 44000 0.25
Table 2.3: Properties of some ﬂuorophoresa and ﬂuorescent proteins. (Data for DsRed and
mRFP1 from [25]. Other data from manufacturers' datasheets [6].)
There are two key advantages to ﬂuorescence imaging. Firstly, many of the ﬂu-
orophores used have high quantum yields, leading to robust signals when using ap-
propriate illumination and acquisition times. Secondly, as described earlier, the ﬂu-
orescence emission can be activated by speciﬁc biologic molecules or events. This
eliminates signal from contrast agent that is circulating and from paths of excretion
(a limiting problem for radiotracers), reducing background noise. This allows very
low concentrations (subnanomolar, and with some activatable agents, picomolar or
better) of enzymes to be detected. The disadvantage of ﬂuorescence imaging is that
there is autoﬂuorescence from tissue that forms a background that ultimately limits
detection sensitivity. A second problem is that light has to get into the animal (to
excite the ﬂuorescent molecules) and back out again (to reach the detector). Because
of the high degree of scattering of both the excitation and emission light, it is not
possible to excite and isolate the ﬂuorescence within very small volumes of tissue
inside the animal. As a consequence of the strong dependence on depth of both the
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intensity of the excitation light and the detection of the emission light, quantitative
analysis of the images, in all but the very simplest cases of a small point emitter,
becomes extremely diﬃcult [6].
Fluorescence imaging can be carried out using conventional CCD cameras. The
use of back-illuminated CCDs and cooling, enhances sensitivity and signal-to-noise
ratio, but for many studies general purpose scientiﬁc CCD cameras are suﬃcient,
because detection sensitivity is limited by autoﬂuorescence rather than by the noise
characteristics of the detector. A simple black box and a lens coupled CCD camera
connected to a computer can yield acceptable ﬂuorescence images showing the light
distribution on the surface of the animal in just a few seconds or minutes [27]. The
second approach to in vivo optical imaging involves introducing reporter genes that
encode for enzymes (known as luciferases) that can catalyze a light-producing reac-
tion. This process is called bioluminescence and luciferases are found in organisms
such as ﬁreﬂies, glow worms and jellyﬁsh [28]. The most commonly used reporter gene
for imaging is the one that encodes for ﬁreﬂy luciferase [29]. This gene is introduced as
a reporter gene. Just prior to imaging, animals are injected with the substrate for the
enzyme. In the case of the ﬁreﬂy luciferase the substrate is luciferin, a small molecule
that rapidly distributes throughout the whole body of the mouse after intravenous or
intraperitoneal injection. In cells that are expressing the luciferase reporter gene, the
luciferin, in the presence of oxygen and ATP (Adenosintriphospat), is converted to
oxyluciferin with the emission of light (peak at 560 nm). The reaction is catalyzed by
the luciferase enzyme and does not occur to any signiﬁcant extent when luciferase is
absent. The generation of an optical signal is therefore speciﬁc to cells that contain
the reporter gene. Mutations of the naturally occurring ﬁreﬂy gene has resulted in
a shifting of the emission peak to around 620 nm, with signiﬁcant amounts of light
being emitted in the 550-700 nm range, improving its sensitivity for in vivo imaging
studies [21].
The advantage of the bioluminescence approach is that there is no need for ex-
ternal light stimulation. There is no problem, therefore, in depth of penetration of
the excitation light as there is with ﬂuorescence, and there is no autoﬂuorescence
background to contend with. The disadvantage is that this approach is limited to
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studying genetically manipulated cells or transgenic mice, or infectious agents such as
bacteria and viruses, as the reporter gene has to be introduced to the organism that
is to be studied. Also, the bioluminescence signals are typically very weak. These low
signals require the use of high quantum eﬃciency CCDs that are cooled to minimize
dark current over the integration time required to obtain an image (typically a few
minutes) [6].
The biggest eﬀorts in optical imaging at the present time are devoted to moving
from a single image of the light intensity projected at the surface of the animal to
tomographic images that provide information on the distribution of the light source
in 3D. This involves acquiring data from a small number of views such that the light
intensity across the surface of the entire mouse can be mapped.
Figure 2.3: In vivo bioluminescence images (in colour) from cancer cells carrying a luciferase
reporter gene. These images show the growth of a pituitary tumour over a period of four
weeks. The greyscale image is a reﬂectance light image of the mouse for anatomic reference
[6].
2.2.3 Magnetic resonance imaging
Magnetic Resonance Imaging (MRI) is one of the more mature technologies for small-
animal imaging. Magnetic resonance microscopy (generally deﬁned as imaging with
a resolution of better ∼ 100 microns) has been around since the mid 1980s and has
found particular applications in neuroscience [30,31] and developmental biology [32].
High-ﬁeld magnets are introduced in small-bore animal imaging systems several years
before they can be achieved for larger bore human applications. Therefore these ani-
mal systems serve as important test-beds and catalysts for developing high resolution,
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high speed and high sensitivity pulse sequences. Most small-animal imaging is cur-
rently carried out on horizontal-bore instruments with ﬁeld strengths between 4.7
T and 9.4 T and bore sizes of 20-40 cm. Research systems with ﬁeld strengths as
high as 11.7 T (40 cm horizontal bore) and 21.1 T (8.9 cm vertical bore) are also
being evaluated for small-animal imaging [33]. Higher ﬁeld strengths are desirable
for high-resolution imaging because the signal-to-noise ratio (SNR) is proportional to
ﬁeld strength, and the detected signal is proportional to the tissue volume within a
voxel. A reduction in voxel size from 1 × 1 × 1 mm to 0.1 × 0.1 × 0.1 mm therefore
results in a 1000-fold reduction in the detected signal.
Since SNR is only linearly proportional to ﬁeld strength, higher ﬁelds only in part
make up for the reduced voxel size in high resolution images. Therefore, images at
resolutions of tens of microns can only be achieved with very long acquisition times,
typically many hours for a whole mouse.
In vivo images of anatomy with a spatial resolution of a few hundred microns can
be achieved in several minutes with MRI when combined with appropriate physiologic
gating to control cardiac and respiratory motion. Sophisticated physiologic monitor-
ing and forced respiration systems have been developed to allow motion-free in vivo
imaging and well controlled physiologic status deep inside a high-ﬁeld magnet [34].
The good soft-tissue contrast achieved by well-designed pulse sequences has led to
MRI becoming the method of choice for following anatomic changes in soft tissue
that may be related to a disease course or an intervention. Furthermore, MRI has
the ability to measure physiological parameters, including water diﬀusion and blood
oxygenation levels (which leads to the contrast used in functional MRI to study brain
activation). The addition of passive contrast agents, such as Gd-DTPA, further en-
hances the utility of MRI, allowing vascular density, permeability and perfusion to be
assessed. Another example of a passive agent is the use of Mn2+ ions for tract-tracing
studies in the brain [35].
Taken together, these MRI methods provide a powerful set of tools for interro-
gating anatomic and physiologic changes that are a consequence of speciﬁc cellular
or molecular alterations in living animals. The development of targeted and acti-
vatable contrast agents for MRI that oﬀer the prospect of direct molecular imaging.
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These agents are based on transition metals or lanthanides that are paramagnetic
and change the relaxation time (either T1 or T2) in tissue regions in which they
accumulate [36].
One area of active research is into optimal RF coil design for high-ﬁeld use. Design
of better volume coils should improve SNR and allow imaging of an entire animal
in signiﬁcantly shorter times. High-powered imaging gradients with fast switching
rates for small-volume imaging have also improved the ability to acquire fast images
at higher signal-to-noise, and further improvements in the gradient coils are also
likely [6].
2.2.4 X-ray computed tomography
In vivo imaging of small animals with CT has a critical role to play in the evolution
of molecular imaging [37, 38]. The conventional anatomic CT with non-speciﬁc con-
trast agents is a relatively straightforward way to obtain high-resolution anatomic
information which is often important to analyze molecular imaging studies obtained
using other modalities (especially nuclear and optical approaches). MicroCT is also
a valuable tool for indirect approaches to molecular imaging [37], for example, imag-
ing changes in vascular density and permeability associated with angiogenesis and
anti-angiogenic therapeutics. MicroCT is the method of choice for tracking changes
in diseases that aﬀect bone. The high resolution of microCT allows very sensitive de-
tection of bone growth, destruction, remodelling and changes in bone density, and is
therefore ideally suited for studying the consequences of diseases such as osteoporosis
and rheumatoid arthritis, and for evaluating the eﬀects of therapeutic interventions
on the progression of these diseases [6]. MicroCT also has the potential to be used as
a fairly high-throughput imaging technique and investigators are considering its use
for phenotypic screening in genetically manipulated mice [39].
Some of the speciﬁc and continuing challenges in moving from specimen imaging
to in vivo imaging have been to reduce the radiation dose, deal with motion artefacts,
change the system geometry to allow the animal to be placed horizontally and remain
stationary during scanning and to decrease imaging time.
To date, microCT systems have made use of 2D x-ray detectors developed for
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specimen imaging or digital mammography, and systems generally acquire data in
cone-beam geometries. This imaging geometry is relatively simple to implement
and the 3D collection makes the most eﬃcient use of the relatively modest x-ray
ﬂux that is emitted by the compact microfocus ﬁxed anode x-ray tubes generally
employed in these applications [40]. These low-power tubes are supported by compact
power supplies and the small x-ray focal spot size oﬀers the potential for very high
spatial resolution. At the same time, the anode current (and hence number of x-rays
produced) of these compact tubes is limited by the small focal spot size and the
ﬁxed anode design when operated continuously for CT acquisition. Typical x-ray
tube parameters used in microCT systems are focal spot sizes in the range of 10-100
microns, and tube currents of at most a few mA at an anode voltage of 25-75 kV. Most
commonly, tungsten anode tubes are being utilized. For CT imaging, the x-ray tube
is generally operated continuously with a shutter to control when x-rays irradiate the
object. A resolution of tens of microns is achievable in some microCT systems [6].
2.2.5 Ultrasound
Ultrasound also has been successfully adapted as a tool for small-animal imaging and
together with the development of novel echogenic contrast agents promises to add
molecular imaging capability in a number of very important areas. Advantages of
ultrasound include real-time imaging, portability, low cost, high spatial resolution
and the absence of ionizing radiation. One of the key trade-oﬀs in ultrasound is
between acoustic frequency, depth of penetration, and spatial resolution. In small-
animal models, a depth of penetration of 1-2 cm is generally suﬃcient, allowing high
frequencies on the order of 20-60 MHz to be used. This leads to a spatial resolution
in the range of tens of microns [6]. One of the really unique capabilities of ultra-
sound is in developmental studies [41], particularly pre-natal studies in genetically
manipulated mice (see ﬁgure 2.4). Genetic manipulations often result in embryonic
lethal phenotypes that do not survive to birth, hence the ability to determine phe-
notypes in utero is extremely important. High-resolution embryonic imaging cannot
be performed noninvasively with any other modality at the present time due to fetal
motion, which requires very fast acquisition. The real-time nature of ultrasound is
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also of importance in studying cardiac anatomy and function in rodents, and opens
up opportunities for image-guided interventions in animal models.
The capabilities of ultrasound go far beyond anatomic imaging for phenotypic
analysis. High frequency Doppler ﬂow mapping enables quantitative measurements of
blood ﬂow not only in major vessels, but importantly, also in the microcirculation [42].
Contrast agents are being developed that promise to give ultrasound a major role in
molecular imaging and therapeutics [43, 44]. In their simplest form, these contrast
agents are small bubbles (typically 1-10 microns in diameter) in which a lipid or albu-
min shell is ﬁlled with a gas such as perﬂuoropropane. These microbubbles produce
very strong ultrasound echoes due to diﬀerences in their compressibility and den-
sity compared to surrounding biologic tissues. In fact a standard clinical ultrasound
system can detect the echo from an individual microbubble, thus in principle, the
sensitivity for detection of such contrast agents is extremely high. Microbubbles are
already in clinical use, where they are used to detect small vessels and capillary beds
by enhancing the signal from the small volume of blood. In addition, microbubbles
have interesting non-linear oscillation properties in response to ultrasound radiation.
With appropriate acoustic pressure, these bubbles can actually burst. By applying
local acoustic pressure to burst the bubbles, the contrast agent can be selectively
destroyed within a small volume of tissue. By imaging the return of the signal as
blood containing intact contrast agent ﬂows into the region, it is possible to quantify
important physiologic parameters such as blood velocity, blood ﬂow and blood vol-
ume in the microvasculature. These measurements can be repeated over and over for
a single contrast agent injection with high spatial and temporal resolution [6].
2.3 General requirements for molecular imaging
The acquisition of ex vivo information in biomedical research has become relatively
easy, because a myriad of specialty reagents, ligands, protocols, and devices have been
commercially developed over the past two decades. On the other hand, molecular
imaging in living subjects presents more theoretical and practical challenges than
in vitro or cell culture detection, primarily because of the need for probes to be
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Figure 2.4: High frequency (40 MHz) ultrasound image of a 13.5-day-old mouse embryo.
The resolution in this image is better than 100 microns. (Adapted with permission of World
Federation of Ultrasound in Medicine and Biology from [45]).
biocompatible, the presence of additional delivery barriers, and the necessity for
developing special in vivo ampliﬁcation strategies [46]. There are several general areas
in which considerable research eﬀorts are ongoing [11,27] and will also be necessary in
the future to perform in vivo molecular imaging (by seeking answers to the questions
in parenthesis) [1]:
• selection of appropriate cellular and subcellular targets to image (what biolog-
ical process is to be imaged?).
• development of suitable in vivo aﬃnity ligands, that is, molecular imaging
probes (what biocompatible chemical/biochemical/ molecular entity can be
used in vivo to distinguish that particular biological process and help to gener-
ate speciﬁc images of that target?).
• delivery of these probes in a manner that eﬃciently overcomes biological bar-
riers (what are the pharmacokinetic attributes of these probes contributing to
successful imaging?).
• ampliﬁcation strategies able to detect minimal target concentrations, usually in
the pico- to nanomolar range (can the imaging signal be ampliﬁed?).
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• development of imaging systems with high spatial/temporal resolution and sen-
sitivity suitable for small laboratory animals, and that ultimately can be trans-
lated to the human patient (what are the imaging modalities and instrumenta-
tion available to achieve molecular imaging in living subjects?)
2.4 Speciﬁc applications of PET molecular imaging
The use of either of PET or SPECT in small-animal biological research has the ad-
vantage that essentially the same methodology can be used in human applications,
thereby facilitating translation to the clinic. The classical example of a transla-
tional research application in molecular medicine is the introduction of STI- 571
(Gleevec r©), a small molecule designed to alter speciﬁc intracellular signalling path-
ways involved in cell proliferation and apoptosis, which lead to chronic myeloid
leukaemia [47]. STI-571 speciﬁcally inhibits the oncogenic protein tyrosine kinase
breakpoint cluster region (BCR)Abelson (ABL), which is constitutively activated by
a chromosomal translocation.
Some PET molecular imaging speciﬁc applications are reported.
2.4.1 Glucose metabolism in brain and heart
The probe of excellence in PET studies of metabolism is 2-deoxy-2-[18F]ﬂuoro-D-
glucose (FDG). It is transported into cells by the glucose transporter and subsequently
converted to the phosphorylated form by hexokinase. FDG-6-phosphate, the product
of hexokinase, cannot be further metabolized and is trapped inside cells, where its
accumulation can be measured in the PET scanner.
In the latest generation of small animal PET systems, the spatial resolution is
suﬃcient (<2 mm) to clearly identify structures such as the thalamus, striatum, and
cortex subunits are readily and to separate extracerebral activity from cerebral ac-
tivity in the adult rat. A range of semiquantitative investigations of brain plasticity
and conscious brain activation have been performed [48] and a series of fully quan-
titative longitudinal studies in a traumatic brain injury model, complete with direct
comparison to quantitative 2DG autoradiography [49], have also been reported. Even
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at this resolution, though, there is a problem with brain FDG studies in small rats
and mice, due to spillover of activity from the Harderian glands into the cortex.
The same spillover problem has been reported in adult rats as well, but with poorer
resolution tomographs [50]. Small animal PET scanners are also being employed to
measure glucose metabolism and myocardial blood ﬂow (with 13N-ammonia) in rat
and mouse heart models of ischemia and infarction. Initial investigations comparing
infarct extent [51] and FDG uptake [52] against in vitro measures are promising. The
group at Sherbrooke University and Prof. Markus Schwaiger of the Nuklearmedizinis-
che Klinik und Poliklinik der Technischen Universitat Munchen, Munich, Germany
have also demonstrated the feasibility of acquiring gated PET images of the rat
heart [53, 54].
2.4.2 Dopaminergic system in rat brain
Some of the earliest small animal PET work used a variety of probes to explore the
dopaminergic system in the rat brain. Probes that reﬂect dopamine synthesis (e.g.,
18F-ﬂuoro-metatyrosine, 18F-FDOPA), D2 receptor binding (e.g., 11C-raclopride, 18F-
ﬂuoroethylspiperone), and dopamine transporter concentration (e.g., 11C-CFT) are
available [10]. These probes are accumulated to a high degree in the striata, which are
fairly large and well separated in the rat brain. Therefore, successful investigations
can be performed even at moderate 3- to 4-mm spatial resolution [55]. This work
demonstrated, for example, the ability of PET to quantify D2 receptor in the living
rat brain [56], the survival and function of neural transplants [5759], and the eﬀects
of drugs on D1 and D2 receptors [60, 61]. An example from one of these studies is
shown in ﬁgure 2.5.
2.4.3 Oncology
Some of the best opportunities for small animal PET imaging are in oncology. Study-
ing transplanted primary tumors is often simple since they can be placed away from
major organs in the thigh, shoulder, or back of the animal. Under these circum-
stances, corrections for partial volume are straightforward. In addition, the usual
variability between one animal and the next is eﬀectively removed and each animal
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Figure 2.5: Coronal section through rat brains showing D1 and D2 receptor binding fol-
lowing injection of 11C-SCH 23390 and 11C-raclopride respectively. Four diﬀerent rats are
shown: control rat; lesioned rat (unilateral ibotenic acid lesion); lesioned rat following graft
of striatal cells from 15-mm crown to rump fetuses; lesioned rat following graft of striatal
cells from 10-mm crown to rump fetuses. Rats with grafts were scanned approximately
10 months post surgery. Note: Loss of D1 and D2 binding signal on right side of image
following lesion and partial recovery of the signal in the rat that received a striatal graft [10].
can be used as its own control. Furthermore, PET can survey the entire animal and
allows the spread of metastatic disease to be observed and monitored [10]. There
is a range of PET probes that are of interest in cancer models, including FDG,
3'-deoxy-3'- [18F]ﬂuorothymidine (FLT), a marker of DNA replication and cell pro-
liferation [62], and labeled antibodies and antibody fragments [63]. The power of
serial PET investigations as a tool for assessing the time course and localization of
antibody fragments is demonstrated in Figure 2.6, which illustrates a mouse imaged
using an anti- CEA minibody, a genetically engineered antibody fragment that binds
with high aﬃnity to carcinoembryonic antigen [64].
2.4.4 Reporter gene expression imaging
The merger of molecular imaging with molecular biology to create methods to mea-
sure reporter gene expression in vivo with PET is an area that has attracted increasing
interest. In analogy with the way Green Fluorescent Protein (GFP) is used as a stan-
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Figure 2.6: Coronal PET image of a mouse injected with a radiolabeled anti-CEA minibody,
a genetically engineered antibody fragment that binds with high aﬃnity to carcinoembryonic
(CEA) antigen. The minibody was radiolabeled with the positron emitter 124I and used
for microPET imaging of LS174T tumor xenograftbearing mice. The mouse shown had a
73-mg tumor on the left shoulder, and was injected with 60 Ci of 124I anti-CEA 18 h before
imaging. Note the absence of anatomical landmarks besides the faint mouse outline. The
engineered antibody fragment (minibody) is also illustrated [10].
dard reporter gene in molecular biology [65], a PET reporter gene (PRG) expresses a
protein that can trap or bind a positron-labeled probe [6671]. These are called the
PET reporter probes. The reporter gene is driven by the same promoter as the gene
of interest (the promoter can be thought of as a switch that turns the expression of
the gene on or oﬀ), such that the gene of interest is always expressed along with the
reporter gene. The retention of the positron-labeled probe by the protein product of
the PRG has been shown to be proportional to the level of reporter gene expression.
In turn, this reﬂects the level of expression of the gene of interest, which has the
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same promoter or is coupled directly to the PRG (i.e., PRG coupled to a therapy
gene) [72]. In this way, the location, magnitude of expression, and time course of
expression levels of any gene that is introduced into a mouse can be monitored in
vivo. This allows gene therapy protocols to be monitored in vivo, both in animal
models and, ultimately, in humans by PET. The same PRG approach can be used
in transgenic mice, where every cell in the mouse carries the PRG. In this case, the
signal is only detected when the promoter driving the PRG is switched on in the nat-
ural location where speciﬁc genes are expressed. This now enables endogenous gene
expression to be investigated in mice models [73]. Figure 2.7 is an image of a mouse
bearing two tumors, each expressing a separate reporter gene, namely the HSV1-tk
gene and the dopamine type 2 receptor (D2R) gene. The mouse was injected in two
diﬀerent instances with two diﬀerent reporter probes, 3-(2'-[18F]ﬂuoroethyl)- spiper-
one (FESP) and 8-[18F]ﬂuoropenciclovir (FPCV), each probe being speciﬁc for one
of the gene reporter systems. The image shows clearly the selectivity of the reporter
probes in each tumor [74].
Figure 2.7: Image of a mouse bearing two tumors, each tumor expressing a diﬀerent reporter
gene. The one on the right carries the HSV1-tk reporter gene and the one on the left, the
D2R reporter gene. The mouse was injected with two diﬀerent reporter probes, FESP and
FPCV, on two separate days. Each probe was speciﬁc for one of the gene reporter systems.
The image shows clearly the selectivity of the reporter probes in each tumor. Background
activity is seen from routes of clearance of tracer, which are renal and gastrointestinal [10].
Chapter 3
YAP-(S)PET technical characteristics
The YAP-(S)PET is a small animal scanner speciﬁcally built to perform PET and
SPECT acquisitions. For this reason the scanner uses planar detector rather than
the more common cylindrical multiring conﬁguration. Another peculiarity is the
utilization of YAlO3:Ce (or YAP:Ce) as scintillator crystal.
The scanner was originally developed ( [75, 76]) at the Department of Physics of
the Universities of Ferrara and Pisa, Italy. From 2003, fully engineered versions of
the scanner have been produced and commercialized by the small italian company
I.S.E. Ingegneria dei Sistemi Elettronici s.r.l., Pisa, Italy [77]. At the end of 2003, an
engineered version of the tomograph with additional research features has also been
realized within a research project at the Center of Excellence AmbiSEN (Ambiente e
Sistema Endocrino e Nervoso) of the University of Pisa and installed at the Institute
of Clinical Physiology (IFC) of the National Research Council (C.N.R.) within a
cooperative research agreement with the Center of Excellence AmbiSEN.
The ﬁrst versions of the scanner had a detector array composed of a 4 × 4 cm2
matrix of YAP:Ce of 20 × 20 crystals, each crystal being 2 × 2 mm wide and 25 or
30 mm long (hereafter named 20 × 20 version). The latest version realized during
the ﬁrst half of 2006 has the detection matrices consisting of 27 × 27 elements,
with crystals 1.5 × 1.5 mm wide and 20 mm long (hereafter 27 × 27 version). At
present, there are only two 27 × 27 version units of the YAP-(S)PET scanner. The
research unit is installed at the Institute of Clinical Physiology (IFC) of the National
Research Council (C.N.R.) within a cooperative research agreement with the Center
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of Excellence AmbiSEN of the University of Pisa; while the commercial version has
been delivered at the Scientiﬁc Institute H. S. Raﬀaele in Milan, Italy, on July 2006.
In this thesis, I discuss the technical characteristics, the calibration procedures and
the performance evaluation of the 27 × 27 version of the scanner, and describe
animal studies performed with both the 20 × 20 and 27 × 27 version.
3.1 The YAP-(S)PET scanner overview
The scanner is made of four detector heads of pixellated crystals of YAP:Ce. Each
matrix consist of 729 (27 × 27) elements of 1.5 × 1.5 × 20 mm3 glued together,
and optically isolated by a 5 µm thick reﬂective layer. This very thin and eﬃcient
reﬂective layer is applied by the manufacturer (Crytur [78]). The matrix is directly
coupled to a position sensitive photomultiplier tube (PS-PMT Hamamatsu R2486,
Hamamatsu Photonics, Hamamatsu City, Japan).
The distance between detectors pairs is ﬁxed to 10 cm in the commercial version.
In the research unit, the heads can be positioned at diﬀerent distances ranging from
10 to 20 cm so as to give the possibility of choosing the maximum spatial resolution
(larger distance in PET mode and smaller distance in SPECT modality) or maximum
sensitivity (smaller distance) conﬁguration (see chapter 5).
The four modules are positioned on a rotating gantry (see ﬁgure 3.1) and opposing
detectors are in time coincidence when used in PET mode.
The scanner can be switched between PET and SPECT modalities without any
change in the detector conﬁguration or in the acquisition system, but simply replacing
the tungsten septum (used in PET for shielding the scintillator from the background
outside the ﬁeld-of-view (FOV)) with a high-resolution parallel hole collimator in
front of each crystal.
The YAP-(S)PET computing architecture is client/server: the on-site PC (server)
that performs data acquisition and motion control can be controlled by a remote PC
(client) connected to a local network.
The PC-controlled head rotation allows tomographic acquisition. The scanner
is equipped with a laser system and motorized bed for the animal positioning and
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motion within FOV. The axial motion of the bed can be controlled via a PC software,
while the vertical position of the bed can be adjusted manually. There are two bed
models available, and both of them have a carbon composition. The ﬂat one (4 cm
wide and 50 cm long) is speciﬁcally designed for mice holding, while the hollow bed
(50 mm in diameter and 50 cm in length) is more suitable for rats (see ﬁgure 3.2).
For both PET and SPECT modalities the scanner has an axial and transaxial
FOV of 4 cm.
Figure 3.1: Photograph of the YAP-(S)PET scanner (left) and partial view of the four
rotating heads (right).
3.2 The main hardware components
3.2.1 Scintillator crystals: YAP:Ce
The ideal detector material for PET systems stops all photons that enter the detec-
tor, and provides high spatial, temporal and energy resolution for the recorded event.
These parameters could not be optimized simultaneously in one single detector ma-
terial or geometry; the optimal PET device must be matched to the source geometry
and imaging requirements [79].
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Figure 3.2: Photograph of the two bed models available with the YAP-(S)PET scanner:
the ﬂat one (bottom of the ﬁgure) for speciﬁcally designed for mice holding, and the hollow
bed (top) more suitable for rats.
In recent years, there has been considerable research in new PET scintillator
materials, especially for high Z materials, to improve the performance of future PET
scanners. An important example is LuAP:Ce, with its high Z, high-density, fast decay
time and relatively high light yield [80]. In high Z materials, the one gamma mean
free path has a shorter extension respect to low Z materials. 90% absorption lengths
for 511 KeV photons is about 25 mm in BGO and more than the double in YAP [81].
Moreover, multiple interactions of the incident photon in the detector (such as when
the photon undergoes a Compton interaction or a photoelectric interaction with an
inner shell electron, with subsequent X-ray emission) are generally closely spaced.
All these eﬀects can limit the achievable spatial resolution. In the past [82], low Z
plastic detectors have been considered for positron imaging due to the relative low
cost. Subsequently, interest has been related to its speed and potential high spatial
resolution [79].
Low Z materials have a photoelectric to Compton ratio very low compared to high
Z detectors. However, the photon which emerges from the ﬁrst Compton interaction
would travel a large distance from the interaction site. Besides, multiple interactions,
especially in thin detectors, will be high improbable. Energy resolution to distin-
guish true and scattered photons will not be possible, since there is no photopeak.
However, locating the site of a photon interaction by using the light produced by a
single Compton electron provides low Z detectors the potential for very high spatial
resolution. A similar behaviour is expected using a medium-Z scintillator, such as
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YAP.
Yttrium Aluminum Perovskite activated by Cerium (YAlO3:Ce or YAP:Ce) is a
monocrystal with the structure of perovskite. The crystal is very hard, mechanically
and chemically stable, and it is not hygroscopic. Its main features are fast scintillation
emission and high light yield that makes this crystal the best compromise for both
PET and SPECT applications [76]. Besides, it can be assembled in crystal matrices
with small pixels for high spatial resolution maintaining its high light output. Other
scintillators, typically used in PET, either do not generate enough light (BGO) for
being used at the energy (140 keV) of the main used SPECT radiotracer (99mTc), are
too expensive (GSO) or are intrinsically radioactive producing signals in the relevant
energy range (LSO: about 400 cps/cm3). In table 3.1, the main characteristics of
YAP:Ce are summarized and compared with those of other scintillators [83].
Material NaI:Tl CsI:Tl BGO GSO:Ce YAP:Ce LSO:Ce
Z 11/53 55/53 83/32/8 64/14/8 39/13/8 71/14/8
Eﬀective
atomic number 51 54 74 60 33 67
(511 keV)
Density (g/cm3) 3.67 4.53 7.13 6.71 5.37 7.42
Index of refraction 1.85 1.80 2.20 1.90 1.95 1.82
Hygroscopic? yes slightly no no no no
Natural
radioactivity no no no no no yes
Wavelength
of maximum 415 550 480 440 370 420
emission (nm)
Decay 30-60 (90%)/ 12/
constant (ns) 230 900 300 600 25 40 (65%)
Radiation length
(cm) 2.9 1.86 1.1 1.38 2.7 1.14
Gamma
Mean Free Path 3.05 2.43 1.11 1.43 2.18 1.22
(511 keV) (cm)
Photoelectric
fraction 18% 22% 44% 25% 4.4% 32%
(511 keV)
Photoelectric
fraction 84% 87% 94% 82.3% 46% 92%
(140 keV)
Absolute light
yield 300 K 38 52 8-9 9-10 17 27-30
(103 photons/MeV)
Table 3.1: Basic charactertistics of some scintillator crystals
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Due to the low photoelectric/Compton ratio in YAP:Ce (4.4 % at 511 keV), most
of the events which contribute to the total absorption peak derive from multiple
interactions within the crystal and not from photoelectric absorption. The position
of one event is the average value of the coordinates of each interaction weighted by
its energy deposition. Hence, the spatial resolution for multiple interactions events
deteriorates. Selecting a suitable energy window mostly single Compton events are
registered and a higher spatial resolution can be obtained.
Figure 3.3 shows simulated pulse height distributions obtained for diﬀerent num-
bers of photon interactions within the YAP:Ce matrix.
Figure 3.3: Simulated pulse height distributions obtained for diﬀerent numbers of photon
interactions within the YAP:Ce matrix.
It is evident that most of single interaction events have a pulse height below
400 keV, i.e., the valley in the pulse height distribution of Fig. 3.3. In small animal
scanners, the scattering from rats or mice is not so important as in clinical scanner, so
the single Compton events can be considered good events. For this reason, YAP:Ce
shows better spatial resolution capabilities with respect to high Z scintillators, such
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as BGO [84]. Since all high Z scintillators have a photofraction below 50% at 511 keV
the events under the full energy peak will have a large contribution from multiple
Compton scattering in the crystal. These events are usually chosen as the best
events. In dense medium Z scintillators, like YAP, by selecting only Compton events,
even in a crystal whose thickness is one gamma mean free path, a high fraction of
these (≈ 60%) will be single interactions, providing, therefore, the correct interaction
position. This percentage is more than any photofraction of any scintillator.
In the YAP-(S)PET scanner it is possible to select the energy window in which
data for reconstruction are taken. In PET mode, choosing the 50-400 keV window
the single Compton events are favoured and a higher spatial resolution reconstruction
is obtained. On the other hand, selecting the whole spectrum (50-850 keV) a higher
sensitivity is obtained.
Chapter 4 of [85] reports the spatial resolution and the sensitivity for both 50-400
and 50-850 keV energy window. The results clearly show how the spatial resolution
improves when using the high spatial resolution energy window (50-400 keV), while
there is a signiﬁcant decrease in sensitivity.
In this thesis, in PET mode we have always used the open energy window 50-850
keV in order to better compare the performance of the new version of the YAP-
(S)PET scanner (27 × 27 version) with the old one (20 × 20 version).
The use of the reduced energy window (140-250 keV) in SPECT mode is justiﬁed
by a reduction in scatter contribution, as described in [86]. In this article, it is
shown how above 140 keV there are about no scatter tails. The test acquisition
was performed with a 10 mm diameter cylindrical phantom, ﬁlled with 99mTc and
surrounded by a 11 mm thick lucite ring.
Thus, in SPECT mode, in this thesis we have always used the reduced energy
window 140-250 keV. There is obviously a reduction in sensitivity, but we gain in
spatial resolution: a critical issue in SPECT modality.
3.2.2 Position Sensitive Photomultiplier Tube (PSPMT)
Before the advent of the Position Sensitive Photomultiplier Tube (PSPMT), the task
of obtaining 2-dimensional information required the use of an arrangement of multiple
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PMTs. This approach was quite expensive and required complex hardware. The
R2486 series was the ﬁrst 3 inch position sensitive PMT developed by Hamamatsu
in 1985 [87], and represented a strong technological advancement for gamma ray
imaging.
Figure 3.4: Photograph of the R2486 PS-PMT tube by Hamamatsu [88].
Figure 3.5: Dimensional outline (on the left) and anode pattern (on the right) of the R2486
PSPMT tube by Hamamatsu [88].
The R2486 tube (see ﬁgure 3.4) consists of a 3 inch PMT with bi-alkali photo-
cathode, 12-stage coarse mesh dynode structure, and 16×16 anode wires crossing one
another in the X and Y directions. The dynode structure consists of two layers: a
focusing grid and multiplication bars. The bars are alternatively crossed to obtain
multiplication along the X and the Y direction (see ﬁgure 3.6). A charge cloud is
generated across the 12 dynode stages and ﬁnally collected by a crossed wire anode
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(see ﬁgure 3.5). The focusing structure limits the spread of the charge (obtained from
a point-like illumination of the photocatode) to 4.3 mm at the last dynode [87], where
the charge is back-reﬂected to the anode wires. The wire pitch is 3.75 mm, thus giving
adequate sampling of the charge distribution. The intrinsic spatial resolution of the
R2486 tubes ranges between 0.9 mm and 0.12 mm, which improves with increasing
charge on the anode. The tube has a circular photo-cathode with an active area of
50 mm in diameter, with respect to an overall diameter of 76 mm. Figure 3.5 shows
the dimensional outline and the arrangement of the anode wires. In the standard
conﬁguration, the two wire ends of wires in the same direction are connected via a
resistive chain. The two ends of each resistive chain (X or Y) produce two charge
pulses: Xa and Xb (or Ya and Yb) . The ﬁnal position is then given by the equation:
X =
Xa − Xb
Xa +Xb
(3.1)
Figure 3.6: Coarse mesh dynode structure. Left: schematic rapresentation of a cross-
section of a PSPMT obtained linking digitized images from electronic microscope of dynode
cross-section. The ﬁgure represents the multiplication process along the X direction where
G is the hexagonal grid, D is the bar dynode and K is the bi-alkali photocathode. Right:
front view image of the coarse mesh dynode obtained by an optical microscope [89].
The general characteristics of the PSPMT R2486 are reported in table 3.2.
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R2486
Spectral response 300 nm to 600 nm
Wavelength of maximum response 420 nm
Photocatode material Bialkali
Minimum eﬀective area 50 mm diameter
Window material (thickness) Borosilicate glass (3.0 ± 0.3 mm)
Dynode structure Coarse mesh
Number of dynode stages 12
Anode structure 16 (X) + 16 (Y) crossed wires
Max HV -1300 V
Max gain 5.0 × 105
Signal rise time 5.5 ns
Table 3.2: General characteristics of the Hamamatsu R2486 photomultiplier tube [88].
3.2.3 Electronic read-out
The electronic equipment is mounted on the back of the rotating gantry of the YAP-
(S)PET scanner (see ﬁgure 3.7). It consists of:
• four High Voltage (HV) units that supply the power to each of the R2486
PSPMTs. The HV value can be set independently for each PSPMT. In the 27
× 27 version of the scanner, PET and SPECT modalities have uncorrelated
HV setting (see ﬁgure 3.8). It makes possible to better exploit the Analog to
Digital Converter (ADC) dynamic range (see section 4.1.1).
• two acquisition boards with dedicated and compact electronic devices for the
PSPMTs signal ampliﬁcation and digitization. Each acquisition board is dedi-
cated to a pair of opposite detectors both in PET and SPECT modalities.
Each PSPMT has two diﬀerent type of output signals: the last dynode and the
four anodic position signals.
The last dynode signals are used for fast timing coincidence. The output signal
from each PSPMT is ampliﬁed by a pre-ampliﬁcation stage produced by ISEsrl
and then sent to the acquisition board for fast timing coincidence. A Constant
Fraction Discriminator (CFD) is used for each photomultiplier tube. In PET
mode, the logic outputs of the CFDs of opposing detectors are sent to a coinci-
dence module that produces the gate signal for the acquisition of the position
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signals (see ﬁgure 3.9). One of the CFD outputs of each pair of detectors is
delayed by 100 ns in order to generate a delayed coincidence window. Events
collected in this window are random events and are used to establish the rate
of the randoms used for random corrections (see chapter 4). In SPECT mode,
the output of each CFD directly generates the gate for the acquisition of the
position signals.
The X-Y signals from the PSPMTs are used to determine the energy deposited
by the γ-rays and the position of detected events. The four position signals
from each PSPMT are processed by a system composed of a peak detector and
a peak sensing ADC. The digitization of the signals is enabled by the gate
signal.
The digital data are transferrerd to the local PC sever via USB2 connection.
In order to improve the count rate capabilities, at the beginning of 2006 a novel
acquisition board has been developed. This new board called FAB (Fast Acquisition
Board) (see ﬁgure 3.10) includes:
• faster ADCs in order to improve the count rate capabilities;
• a novel electronic pile-up rejection circuitry that allows to improve the image
quality. (An application for patent has been ﬁled by ISEsrl for this circuit).
• more on-line counters in order to have a complete control of what is going on
during the acquisition.
3.2.4 SPECT collimator
The purpose of a collimator is to form the projection image by permitting gamma-
rays photons approching the camera from certain directions to reach the crystals
while absorbing most of the other photons. Several kinds of collimator can be found:
pinhole, parallel-hole, converging and diverging holes, fan beam and more. The most
commonly used collimator is the parallel-hole, particularly for human scanners. In
small animal imaging, where one would like a spatial resolution between 1 and 3 mm,
40 Chapter 3. YAP-(S)PET technical characteristics
Figure 3.7: Photogtaph of the YAP-(S)PET electronics on the back of the gantry.
Figure 3.8: The four high-voltage (HV) supplies for each PSPMT of the YAP-(S)PET
scanner.
one of the diﬃculties of this design is to make very small diameter but long collimator
holes [90].
In the YAP-(S)PET scanner the collimators can be easily mounted or removed
from the detectors head, replacing the tungsten septum used in PET for shielding the
scintillators from the background outside the FOV (see ﬁgure 3.11). The collimators
are made of lead with 0.6 mm hexagonal holes and are 20 mm thick. The septa
between holes are 0.15 mm. A particular of the holes of the collimator is shown in
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Figure 3.9: Schematic rappresentation of the electronics for the coincidence acquisition of
the signals from a pair of opposing detectors.
Figure 3.10: The new acquisition board FAB (Fast Acquisition Board) of the YAP-(S)PET
scanner.
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ﬁgure 3.11. The collimator geometrical eﬃciency g, deﬁned as the fraction of gamma-
rays passing through the collimator per gamma-rays emitted by the source toward
the collimator, is given by [91] g ≈ [K d2/L(d + t)]2, where d is the hole diameter,
L is the thickness of the collimator, t is the thickness of the intra hole septa and K
is a factor depending on the geometry of the holes. In the case of hexagonal holes
K=0.26. With d=0.6 mm, t=0.15 mm, and L=20 mm the geometrical eﬃciency
results 4×10−5.
Figure 3.11: PET septum and SPECT collimator (on the left) with zoom of the collimator
holes (on the right).
3.3 The software tools
3.3.1 Client/server architecture
The YAP-(S)PET scanner architecture is client/server.
The on-site PC (server) is dedicated to electronic equipment control, data acqui-
sition and motion control.
In the next sections, I will go through a detailed description of the YAP-(S)PET
client characteristics. It will help the comprehension of the next chapters.
The YAP-(S)PET client application is characterized by a user-friendly graphic
interface. It allows to check and set up all the parameters regarding data acquisition,
data analysis and image reconstruction from any remote computer connected via a
local network to the server.
The YAP-(S)PET client main panel houses some menus and a command window
with four icons (see ﬁgure 3.12).
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The menus are: File and Operations. The Operations menu contains two groups
of commands. The Operative phase group includes the same commands of the
incons of the command window. The Server-side operations menu allows to choose
the scanner acquisition mode (PET or SPECT), and to set the distance between the
heads of each couple.
Each icon of the command window corresponds to a diﬀerent command: Acqui-
sition, Analysis, Reconstruction and Display.
Figure 3.12: Main panel of the YAP-(S)PET client graphic user-friendly interface.
3.3.2 Acquisition
The Acquisition panel (see ﬁgure 3.13) allows to set the acquisition parameters. Two
diﬀerent types of acquisitions are possible: Preset Count and Preset Time.
In Preset Count mode, the counting interval ends when a preselected number of
events has been acquired.
In Preset Time mode, the counting interval begins when the Start button is
pressed and is terminated automatically when the selected counting time has elapsed.
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Diﬀerent parameters can be set for both the acquisition modalities:
• the number of views, ranging from 1 (planar acquisition) to 128. The step is
2n, with n running between 0 and 7.
• in Preset Count mode only, the number of events per view. Actually, the user
can set the number of blocks to be acquired per view. Each block contains 63
events, all of them are registered with the same time label with respect to the
beginning of the acquisition. The number of blocks ranges from 1 to 108.
• in Preset Time mode only, the number of acquisitions, the duration (in time)
and the delay between an acquisition and the following one. This acquisition
mode is particularly suitable for dynamic acquisitions.
• the start and the end angle of gantry rotation. The start angle ranges from 00
to 3590. The end angle can be 900, 1800 or 3600. If the number of views is equal
to 1, the start and end angles coincide.
• the bed initial position and the total length to scan. The whole-body acquisi-
tions are performed with the standard protocol of translating the bed through
the scanner at discrete, overlapping steps. Each step requires a bed advance-
ment of 20 mm, i.e. half of the FOV dimension. The maximum length to scan
is 160 mm, corresponding to 7 bed positions.
• the radioisotope used for the acquisition. This information is used by the Client
software to correct acquired data for decay process.
• injection time of the radioisotope. It is an important parameter for tracer
kinetic modeling.
Some parameters displayed in the Acquisition panel allow to monitor the progress
of the acquisition:
• the total number of the acquired events.
• the remaining time, that is the time remaining to the end of the acquisition.
In Preset Count mode, the computation of the remaining time is performed on
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the basis of the rate of acquired events and the decay time of the radioisotope
used.
• several on-line counters that measure the rate of acquired events by each single
head or pair of heads. The displayed rate (cps) are: registered events by each
pair of heads; single events acquired by each head; true coincidence registered by
each couple of heads; false coincidence acquired by each couple of heads; pile-up
events acquired by each head; saturation events registered by each head.
• the number of the current view in the running acquisition and the corresponding
gantry angle (in degrees).
• the number of the acquired events in the current view.
• the number of bed positions for whole body studies and the number of acquisi-
tion in dynamic studies.
Figure 3.13: Acquisition panel of the YAP-(S)PET client user interface during a calibration
measurement in PET mode.
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3.3.3 Analysis
Analysis, as Reconstruction and Display tools, can be accessed by clicking on the
corresponding icon in the Acquisition panel (ﬁgure 3.12). The selection of the ﬁle
opens the Yappet File Manager window (see ﬁgure 3.14).
Figure 3.14: Yappet File Manager window for Analysis, Reconstruction and Display opened
from a static acquisition of a the derenzo-like phantom list-mode ﬁle.
The Analysis tool concerns the raw data analysis and the sinograms production.
The data are acquired in list-mode binary format and stored in memory in blocks
of 64 events. For each pair of γ-rays detected in PET mode, the four position signals
from each PSPMT and the related time are registered. In SPECT mode, the detection
of a single γ-ray implies the registration of the four position signals of the single
PSPMT and the related time.
Two diﬀerent type of list-mode ﬁles can be produced and processed: the calibra-
tion and measurement ﬁles.
The calibration acquisitions are used in the calibration and maintenance phases
of the scanner. The raw analysis that is possible to perform on these ﬁles generates:
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• the planar image of each YAP:Ce matrix, used for the pixel identiﬁcation and
the generation of a Look Up Table (LUT) of the geometric position of each
single crystal.
• the energy spectrum of each single crystal and the sum of them for each head,
necessary to perform the energy calibration and to check the proper function-
ality of the scanner.
• the eﬃciency corrections used to normalize the yield of the diﬀerent crystals of
each matrix (see chapter 4).
It is possible to choose the raw ADC channel limits for each analysis performed.
Measurement acquisitions refer to all the non calibration acquisitions gen-
erally performed. The measurement list-mode ﬁles can be processed as calibration
acquisition besides allowing the sinogram generation.
The system operates in 3-D data acquisition mode without septa. The collected
data can be stored in 2-D (PET and SPECT mode) or 3-D (only PET mode) sino-
grams.
In 2-D sinograms only data coming from direct planes are processed and the
oblique lines of response (LORs) are rejected.
The 3-D sinograms (3-D Positron Volume Imaging o 3-D PVI) take in account
both direct and cross-plane detected events, thus storing all the coincidence data
acquired by the scanner. Two diﬀerent approaches are usually used to reconstruct
from 3-D coincidence PET data: the rebinning algorithms and the fully 3-D approach
of the 3-D reprojection (3-DRP) [92].
The 3-DRP algorithm is a 3D extension of the 2D ﬁltered backprojection (FBP)
algorithm and has a very high computational complexity.
This is why at present the YAP-(S)PET Analysis tool implements only rebinning
algorithms: single slice rebinning (SSRB or MSRB) and Fourier rebinning (FORE).
A rebinning algorithm is deﬁned as an algorithm which sorts (rebins) the 3-D
acquired data into a stack of ordinary 2-D sinograms. These rebinned data are
geometrically equivalent to data collected in the conventional 2-D mode and can
therefore be reconstructed by applying 2-D reconstruction algorithms (FBP, OSEM)
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to each slice separately. Unlike standard 2-D sinograms, the rebinned sinograms
are less noisy because they employ much more data (the oblique LORs) than those
acquired in 2-D mode [93].
In the SSRB or MSRB algorithm, each oblique coincidence line is assumed to have
arisen from a parallel plane midway between the axial points of interaction of the two
γ-rays in the opposite detectors [94]. Along the central axis of the scanner, this
approximation works perfectly. However, it steadly becomes worse with increasing
distance from the central axis. This approach yields reasonably acceptable images
when the object being imaged takes up a small fraction of the FOV and when the
axial acceptance angle (the maximum oblique angle accepted) is small [95]. In the
YAP-(S)PET Analysis tool, the SSRB maximum span is ﬁxed to 15 LORs while
MSRB accept all the possible inclinations of the LORs.
The FORE techinque relates the 2-D Fourier transform of an oblique sinogram
to the 2-D Fourier transform of the direct sinogram of a slice shifted axially by a
frequency-dependent oﬀset. Although this is still an approximate method, it yields
substantially better results than SSRB, even for large objects and large acceptance
angles [96], while retaining much of the advantage in terms of short reconstruction
times.
In SPECT mode, each sinogram for each head can be produced besides the sino-
gram sum. Each sinogram is composed of 27 slices (1.5 mm thickness), has 53 spatial
bins (the number of bins used to digitize the radial positions respect to the center
of the FOV) and a number of angular bins depending on the number of views of
the SPECT acquisition and on the angular rebinning. For example, in a SPECT
acquisition of 128 views over 1800, the number of angular bins will be 128 with
angular rebinning or 256 without rebinning (sinogram produced over 1800 or 3600
respectively).
In PET mode, the single sinogram is related to the couple of detectors instead of
the single head. The sinograms can be produced with both 27 or 53 slices (0.75 mm
thickness) in order optimize the axial sampling of the 3D image. The single slice has
53 spatial bins and a number of angular bins depending on the head-to-head distance
(see section 3.1) and on the angular rebinning. The angular rebinning is determined
3.3. The software tools 49
on the basis of the minimum detectable angle (δmin). Referring to ﬁgure 3.15, the
mathemathical expression of δmin is:
tan(δmin) =
lsino
2(R + DOI)
≈ δmin (3.2)
lsino is the spatial sampling, R is half the head-to-head distance and DOI is the
most probable interaction depth (in the YAP-(S)PET 27 × 27 version it is set to
8mm).
The approximation is justiﬁed up to lsino ¿ R. In our case, lsino is 1.5 mm or 0.75
mm and R ranges from 50 to 75 mm. The number of angular bins (Nθ) over 3600 is
obtained by the expression:
Nθ =
pi
δmin
(3.3)
If a PET acquisition is performed, i.e., in the conﬁguration with head-to-head
distance of 12.5 cm (R=62.5 mm), Nθ will be 148 or 296 according to the sinogram
produced with or without angular rebinning.
Figure 3.15: Left: Two detectors of a detection couple (PET modality) faced one another.
The minimun detectable angle is visualized . Right: Sketch of the geometric conﬁguration
for the determination of the number of angular bins.
During each analysis process of both calibration or measurement acquisitions, a log
ﬁle containing information about the acquisition is created. The log ﬁle is structured
as a table, whose rows refer to a single view of the acquisition (see ﬁgure 3.16). The
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ﬁnal row reports the whole contribution of all the views. For each performed scan
(dynamic frame or bed position) a table is generated. The columns of each table
contain the following information (from left to right of ﬁgure 3.16):
• percentage of acquired events eﬀectively used in the analysis.
• percentage of rejected events for energy values.
• percentage of rejected events for ADC values.
• percentage of real events. This percentage is obtained by the number of CFD
triggeres. The CFD starts every time a good event arrives. Nevertheless, due
to dead time, during the acquisition of one event the electronic equipment can
be unable to detect another event. By registering the number of CFD triggers,
it is then possible to know the number of real events and to express them as
a percentage of the acquired events (obviously this percentage is greater than
100%).
• percentage of random events, available only in PET modality. (See section 3.2.3
for the explanation on the determination of random events).
• percentages of events used by each head (FT in ﬁgure 3.16 stands for pho-
totube). These percentages are related to the percentage of acquired events
eﬀectively used in the analysis (column Used of ﬁgure 3.16).
• duration of the acquistion of the view.
3.3.4 Reconstruction
The goal of image reconstruction is obtain the 3D distribution of the activity in
the object that is being scanned, using externally detected radiation. In order to
perform tomographic reconstruction, a set of views should be acquired at discrete
angles around the object, so that each view supplies a 2-D projection of the 3-D
activity distribution. As explained before, in the YAP-(S)PET scanner this set of
2-D projections is sorted in a set of 2-D sinograms. The 3-D image is then composed
by stacking the slices reconstructed with 2-D methods.
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Figure 3.16: Log ﬁle of a static acquisition of a derenzo-like phantom.
In the YAP-(S)PET software, once the acquired data are stored in sinograms (see
section 3.3.2), diﬀerent type of reconstruction can be performed. The Filtered Back
Projection (FBP), the Maximum Likelihood Expectation Maximization
(ML−EM) and the Ordered Subsets Expectation Maximization (OSEM).
The FBP is an analytic reconstruction algorithm that uses the central-section
theorem. The implementation is based on the following steps [95]:
• compute the 1-D Fourier transform of the ﬁrst projection angle in the sinogram;
• multiply this by the ﬁlter function;
• take the inverse Fourier transform;
• backproject the modiﬁed (ﬁltered) projection;
• repeat the procedure for all angles around the object.
The mathematical formulation is:
f(x, y) =
1
N
N∑
i=1
p′(x cosφi + y sinφi, φi) (3.4)
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Figure 3.17: Image Reconstruction panel with FBP reconstruction selected. The cut-oﬀ
frequency expressed in pixel actually is expressed in pixel/FOV.
where
p′(r, φ) = 1
2pi
FT−1{FT[p(r , φi)] · |νr |} (3.5)
FT and FT−1 are the direct and inverse Fourier transform, respectively. N is
the number of diﬀerent equally spaced projection angles over which data have been
acquired: p(r, φi) is the number of counts in the sinogram element angle φi and radial
oﬀset r, and f(x,y) is the activity distribution. |ν| is the reconstruction ﬁlter, known as
Ram-Lak (Ramachandran and Lakshminarayanan [97]) or ramp ﬁlter because of its
shape in frequency domain (see ﬁgure 3.18). It ampliﬁes the high-spatial frequencies
with respect to the low-spatial frequencies. The typical 1/r blurring eﬀect introduced
by the backprojection is so reversed.
Ampliﬁcation of the high-spatial frequencies also leads to ampliﬁcation of high-
frequency noise. A typical projection view contains a range of frequencies, with
tendency for higher amplitudes at low frequencies and lower amplitudes at higher
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frequencies. On the contrary, statistical noise (noise related to the ﬁnite number of
annihilation photon pairs contributing to each element in the proﬁle) has a uniform
spectral appearance and contributes equally at all frequencies. Thus, the ramp ﬁlter
leads to degradation of signal-to-noise ratio (SNR) since higher frequencies are re-
sponsible for the ﬁner details (rapidly changing activity, sharp edges, and so on) in a
reconstructed images. By modiﬁng the reconstruction ﬁlter, it is possible to obtain
a trade-oﬀ between the SNR and spatial resolution of the reconstructed image. A
simple way to do this is to cut oﬀ the ramp ﬁlter at a frequency νcutoff < νmax. Other
methods foresee the use of apodizing windows multiplied by the ramp ﬁlter, resulting
in a reduced magnitude at high frequencies. This ﬁltering avoids a sharp change in
the ﬁlter at the cut oﬀ frequency reducing the chances of introducing artifact into
the reconstructed images.
In the YAP-(S)PET Reconstruction tool, the cut-oﬀ frequencies value is auto-
matically set to the Nyquist frequency, but it is also possible to select the desidered
cut oﬀ frequency. In the Image Reconstruction panel (see ﬁgure 3.17), the cut oﬀ
frequency expressed in pixel actually refers to pixel/FOV, that is in the typical fre-
quency expression pixel/mm. Besides the ramp ﬁlter, the following types of ﬁlter can
be choosen: Shepp-Logan [98], Shepp-Logan modiﬁed, Hann, Low Pass Cosine and
Noise. The mathematical expression of the used ﬁlters are:
Ramp: H(ν) = |ν|
Shepp-Logan: H(ν) = 2 νcut−off
pi
sin
( |ν|pi
2 νcut−off
)
Shepp-Logan modiﬁed: H(ν) = 2 νcut−off
pi
sin
( |ν|pi
νcut−off
)
Hann: H(ν) = 0.5 |ν|
(
1 + cos
piν
νcut−off
)
Low Pass Cosine: H(ν) = |ν| cos
( |ν|pi
2 νcut−off
)
Noise: H(ν) = |ν|
0.01 + |ν| ln[3
2
exp(1 + |ν|2)]
Figure 3.18 shows the graphs of the ﬁlters implented in the YAP-(S)PET Re-
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construction tool. The values reported on the y-axis are multiplied by a constant
factor [99].
Figure 3.18: Graphs of the ﬁlters implemented in the YAP-(S)PET Reconstruction tool
for the FBP reconstruction mode. The Spatial frequency expressed in pixel actually refers
to pixel/FOV, that is in the typical frequency expression pixel/mm. The values reported
on the y-axis (Weight) are multiplied by a constant factor [99].
The FBP algorithm is fast and relative easy to implement, that is why it is the
most widely used reconstruction method in nuclear medicine. Nevertheless it does
not allow to take in account various physical aspects of the imaging system and data
acquisition, such as system geometries, detector properties, scattering evaluation,
attenutation correction and so on.
The Maximum Likelihood Expectation Maximization algorithm, since its
introduction to the ﬁeld of image reconstruction in 1982 by Shepp and Vardi [100],
remains the basis for the most popular statistical reconstruction method and has
provided the foundation for many other methods. Likelihood is a general statisti-
cal measure that is maximized when the diﬀerence between the measured and the
estimated projection is minimized. The Expectation Maximization (EM) maximizes
likelihood under a Poisson data model. It implicitly treats the projection data as hav-
ing a Poisson distribution determined by the counting statistics in each projection
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bin and thus takes into account the statistical noise of the data.
The reconstruction problem can be written as follows:
sj =
∑
i=1
Mi,jai (3.6)
where ai is the activity in an image pixel i and sj is the number of counts in pro-
jection element j. The i-index runs on all the FOV pixels, while the j-index covers all
the LORs. Mi,j is the matrix that provides the probability that gamma rays emitted
in the pixel i are detected in the projection element j. This matrix provides the model
of the imaging system correlating the positron emission and photon detection. In the-
ory, this matrix should include all the parameters to exactly describe the tomograph:
system geometry, detector proprierty, scattering evaluation, attenuation correction,
and so on. In ML−EM algorithm implemented in the YAP-(S)PET Reconstruction
tool, only the detection geometry is considered. The Mi,j elements number is given
by the product between the sinogram space and the number of pixels that are used to
divide the FOV. Since the Mi,j matrix matrix has a size that does not allow storing
all the elements, the storage space was drastically reduced by considering both the
symmetry and the sparse properties of the probability matrix [101].
The ML−EM algorithm can be written as:
ak+1i =
aki∑
j Mi,j
∑
j
Mi,j · sj∑
iMi,j · aki
(3.7)
The meaning of the terms in equation 3.7 can be better explained with reference
to ﬁgure 3.19 [102]. We start with an initial image guess a0 that is the entire image
set to a costant value. The ﬁrst step of the ML−EM algorithm (1) foward projects
the initial image guess nto the projection domain. Then, (2) these projections are
compared with the measured projections, s. This forms a multiplicative correction
factor for each projection, which is then (3) backprojected onto the image domain
to obtain a correction factor for the initial image estimate. This image domain
correction factor is then (4) multiplied by the current image estimate and divided by
a weighting term based on the system model to apply the desired strength of each
image correction factor. The new image estimate is now reentered in the algorithm
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as the next image; the algorithm repeats itself while the estimate approaches the
maximum likelihood solution. When the estimate projetion data exactly equalize the
measured projection data sj (substituting from equation 3.6):
ak+1i = a
k
i (3.8)
and the image does not change any more. This never actually occurs in practice
because of noise in the data and approximations in Mi,j.
As the ML−EM algorithm iteratively guesses an image estimate, the low frequency
components of the image appear within the ﬁrst few iterations. As the Mamimun
Likelihood estimate is approached, more and more high frequency deﬁnition is re-
solved in the image, eﬀectively adding more variance to the reconstruction. The
convergence rate of ML−EM is image dependent, but usually requires approximately
20-50 iterations to reach an acceptable solution [102].
In ML−EM algorithm implemented in the YAP-(S)PET, it is either possible to
freely choose the number of iterations to be performed during the reconstruction or
to set the automatic procedure that determine the number of iteration on the basis
of an empirical parameter [101].
Due to the possibility to include the detection process in the probabilty matrix
Mi,j, the ML−EM algorithm leads to potentially more accurate images. On the
other hand, the reconstruction time is considerably longer than the FBP approach.
A number of approximations have been developed to speed up these algorithms.
One of the most popular is the Ordered Subsets Expectation Maximiza-
tion (OSEM) introduced in 1994 by Hudson and Larkin [103]. With OSEM, the
projection data are grouped in subsets of projection views. Then, the ML−EM al-
gorithm is applied to the projections in the ﬁrst subset and the obtained image is
used as starting image for the next subset. An iteration of OSEM is then deﬁned as
a single pass through all the speciﬁed subsets. Further iterations may be performed
by passing through the same ordered subsets, using the reconstruction provided by
the previous iteration as a starting image. When there is only one subset, OSEM is
the same as ML−EM. Even though OSEM resembles ML−EM, this computationally
convenient method is not guaranteed to converge to the ML solution. In practice, its
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convergence is similar to ML−EM and approaches the ML solution roughly B times
faster than conventional ML−EM, where B is the number of subsets.
In the YAP-(S)PET Reconstruction tool, it is possible to choose up to six subsets
and a maximum of 1000 iterations for both ML−EM and OSEM algorithms. It is also
possible to choose the display of the reconstructed image of some of the interemediate
itereations, besides the last one.
Figure 3.19: Flow diagram of the ML−EM algorithm. Starting with an initial image guess
(a0) in the upper left, the algorithm iteratively chooses new image estimates based on the
measured projections, s [102].
Other reconstruction methods for the YAP-(S)PET scanner are under investi-
gation. In particular, a multi-Ray based system matrix generation for 3-D PET
reconstruction [104].
3.3.5 Display
The end result of the Reconstruction process is a 3- D image volume where each
individual voxel (volume element) represents the regional tissue radioactivity concen-
tration.
The digital images so produced are saved in a proprietary raw data format (imm).
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The matrix size of the transaxial cross-section images can be 64 × 64, 128 × 128 or
256 × 256 corresponding to a pixel dimension of 1.5 mm/2, 1.5 mm/4 or 1.5 mm/8
respectively (1.5 mm is the YAP crystal pitch). The number of slices in the axial
dimension can be 27 or 53, corresponding to 1.5 or 0.75 mm sampling, respectively.
The pixel depth is 32 bits (4 bytes) and the data are stored in memory with Little-
Endian byte order 1. Image data can also be saved in the DICOM (Digital Imaging
and Communications in Medicine [105]) standard format.
The images display and processing can be performed with variuos imaging software
provided with the YAP-(S)PET scanner: ImageJ, AMIDE and P-MOD software.
The free and open source ImageJ [106] is a public domain Java image processing
program inspired by NIH (National Institute of Health [107]) Image for the Macintosh.
It has been developed by Wayne Rasband at the Research Service Branch, of the
NIH, Bethesda, Maryland, USA. It can run virtually on all operating systems since it
has been written in Java 1.1. ImageJ is the imaging software embedded in the YAP-
(S)PET Analysis and Reconstruction tools and enables to automatically display both
sinograms and images.
AMIDE (Amide's a Medical Imaging Data Examiner) [108] is a completely free
tool for viewing, analyzing, and registering volumetric medical imaging data sets. It
has been developed using GTK+/GNOME, and runs on any system that supports
the toolkit (Linux, Windows, Mac OS X with ﬁnk, etc.).
PMOD [109] is a proprietary software produced and commercialized by PMOD
Technologies Ltd., Zurich, Switzerland. It has been written in Java 2 and is currently
oﬀered under Windows, Linux and MacOS X operatin systems. PMOD consists of a
set of user-friendly and powerful tools, each corresponding to a major task. Among
the main tools, the general kinetic modeling contains a comprehensive set of models
for the analysis of time-activity data. The cardiac tool is tailored to assess function
in cardiac segments by full kinetic modeling, and to compare the outcome against
normal databases. The image fusion tool does not only allow to register images, but
also enables the user to explore the calculated functional images in detail.
1In computing, endianness is the byte ordering in computer memory used to represent data. In
the Litte-Endian byte order the least signiﬁcant byte (LSB) value is at the lowest address. The
other bytes follow in increasing order of signiﬁcance.
Chapter 4
Calibration procedures
Every PET or SPECT scanners needs quality control and calibration procedure to
work properly and garantee adequate scanner performance.
Thus, when in the ﬁrst half of 2006, the new version of YAP-(S)PET scanner with
new detection matrices and electronic boards was completed (see chapter 3), new cal-
ibration procedures became necessary. These procedures concern both hardware and
software issues and are performed on the basis of the calibration procedure developed
for the ﬁrst YAP-(S)PET scanner and described in [85].
The hardware calibrations include both electronics and mechanics settings such
as adjustment of PMT gain or precise positioning of the center of rotation (COR).
They are performed during the installation and commissioning of the scanner and
have to be repeated every time speciﬁc hardware upgrade are made on the scanner.
The sotfware calibrations concern deﬁnition of crystal and energy maps, and eﬃ-
ciency corrections. Unlike the hardware, the software calibrations must be performed
on a regular basis to maintain the scanner performance.
The calibration procedures were performed for 100, 125 and 150 mm head-to-head
distance.
4.1 Hardware procedures
Several parameters inﬂuence the YAP-(S)PET performance both in PET or SPECT
modality. Among these, the more susceptable to variation during a new installation
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are:
• the High Voltage (HV) of the photomultiplier (PSPMT) tube of each single
head.
• the center of rotation of the scanner.
4.1.1 HV settings
The HV value can be indipendently set for each PSPMT (see section 3.2.3).
The optimal regulation is the one that oﬀers the best trade oﬀ between a high
gain and few saturations of the ADC for the signals of the PSPMT.
PET modality
It is recommended to use a pure positron emitting source (e.g., 18F), since the
use of a source that emits also other photons (e.g., 22Na) could alter the evaluation
of the saturations. A fraction of saturation events can in fact be generated by the
coincidence between a gamma ray of 511 keV and the additional gamma ray (1274
keV for 22Na).
To appropriately take in account possible PSPMT photocatode variations, two
diﬀerent type of acquisitions can be performed:
• a single view acquisition with a planar source that evenly illuminate all the
YAP matrix and consequently the whole PSPMT photocatode.
• a tomographic acquisition employing a point or a linear source.
The measurements were performed with a linear source of 68Ge with an activity in
the range of 13-16 MBq (500-600 µCi). This source is identical to the source usually
employed in clinical PET calibration, but has lower activity. A four view acquisition
over 3600 was performed and at least 12 Mevents were acquired.
The spectra of the four anodic position signals of each PSPMT are generated by
the raw analysis of the calibration listmode ﬁle (see section 3.3.3). Each spectrum
reports the number of counts as a function of the ADC channel (see ﬁgure 4.1). Since
12 bits were used to display the ADC channels, the maximum value is 4096.
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The saturation of xa position signal of head 2 is visible in ﬁgure 4.1 (red line).
Neverthelss, in this case the HV setting of the head was not modiﬁed, since the
other position signals use a wide portion of ADC range and do not show signiﬁcant
saturation.
Figure 4.1: Position signals (xa, ya, xb, ya) spectra of head 2. xa spectrum shows a
saturation.
On the contrary, when spectra such as the one represented by the cyan line in
ﬁgure 4.2 take place, a HV regulation is necessary. Figure 4.2 represents the histogram
obtained by the sum of the four anodic position signals, the cyan line is related to
the head 4 of the YAP-(S)PET scanner.
Since the single and summed anodic position signals histograms, ﬁgure 4.1 and
4.2, respectively, give information about saturation and gain of the PSPMT, they are
very helpful for HV setting and control.
SPECT modality
The SPECT procedures for HV setting are performed in the same way as in PET
mode, so no further details will be provided.
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Figure 4.2: Raw energy spectra for each heads.
However, it is worthwhile to note that now the used source must be single gamma
emitting.
As for PET modality, two diﬀerent type of acquisitions can be performed to take
in account possible PSPMT photocatode variations: single view acquisition with
a planar source or tomographic acquisition with linear source. We performed the
acquisition with a glass capillary (of 44.7 µl volume, inner 0.8 mm, outer diameter
1.2 mm, respectively) ﬁlled with 111 MBq (3 mCi) of 99mTc. A 4 views acquisition
over 3600 was performed and at least 3 Mevents were acquired.
4.1.2 Center of rotation
In the reconstruction of images from projections it is assumed that the image matrix,
representing the activity distribution in a section, has a constant relationship to the
data acquisition matrix (detector matrix). In other words, it is critical that the
mechanical center of rotation coincides with the center of rotation (COR) deﬁned
for the projection data used for reconstruction. The non-perfect alignment between
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detector and image matrix for diﬀerent angles of data acquisition, means that the
COR is moving during the acquisition. It causes blurring in the reconstructed image,
resulting in a loss of spatial resolution.
Since it is extremely diﬃcult to make a mechanically or rotationally perfect gantry,
measure of misalignment and hardware or software corrections must be performed.
Software corrections are usually adopted by manufacturers to take into account the
detectors misalignment respect to the real rotation center. The YAP-(S)PET software
correction procedure is still under evaluation, so at the moment the COR corrections
are performed with an hardware procedure. It consists in mechanical corrections
realized with the help of Johnson blocks, a series of calibration blocks.
In PET mode, the COR misalignment is related to the shift between the center of
rotation and the axis joining a pair of detectors: no information about the absolute
shift of the single head can be obtained. The SPECT COR misalignments produce
more image degradation with respect to PET acquisitions, and in severe case lead to
generation of ring or annular artifacts. For these reasons, the COR misalignment is
evaluated in SPECT modality and then checked in PET mode.
SPECT modality
The simplest way to measure the COR misalignment is to perform an acquisition
over 3600 of an oﬀ-axis point or line source [110]. The amplitude of the sine wave
of the sinogram is the distance of the point source from the center of rotation. The
advantage of using a line source is the capability of measuring the center of rotation
for each axial slice at the same time.
We performed the acquisition with a glass capillary (44.7 µl volume, inner diam-
eter 0.8 mm, outer 1.2 mm) ﬁlled with 111 MBq (3 mCi) of 99mTc. A 128 views
acquisition over 3600 was performed and at least 3 Mevents were acquired. The cap-
illary was ﬁlled for a length at least equal to the FOV transaxial dimension (4cm)
and placed oﬀ-axis parallel to the axial direction.
The collected data were sorted in 2-D sinograms and a 140-250 keV energy window
was used. In order to produce correct sinograms, software corrections must be per-
formed on the acquired data. The center of rotation measurement is then performed
after software correction procedures (see section 4.2).
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The 2-D sinograms are produced for each head and without angular rebinning, so
for an acquisition of 128 over 3600 each sinogram has 128 angular bins (see section
3.3.3).
Once the sinograms for each head are produced, the YAP-(S)PET software tool
Center calculator dialog (see ﬁgure ??) allows to ﬁt each slice of the sinogram with
a sinusoid and to estimate the COR oﬀset. The function used to ﬁt each slice of the
sinogram is:
s(θbin) = A0 +A · sin
(
2pi
Nθ
· θbin + φ
)
(4.1)
where s is the radial coordinate of the sinogram, θbin is the angular bin in the
slice, Nθ is the number of angular bins (see equation 3.3), φ is the phase.
Since the produced sinograms have 27 spatial bins (running between 0 and 26),
the A0 value for a good center of rotation alignment is 13.
For each head and for each slice of the sinogram the shift from the right COR
value (∆COR) is shown by the tab nearby the gray square indicating the number of
the head in ﬁgure 4.3. The average COR error in the direction perpendicular to the
axis joining a couple of detectors in the transaxial plane, is given by the following
relation:
Eerr COR =
1
Ns
Ns∑
i=1
∆COR (4.2)
where Ns is the number of axial slices of the sinogram.
Besides COR misalignment due to mechanical shift of the axes of rotation, also
both local and global deviations of the parallel holes with respect to the perpendicular
direction to the detector surface may aﬀect the center of rotation [110]. In order to
separate the two contributions, two acquisitions of the COR were performed. The
second one with the collimators rotated of 1800 respect to the their axis (forth to
back rotation). If there are variations in collimator hole angle, the COR shift error
(∆COR,1800) assumes the same abosolute value but with opposite sign of ∆COR. On
the contrary, ∆COR and ∆COR,1800 assume diﬀerent values. The head shift (∆) is
obtained by averaging the value of the two COR oﬀset.
4.2. Software procedures 65
In this way the contribution of the collimator misalignment is bypassed. The head
shift so evaluated is corrected mechanically with Johnson blocks by moving up or
down the head.
If ∆ oﬀset of a head is under 1/10 of mm, we do not apply any corrections to the
center of rotation.
Due to COR variability caused by the collimator holes angle, the SPECT cor-
rections to the center of rotation can not be appropriate for PET purposes. Once
adjusted the COR in SPECT mode, it is then necessary to repeat the measurements
in PET modality.
PET modality
The acquisition was performed with the same 68Ge linear source employed in HV
setting (see section 4.1.1) placed about 1 cm oﬀ axis. A 128 views acquisition over
3600 was performed and at least 15 Mevents were acquired.
The collected data were sorted in 3-D MSRB sinograms without angular rebinning
and a 50-850 keV energy window was used. The COR oﬀset is obtained by ﬁtting the
sinogram of each couple with a sinusoid function (see equation 4.1 and ﬁgure 4.3).
In PET modality, the oﬀset gives only the distance between the center of rotation
and the axis joining a couple of detectors: no infomation about the absolute shift of
the single head can be obtained.
If the oﬀset of a couple of detectors is under 1-2/10 of mm, we do not apply any
corrections to the center of roataion.
4.2 Software procedures
The software calibration procedures consists essentially of three procedures:
• Pixel identiﬁcation
• Energy correction
• Eﬃciency corrections
These procedures must be perfomed for both PET and SPECT modalities and
were realized through the planar source acquisistion described in the next section.
66 Chapter 4. Calibration procedures
Figure 4.3: PET 2-D sinogram produced without angular rebinnig for the head pair 3-4.
The measured pair of heads is + 0.08 mm.
4.2.1 Pixel identiﬁcation
To correctly determine the lines of ﬂight (LORs) of the detected photons, it is nec-
essary to identify the YAP crystal array pixels in which the interaction takes place.
The identiﬁcation procedure associates each interacting photon (event), detected
in the crystal that faces the center of the tomograph, to the geometric center of the
YAP crystal in which the interaction has occured. A Cartesian coordinates system
(x,y) is used.
In both PET and SPECT modalities a uniformly ﬁlled planar source is used to
evenly illuminate each detector matrix.
PET modality
The planar source was ﬁlled with about 11 MBq (∼ 300 µCi) of a solution of 18F
and placed in the center of the FOV (see ﬁgure 4.4) in order to obtain a ﬂood ﬁeld
illumination for each head of the couple of coincidence detectors. An acquisition of 2
views over 1800 is performed. Since the accuracy of the calibration measurement is
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determined by a good acquisition statistics, 100-200 Mevents were acquired.
Figure 4.4: Sketch of the positiong of the planar source used to perform PET or SPECT
Pixel Identiﬁcation procedure.
The acquired data of each head are organized by the YAP-(S)PET software tool
Pixel Identiﬁcation Panel in a 2-D histogram image based on the calculated x,y
positions (see ﬁgure 4.5).
Due to the position non linearity determined by the photocatode nonuniformity
and gain variation of the mesh dynodes, the image is not uniform. The data are
clustered in small localized areas corresponding to individual crystal elements and
there is a small amount of overlap. Nevertheless, the separation between the center
of the crystals is enough to allow each x,y location assignment in the Cartesian
coordinate system by a Look Up Table (LUT). The single crystal identiﬁcation and
spatial assignment is performed by the Pixel Identiﬁcation software tool through
the following operations:
• automatically ﬁnds the center of each crystal and allows a manual operation
when the automatic procedure fails (see ﬁgure 4.5).
• progressively enumerates (from top to bottom and from left to right for each
row) each crystal of the YAP matrix (see ﬁgure 4.6).
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• uses a numeric algorithm (the Manhattan algorithm) to calculate the distance
between the centers of two contiguous crystals.
• deﬁnes a geometric region around the center of each crystal and assignes to the
center of the crystal all the events inside this region (see ﬁgure 4.6).
The crystal position matrices so determined are saved in binary ﬁles in both
YAP-(S)PET client and server applications (see section 3.3.1), and are used in all the
subsequent acquisitions until a new pixel identiﬁcation procedure is performed.
Figure 4.5: PET mode images. (a) 2-D histogram image based on the calculated x,y
positions of the events detected by head 3 in PET mode. (b) Automatically identiﬁcation
of the center of each crystal in the 2-D histogram image.
Figure 4.6: (a) Enumeration of the center of each crystal in the 2-D histogram image. (b)
Geometric region around the center of each crystal of the 2-D histogram image. All the
events inside this region are assigned to the center of the crystal.
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SPECT modality
The SPECT pixel identiﬁcation procedure is performed in the same way as in
PET mode; further details are given and only the diﬀerence with respect to PET
modality are highlighted.
The planar source was ﬁlled with 185 MBq (∼ 5 mCi) of a solution of 99mTc and
placed at the center of the FOV in order to ﬂood illuminate each single head. An
acquisition of 4 views over 3600 is performed and at least 120 Mevents are acquired.
Figure 4.7 shows the image obtained by the even illumination of the detector matrix
1 (a) and the same image with the the center of each crystals automatically found by
the software tool (b).
Figure 4.7: SPECT mode images. (a) 2-D histogram image based on the calculated x,y
positions of the events detected by head 3 in PET mode. (b) Automatically identiﬁcation
of the center of each crystal in the 2-D histogram image.
4.2.2 Energy corrections
Once the matrix of the center of the crystals is imported into the listmode ﬁle of the
planar source acquisition, an energy spectrum of each crystal can be produced by the
YAP-(S)PET software. The spectra are reported as a function of the channels (see
ﬁgure 4.8). Then an energy-channel calibration is necessary.
PET modality
The YAP-(S)PET software tool, Energy correction panel, automatically perform
a gaussian ﬁt on each spectrum of detector matrix crystals (729 per each detector
matrix) to ﬁnd out the photopeak channel value. If the automatic ﬁt fails, manual
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tuning is possible. The energy-channel calibration factor is then obtained by the
ratio between the energy and channel value of the photopeak. For positron emitters,
the energy value is 511 KeV. Since the calibration is performed per each spectrum, a
correction matrix is obtained. Typical corrections value as obtained for head 3 of the
YAP-(S)PET scanner are presented in ﬁgure 4.9. This procedure allows to remove
the diﬀerence in energy response among the crystals of the detector matrix and the
diﬀerent zones of the photocatode. It is then possible to produce a summed energy
spectrum for each detector head (see ﬁgure 4.10).
The energy correction matrices, as crystal position matrices, are saved in binary
ﬁles in both YAP-(S)PET client and server application and used in all the subsequent
acquisitions until a new calibration procedure is performed.
Figure 4.8: A typical PET spectrum of a of a single crystal of the head 3. The red line
represents the gaussian ﬁt of the photopeak.
SPECT modality
The SPECT energy calibration is performed as in PET mode.
It is worthwhile to note that each single gamma emitter has a peculariar photopeak
energy value, i.e., for 99mTc it is 140 keV. If radionuclides diﬀerent than 99mTc are
used, a speciﬁc energy calibration procedure must be perfomed.
Figure 4.11 reports the summed calibrated energy spectrum for head 1 of the
scanner.
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Figure 4.9: Examples of energy correction coeﬃcients obtained ofr head 3 in PET mode.
Figure 4.10: Summed energy spectra for head 3 in PET mode.
4.2.3 Eﬃciency corrections
Eﬃciency calibrations are necessary to normalize the diﬀering responses of individual
crystals. The corrections are performed both in PET and SPECT modalities.
PET modality
In PET mode, the diﬀerences among crystals responses are mainly due to photo-
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Figure 4.11: Summed energy spectra for head 1 in SPECT mode.
catode nonuniformity and diﬀerent dimension of the crystals [111].
Even if less important than in SPECT modality, PET eﬃciency corrections are
essential in producing artefact-free images [112].
The eﬃciency corrections are applied LOR per LOR. The most straightforward
way to obtain a full set of normalization coeﬃcients is to perform an acquisition with
an uniformly ﬁlled planar source, where every possible LOR is illuminated by the
same coincidence source [112].
We employed the planar source and performed the acquisition described in section
4.2.1. For each angular view, only the events detected in that geometric conﬁguration
are considered. At the end of the acquisition two identical views, one for couple
of detectors, are obtained. After having corrected the data for the source decay
during one view and the other, it is possible to obtain the eﬃciency corrections. The
eﬃciency factor (εi,j) for the coincidence LOR between a given pair of detectors is then
estimated as the ratio between the number of coincidences measured in that LOR
during the planar acquisition (Ci,j), and the number of coincidences which would
have been measured if the sensitivities of the detectors were uniform. This latter
is estimated as the mean number of coincidences detected, averaged over all active
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LORs [113].
εi,j =
Ci,j∑
i,jCi,j
· 7292 (4.3)
where 729 is the number of YAP crystals in each detector matrix (see section 3.1).
The normalization factors (Pi,j) that are then used to correct the phantoms or
animals acquisitions are proportional to the inverse of the counts recorded in any
given LOR.
Pi,j =
1
εi,j
(4.4)
SPECT modality
In SPECT mode, the diﬀerent response of the crystals can be due to the following
issues:
• the crystal - collimator coupling, that can be more or less favourable in terms
of portion of the crystal covered by the collimator septum.
• nonuniformity of the photocatode.
• the diﬀerent dimension of the crystals.
As for the PET mode, the eﬃciency corrections were obtained by performing an
acquisition with an uniformly ﬁlled planar source. Four angular views over 3600 were
performed (see section 4.2.1) and for each view only the events detected in the head
at the right the planar source were considered. Four identical views, one for each
head, were obtained. After the correction for the source decay during the diﬀerent
views, it is possible to obtain the global correction coeﬃcients of the four heads.
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Chapter 5
Performance evaluation
To objectively compare the performance of diﬀerent emission scanners (PET or
SPECT) guidelines must be developed on how certain parameters (such as spatial
resolution and sensitivity) should be evaluated and presented. National Electric Man-
ufacturers Association (NEMA) is the organization that provides standardization
procedures. For clinical PET scanners, NEMA NU2-1994 [114] and the subsequent
NEMA NU2-2001 [115] are the reference documents. NEMA NU1-1994 [116] is the
reference standard for clinical SPECT scanners.
Since there is no overall accepted evaluation standard for small animal PET imag-
ing systems, the practice followed by several groups ( [117123]) consists of rescaling
the performance characteristics evaluation reported for clinical PET scanners [115].
Recently, NEMA has created a task force, Animal PET Scanner Standard Task
Force [124], in order to standardize the measurements to carry out the performance
evaluation of small animal PET scanners. The aim of this work ﬁnds its roots in
several motivations: the increasing number of dedicated small animal systems, the
growing interest in small animal PET scanners and the impossibility in applying a
part of clinical NEMA standards [125]. The latest version of the draft documents for
the task force working on the proposal for a new small animal PET standard to be
submitted to NEMA has been updated on June 22nd, 2007 [126].
In this chapter, the PET performance of the YAP-(S)PET scanner have been
evaluated following the standards proposed by the PET NEMA task force for small
animal scanners [127], [128]. Since the lack of small animal SPECT performance
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standardization, the SPECT performance of YAP-(S)PET scanner has been evaluated
by rescaling the clinical SPECT NEMA reference standards NU1-1994 [116].
For both PET and SPECT modalities, the performance were evaluated at diﬀerent
head-to-head distances (see section 3.1): in particularly 10, 12.5 and 15 cm.
5.1 PET modality performance
5.1.1 Spatial resolution
The reconstructed image spatial resolution for PET scanners can be nicely described
in terms of FWHM by the empirical formula of Moses and Derenzo [129]:
FWHM = a
√
(d/2)2 + b2 + r2 + (0.0022D)2 + p2 (5.1)
where d is the detector size, b the position decoding accuracy, r the positron range,
D the detector distance, used here to describe the annihilation photon non-collinearity
(0.5 D tan 0.250 = 0.0022 D), and p the parallax error.
The factor 1.1 < a < 1.3 depends on the algorithm used to reconstruct the image
and typically takes a value of 1.2 when using FBP with a ramp ﬁlter.
The ﬁrst two terms under the square root form what is referred to as the intrinsic
detector resolution consisting of the geometric and decoding resolution factors.
The positron range in tissue has an inverse cusp like distribution consisting of
a narrow spike and long exponential tails. Whereas the actual FWHM is very small
[130], the eﬀective FWHM taking into account the broadening due to the entire range
distribution (r=2.35 rms) provides a more realistic estimate of the image blurring
resulting from positron range. For 18F (one of the most common positron emitters)
the FWHM is 0.13 mm, while the eﬀective FWHM (r=2.35 rms) is 0.54 mm.
The contribution from non-collinearity to resolution is signiﬁcant (2.1 mm) in
clinical whole-body scanner having a diameter D≈80 cm, but is almost negligible (≤
0.33 mm) in a small animal scanner with D ≤ 15 cm.
Assuming that the positron range and annihilation photon non-collinearity can be
minimized by using radioisotopes with low energy positrons such as 18F and a small
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detector distance, the image resolution degradation would still amount to about 0.7
mm for a parallax error around zero. With reference to equation (5.1):
FWHM = a
√
(0.54)2 + (0.0022× 150)2 + p2 ≈ 0.7mm (5.2)
Since the parallax error can no completely be avoided, the achievable intrinsic
detector resolution will always exceed 0.7 mm.
Figure 5.1 [131] reports the eﬀects of non-collinearity and positron range as a
function of crystal size for several small animal scanners. It shows that the positioning
accuracy, and so the spatial resolution, scales down with the size of individual crystals.
On the basis of this assumption and on the results of performed simulation [132],
in the 27 × 27 version of the YAP-(S)PET scanner 3 (YAP-(S)PET II) the crystal
pitch was reduced from 2.0 down to 1.5 mm.
Figure 5.1: Intrinsic spatial resolution of several existing tomographs as a function of
detector size. Data have been labeled according to the type of position decoding scheme
used to identify the crystal of interaction [131].
In accordance with the NEMA Animal PET Scanner Standard Task Force draft
documents [126], the spatial resolution measurements have been performed by imag-
ing point sources in some scatter media, and then reconstructing images with no
smoothing or apodization. Although this does not represent the condition of imag-
ing a subject in which there is signiﬁcant tissue scatter, or where a limited number
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of acquired events require the use of a smooth reconstruction ﬁlter, the measured
spatial resolution provides a reproducible comparison among scanners, indicating the
highest achievable performance for a given mode of acquisition. The purpose of this
measurement is to characterize the widths of the reconstructed image point spread
functions (PSF) of compact radioactive sources. The width of the spread function is
deﬁned by its FWHM.
The spatial resolution was measured with a 22Na point-like source of 1 mm in
diameter, embedded in the geometrical center of a lucite support measuring 23.5 mm
× 11 mm and 2 mm in height (see ﬁgure 5.2). The activity of the source was 370 kBq
(10 µCi) on May 23rd 2001 (t1/2= 2.61 y). The average range of the 22Na positrons
in this support is similar to the average range of the 18F positrons in water because
both isotopes have similar average emission energy (E22Na = 216 keV, E18F = 250
keV). As a result, one can safely assume that the 22Na source size was dominated by
its physical dimensions.
Figure 5.2: Sketch of the 22Na point-like source used for spatial resolution and sensitivity
measurements. The source has been provided by Campo Verde srl.
Experimental procedure
The spatial resolution measurements were performed by ﬁxing the 22Na source
parallel to the axis of the YAP-(S)PET scanner, and located at the at various radial
oﬀsets along the x axis in the transaxial plane: 5, 10, 15 mm (see ﬁgure 5.6).
The measurements were repeated for 100, 125, 150 mm head-to-head distances.
The acquisitions were performed over 1800 with 128 views. At least four hundred
thousand counts have been acquired in each source positions and for each head-to-
head distance.
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Data analysis
The collected data were processed via 3-D MSRB sinograms (see section 3.3.3) and
then reconstructed with FBP algorithm with ramp ﬁlter with cut oﬀ at the Nyquist
frequency. A wide-open energy window 50-850 keV was used.
Three components of the spatial resolution were measured: the radial and tan-
gential in the transaxial plane, and the axial component along the axis of the scanner
(see ﬁgure 5.3). The spatial resolution of the point source response function (PSF)
in all three directions was determined by taking proﬁles through the image volume
in three orthogonal directions, through the peak of the distribution.
In order to measure the width of the PSF as accurately as can practically be
achieved, its FWHM should span at least ﬁve pixels (see NEMA proposal for small
animal PET scanners [126]). The pixel size should be made no more than one-ﬁfth
of the expected FWHM in the transverse dimensions during reconstruction. For this
reason, a matrix size of 128 × 128 pixels have been used for the transaxial cross-
section of the reconstructed image (0.38 mm for an expected resolution of about 2
mm).
Figure 5.3: Illustration of the radial, tangential and axial component of the measured
spatial resolution.
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Each FWHM was determined by linear interpolation between adjacent pixels at
half of the maximum value of the response function (see ﬁgure 5.4). The maximum
value was determined by a parabolic ﬁt using the peak point and its two nearest
neighboring points respectively. Values were then converted to distance in millimeters
by multiplication with the pixel size. The dimension of the source (1 mm in diameter)
was not subtracted from the obtained FWHM.
Figure 5.4: Plot of the point source response function (PSF) for the 22Na point source.
Results
Radial (RFWHM), tangential (TFWHM) and axial (AFWHM) FWHM resolutions are
reported in ﬁgure 5.5 for each radial source position in the FOV (5, 10 and 15 mm)
and for each head-to-head distance (100, 125 and 150 mm). The data are reported
in table 5.1.
Radial, tangential and axial spatial resolution have the same trend across the
FOV for all three head-to-head distances (ﬁgure 5.5 (a), (b) and (c)).
The radial spatial resolution shows a little improvement as the radial oﬀset in-
creases, while the tangetial spatial resolution increases slowly approaching the edge
of the FOV.
The axial resolution degrades as the source radial oﬀset exceeds 5 mm. This is
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due to the rebinning method (MSRB, see section 3.3.3) used during the sinograms
production.
As can be easily seen from the 15 mm radial oﬀset, the axial degradation is more
pronounced at shorter head-to head distance: 4.6 mm at 100 mm with respect to 3.9 at
150 mm. This trend can be explained by the wider acceptance angle (more signiﬁcant
parallax error) oﬀered by closer detectors conﬁguration. The parallax error, infact,
manifests itself as a degradation of the axial spatial resolution for oﬀ-center sources
because of obliquely incident gamma rays that can penetrate the crystals adjacent to
that of incidence, thus modifying the real LOR.
Head-to-head
Position (mm) RadialFWHM TangentialFWHM AxialFWHM
distance (mm)
100
0 2.13 2.31 1.92
5 2.00 2.43 2.48
10 1.82 2.81 3.63
15 1.81 3.00 4.63
125
0 2.04 2.32 1.87
5 1.93 2.21 2.30
10 1.81 2.54 3.44
15 1.74 2.71 4.39
150
0 1.96 2.18 1.87
5 2.08 2.10 2.17
10 1.77 2.31 3.03
15 1.91 2.45 3.92
Table 5.1: Image spatial resolution in radial, tangential and axial directions as a function
of the source radial position and the detectors distance. A 50-850 keV energy window was
used.
5.1.2 Sensitivity
The sensitivity of a positron emission tomograph is expressed as the rate (expressed
in counts per second) of true coincidence events detected for a given source strength.
Two diﬀerent protocols were followed to evaluate the absolute system sensitivity:
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Figure 5.5: Radial (RFWHM), tangential (TFWHM) and axial (AFWHM) FWHM resolutions
for each radial position of the 22Na point source in the FOV (5, 10 and 15 mm) and for each
head-to-head distance: (a) 100, (b) 125 and (c) 150 mm. A 50-850 keV energy window was
used.
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a-) the one described in the NEMA NU2-2001 [115] and rescaled for small animal
imaging that employs a 22Na point source;
b-) the procedure reported in the NEMA proposal for small animal PET scanners
[126], in which a tube ﬁlled with known amount of activity is placed inside a
series of sleeve with increasing thickness.
a-) 22Na point source
Experimental procedure
We used the same 22Na point source employed for the spatial resolution measure-
ment (activity source 370 kBq  10 µCi  on May 23rd 2001, t1/2= 2.61 y).
Although 22Na has an additional 1275 keV gamma ray emission, the eﬀect on the
sensitivity measurement is in the percentage order. In fact, at the center of the FOV,
even considering that the detection eﬃciency of a 1275 keV gamma ray is the same as
for the 511 keV, and using no energy discrimination, the relative probability of such
a false coincidence (i.e., P(1275/511)/P(511/511)) is less than 1.5% [120].
The transaxial sensitivity was characterized by positioning the 22Na point source
at various radial oﬀsets along the x and y axis: 5, 10, 15 and 20 mm.
The axial sensitivity was evaluated for the source placed at the center of the FOV
and at 5, 10, 15 and 20 mm of axial oﬀset (see ﬁgure 5.6).
Both the axial and transaxial sensitivity measurements were performed for 100,
125, 150 mm head-to-head distances.
The acquisitions were performed over 1800 with 128 views. At least hundred
and half thousand counts have been acquired in each source positions and for each
head-to-head distance.
To better investigate the sensitivity trend towards the head-to-head distance, we
performed several acquisitions at various head-to-head distances (ranging from 100
to 150 mm at ﬁne steps) with the source place at the center of the FOV.
Data analysis
The number of detected coincidences (Cj) and the acquisition time (Tacq,j) were
registered for source position and for each head-to-head distance in order to obtain
the counting rate (Rj) in counts per second (cps).
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Figure 5.6: Illustration of the positioning of the 22Na point source to measure the absolute
system sensitivity using a rescaled version of the protocol described in in the NEMA NU2-
2001 [115].
Rj =
Cj
Tacq,j
(5.3)
Cj and Tacq,j were obtained by the ﬁnal row of the column Used% and Dt(s)
of the YAP-(S)PET log ﬁle, respectively (see section 3.3.3).
A wide-open energy window 50-850 keV was used and the measured random counts
(ﬁnal row of the column Casual% the YAP-(S)PET log ﬁle (see section 3.3.3)) were
subtracted from the data.
Results
The transaxial and axial sensitivity at diﬀerent position in the FOV for 100, 125
and 150 mm head-to-head distances are reported in ﬁgure 5.7. The data are reported
in table 5.2.
The transaxial sensitivity shows approximatively the same trend for both x and y
FOV axis source position. Only towards the edge of the FOV (radial oﬀset 20 mm)
the y component is slightly better that the x one for 100 and 125 mm head-to-head
distances. Due to rotation invariance the x and y radial distance should show exactly
the same trend. The small diﬀerence at the edge of the FOV for closer detectors
distance can be explained with a major scatter contribution along the x component
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FOV axis Source position (mm) Head-to-head distance (mm)
100 125 150
0 2.94 2.02 1.49
x
5 2.68 1.93 1.33
10 2.23 1.53 1.11
15 1.77 1.20 0.86
20 1.33 0.90 0.65
y
5 2.71 1.86 1.35
10 2.25 1.54 1.12
15 1.79 1.22 0.89
20 1.61 1.08 0.64
z
5 2.27 1.54 1.11
10 1.61 1.05 0.75
15 0.86 0.55 0.38
20 0.26 0.14 0.09
Table 5.2: Sensitivity values (%) for each radial and tangential position of the 22Na point
source in the FOV (5, 10, 15 and 20 mm) and for each head-to-head distance: 100, 125 and
150 mm. A 50-850 keV energy window was used.
due to the source shape (see ﬁgure 5.2), i.e., a parallelepiped.
Both transaxial and axial sensitivity have a maximum at the center of the FOV
(CFOV) and decrease moving towards the edge of the FOV. For the axial sensitiv-
ity the decrease is almost linear in accordance with the triangular shape typical of
sensitivity proﬁle in the axial direction of the 3-D PET acquisition [95]. At the axial
extreme of the FOV, the sensitivity is equivalent to the 2-D data acquisitions.
The maximum sensitivity value is 2.94% (29.4 cps/kBq or 1088 cps/µCi), reg-
istered at the CFOV for the closest head-to-head distance (100 mm). The CFOV
sensitivity decreases down to 1.5% (about 50%) at the largest distance (150 mm).
In ﬁgure 5.8 the sensitivity at the center of the FOV is reported as a function of
the head-to-head distance. Due to the reduced solid angle coverage, the sensitivity
decreases by raising the detectors separation.
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Figure 5.7: Sensitivity values (cps/Bq)% for each radial and tangential position of the 22Na
point source in the FOV (5, 10, 15 and 20 mm) and for each head-to-head distance: (a) 100,
(b) 125 and (c) 150 mm. A 50-850 keV energy window was used.
5.1. PET modality performance 87
Figure 5.8: Sensitivity values (%) at the center of the FOV as a function of the head-to-head
distance. A 50-850 keV energy window was used.
b-) Linear source and NEMA phantom
Experimental procedure
Since the emitted positrons annihilate in matter, to create pairs of gamma rays a
signiﬁcant amount of material must surround the linear source to ensure annihilation.
This surrounding material also attenuates the gamma rays, so it is not possible to
measure sensitivity without interference from attenuation. To obtain at an attenua-
tion free measurement, successive measurements are made with a uniform line source
surrounded by known absorbers. From these measurements, the sensitivity with no
absorber can be extrapolated. This measurement technique is based on the work
described in [133].
The test equipment required for this measurement is the sensitivity phantom (see
ﬁgure 5.9) elaborated by the Animal PET Scanner Standard Task Force [124]. The
actual sizes and thicknesses of the metal tubes are not critical, nor is the material,
but the wall thicknesses must be known precisely, and all tubes must be made of the
same material. As reporter in the NEMA proposal [126], we used metal tube of 2.5
mm thickness each. The dimension of the inner and outer diameter are reported in
table 5.3.
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Tube number Inside Diameter (mm) Outside Diameter (mm)
1 3.9 6.4
2 7.0 9.5
3 10.2 12.7
4 13.4 15.9
5 16.6 19.1
Table 5.3: Inside and Outside diameter of the diﬀerent metal tubes of the sensitivity
phantom described in the NEMA proposal for small animal PET scanners [126].
Figure 5.9: Sketch of the sensitivity phantom used for the sensitivity evaluation described
in NEMA proposal for small animal PET scanners [126].
A linear source in a plastic tube ﬁlled with about 13 MBq ( 350 µCi) of 18F was
placed inside the smallest of the metal tubes described in table 5.3, and the whole
system was suspended in the center of the transaxial ﬁeld of view, aligned with the
axis of the scanner. The counting rate was measured in this position, and then the
other metal tubes were added, one at a time, and the counting rate measured for
each set of metal tubes.
The acquisitions were performed over 1800 with 128 views and repeated for 100,
125, 150 mm head-to-head distances.
The amount of radioactivity used is low enough so that the counting losses are
less than one percent and the random event rate due to the test source activity is less
than 5% of the trues rate. At least 8 Mevents were acquired in each source positions
and for each head-to-head distance.
Data analysis
The number of coincidences detected (Cj) and the acquisition time (Tacq,j) were
registered for each sleeve and for each head-to-head distance, in order to obtain the
counting rate (Rj) in counts per second (cps).
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Rj =
Cj
Tacq,j
(5.4)
The measured random counts were subtracted from the data.
The initial radioactivity at the beginning T0 of an acquisition was found using the
activity Acal as recorded in the dose calibrator at time Tcal according to the following
equation:
A0 = Acal exp
(
Tcal − T0
T1/2
ln2
)
(5.5)
where T1/2 is the half-life of the radioisotope (109.8 min for 18F).
The average radioactivity for a particular acquisition (Aave) was found using the
activity A0 at the beginning of the acquisition (5.5), the half-life of the radionuclide
T1/2 and the duration of the acquisition Tacq, according to the equation:
Aave =
A0
ln2
(
T1/2
Tacq
){
1− exp
(−Tacq
T1/2
ln2
)}
(5.6)
The activity presents in the FOV was calculated with the relation:
AFOV =
Aave
L
∗DFOV (5.7)
where L is the length of the plastic tube ﬁlled with 18F (in our case about 5 mm)
and DFOV is the dimension of the FOV expressed in cm, i.e., 4 cm for the YAP-(S)PET
scanner (see chapter 3).
Results
The system sensitivity (Sj) was evaluated as the ratio between the counting rate
Rj (5.4) and the activity in the FOV, AFOV (5.7).
Sj =
Rj
AFOV
(5.8)
For each head-to-head distance, a graph of the system sensitivity Sj versus the
accumulated sleeve wall thickness used in the measurement j (Xj) were produced (see
ﬁgure 5.10.
The sensitivity with no attenuation was extrapolated by ﬁtting the data with the
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Figure 5.10: Sensitivity values (cps/kBq) as a function of the accumulated sleeves of the
metal tubes of the sensitivity NEMA phantom [126]. The sensitivity was evaluated for (a)
100, 125 and (c) 150 mm head-to-head distance. The y values are represented in log scale.
A 50-850 keV energy window was used.
following equation:
Sj = S0 exp (−2 · µ · Xj) (5.9)
where the unknowns are the attenuation coeﬃcient µ and the sensitivity with no
attenuation S0.
To simplify the ﬁt, we reported log (Sj) vs. Xj and used a linear ﬁt to determine
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S0.
The S0 values obtained for diﬀerent head-to-head distance are reported in table
5.4.
As expected, the sensitivity increase as the head-to-head distance is reduced. It
is due to the greater solid angle covered by the detectors when the heads are nearer.
The diﬀerence between the sensitivity at 150 mm and 100 mm is greater than 50%,
increasing from 0.7% to 1.7%.
Head-to-head S0
distance (mm) (cps/kBq)
100 17.0
125 12.5
150 7.0
Table 5.4: Sensitivity values (cps/kBq) at the center of the FOV for diﬀerent head-to-head
distance (100, 125 and 150 mm) evaluated according the the procedure reported in the
NEMA proposal for small animal PET scanners [126]. A 50-850 keV energy window was
used.
5.1.3 Scatter fraction
The scatter fraction is a measure of the contamination of the data from scattered
photons.
The scattering of the gamma rays emitted by the annihilation of positrons within
the object before being detected results in wrong located coincidence events.
The scatter fraction (SF) is deﬁned as the dimensionless ratio of scattered co-
incidence events to the total events (sum of scattered and true coincidence events)
measured at low count rate to minimize random coincidences and dead time.
The phantoms suggested by the NEMA Animal PET Scanner Standard Task
Force [124] for SF have sizes related to typical animals used in the laboratory.
The YAP-(S)PET is a scanner dedicated to the imaging of small animals, partic-
ularly rats and mice. In the SF measurements, we concentrate on the evaluation of
SF for the mouse-like phantom.
The mouse-like phantom (see ﬁgure 5.12) is made of a solid right circular cylinder
composed of high density polyethylene (density 0.96 g/cm3) 7 cm long and 2.5 cm of
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diameter. A cylindrical hole (3.2 mm diameter) is drilled parallel to the central axis
at the radial distance of 1 cm.
The test phantom line source insert is a clear ﬂexible tubing with a ﬁllable section
1 cm shorter than the cylindrical phantom with an inner diameter of 2.1 mm and an
outside diameter of 4.2 mm. Once ﬁlled with a known quantity of activity, the linear
source is threaded through the hole in the mouse-like phantom.
Figure 5.11: Photos of the NEMA mouse-like phantom [126] used for scatter fraction and
NEC measurements.
Experimental procedure
A line source of 5 cm ﬁlled with about 600 kBq (∼ 16 µCi) of 18F was inserted
in the cylindrical hole of the mouse-like phantom such that the region of activity
coincides with the central 5 cm length of the phantom. The phantom was then
centered in the transverse and axial plane of the FOV, but rotated so that the line
source insert was positioned nearest to the animal bed (see ﬁgure 5.11).
The acquisitions were performed over 640 with 128 views and repeated for 100,
125, 150 mm head-to-head distances. A wide-open energy window 50-850 keV was
used.
The amount of radioactivity was chosen low enough to guarantee a random rates
less than 1% of true rate. In this case, the contribution of random events can be
considered negligible, and the total events can be assumed to consist only of true and
scattered counts. At least eight hundred counts were acquired for each head-to-head
distance.
Data analysis
The collected data were sorted in 3-D MSRB sinograms (see section 3.3.3). A
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Figure 5.12: Sketch of the positiong of the mouse-phantom used for scatter fraction and
NEC measurements.
wide-open energy window 50-850 keV was used.
All pixels in the sinogram located farther than 8 mm from the edges of the phan-
tom were set to zero. In other words, only the data within a band 1.6 cm wider than
the phantom were kept in the analysis. Since the FOV of the YAP-(S)PET scanner
spans over 4 cm in both axial and transaxial dimensions, we did not discard any data.
For each projection angle a within the sinogram, (i.e. 148 for no angular rebinning
sinograms for a head-to-head distance of 12.5 cm) (see section 3.3.3), the location of
the center of the line source response was determined by ﬁnding the pixel having
the greatest value. Each projection was shifted so that the pixel containing the
maximum value was aligned with the central pixel of the sinogram. After alignment,
a sum projection was produced so that a pixel in the sum projection was the sum of
the pixels in each angular projection having the same radial oﬀset as the pixel in the
sum projection.
C(r) =
∑
a
C(r − rmax(a)), φ) (5.10)
where
 r is the number of bin in a projection. We have chosen a number of projection
bins double of the number of spatial bins in the sinogram (53, see chapter 4).
 φ is the angular bin in the sinogram (i.e. 148 for no angular rebinning sinograms
for a head-to-head distance of 12.5 cm) (see section 3.3.3).
 rmax(a) refers to the location of the maximum value in projection φ.
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The counts CL and CR, the left and right pixel intensities at the edges of a 14
mm wide strip at the center of the sinogram, are obtained from the sum projection
(see ﬁgure 5.13). Linear interpolation was employed to ﬁnd the pixel intensities at
± 7 mm from the central pixel of the projection. Referring to ﬁgure 5.13), the 14
mm wide strip spans from bin 45 to bin 63 for a total of 19 bins. The counts CL
are obtained by summing all pixels from bin zero up to bin 44. The counts CR are
obtained by summing all pixels from bin 64 up to bin 106. The average of the two
pixel intensities CL and CR was multiplied by the number of pixels between the edges
of the 14 mm wide strip, and the product added to the counts in the pixels outside
the strip, to yield the number of random plus scatter counts Cr+s (area highlighted
in yellow in ﬁgure 5.13).
Cr+s = counts CL+counts CR+(counts at bin 45 + counts CR + (counts at bin 63)·19/2)
(5.11)
The total event count CTOT is the sum of all pixels in the sum projection (yellow
and red areas in ﬁgure 5.13).
The average activity Aave during the acquisition was calculated with equation
(5.6).
Since we performed an acquisition in which the contribution of random events can
be considered negligible (less that 1% of true rates), it is assumed that Cr+s has a
negligible number of random counts and consists only of scatter counts, and likewise,
CTOT consists only of true and scatter counts.
The system scatter fraction SF is then computed as the ratio of Cr+s to CTOT.
SF =
Cr+s
CTOT
(5.12)
Results
The SF values obtained for the mouse-sized phantom for diﬀerent head-to-head
distances are reported in table 5.5.
As expected, the SF is higher for closer head-to-head conﬁguration (100 mm) due
to greater solid angle covered by the detectors.
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Figure 5.13: Aligned and summed projections of the sinograms produced by the scatter
fraction acquisition. The scatter events (yellow) are estimated by ﬁtting the projection tails
up to ± 7 mm from the center of the summed projection proﬁle. A 50-850 keV energy
window was used.
Head-to-head SF (%)distance (mm)
100 27
125 24
150 22
Table 5.5: Scatter fraction values (%) for diﬀerent head-to-head distances: 100, 125 and
150 mm. A 50-850 keV energy window was used.
It is important to note that the SF takes into account the scattering events oc-
curred both in object and detectors.
In order to evaluate the scatter in the object, it would be necessary to perform the
scatter fraction measurement by a dual-acquisition method [134, 135]. This method
consists in performing an acquisition with the line source inserted in the phantom and
an acquisition with the same line source suspended in air. The diﬀerence between the
scatter fraction in the phantom and the scatter fraction in air provides the scatter in
the object.
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In [135], it is shown that for a Lucite phantom of 4 cm in diameter and 4 cm in
length with a 18F line source inserted in a 2 mm hole drilled along its axial direction
at its center, the scatter fraction is 33%. The scatter fraction of the line source alone
is 26%. Then, the scatter contribution due to the Lucite phantom is only 7% and the
scatter fraction of the line source alone (26%) gives an estimate of the scatter due to
the scanner geometry and to the multiple interaction within the crystals.
At present time, no scatter correction is performed on the YAP-(S)PET data, but
in the multi-Ray 3-D PET reconstruction tool under evaluation (see section 3.3.4)
the crystal scatter is taken into account by means of Monte Carlo simulations [104].
5.1.4 Count rate performance
The measurements of count losses and random rates express the ability of a positron
emission tomograph to measure highly radioactive sources with accuracy.
Noise equivalent count (NEC) rate, which incorporates the noise eﬀects of sub-
tracting the randoms and scatter count components, provide a direct link between
image signal-to-noise ratio and the scatter, randoms and trues coincidence count
rates [136]. The measurements of noise equivalent count rates is based on the work
described in [136].
The purpose of these measurements is to evaluate the eﬀects of system dead-time
and the generation of random events at several levels of source activity.
Experimental procedure
We employed the same phantom used for SF measurements (see section 5.1.3).
The line source of 5 cm was now ﬁlled with about 150 MBq (∼ 4 mCi) of 18F
and inserted in the cylindrical hole of the mouse-like phantom such that the region
of activity coincides with the central 5 cm length of the phantom.
The acquisitions were performed over 1800 with 64 views and repeated for 100,
125, 150 mm head-to-head distances. A wide-open energy window 50-850 keV was
used.
The amount of radioactivity was chosen high enough in order to provide apprecia-
ble scanner dead time. Regular measurements were then taken while the activity in
the phantom decays over several half-lives. Overall, 23 acquisitions were performed.
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Data were acquired at intervals more frequent than half the radionuclide half-life
T1/2. The durations of the individual acquisitions, Tacq,j, was less than one fourth of
T1/2. At least eight hundred counts were acquired for each head-to-head distance.
A decrease in the ratio of the random event rate to the true event rate accompanies
the activity decay, till the random rates are less than 1% of true rates.
Data analysis
For each acquisition j the noise equivalent count rate RNEC,j is computed as fol-
lows:
RNEC,j =
R2t,j
RTOT,j
(5.13)
where Rt,j, Rs,j and Rr,j are the true, the scattering and the randoms event rate
of the j-th acquisition, respectively.
The various rates were calculated with the following equations:
Total event rate: RTOT,j =
CTOT,j
Tacq,j
True event rate: Rt,j = RTOT · (1− SF)
Random event rate: Rr,j = RTOT − Rt,j
(1− SF)
Scatter event rate: Rs,j = Rt,j · SF
(1− SF)
CTOT,j and Tacq,j were obtained by the ﬁnal row of the column Used% and
Dt(s) of the YAP-(S)PET log ﬁle, respectively (see section 3.3.3).
In the other rates equation, SF is the scatter fraction value as obtained with
equation 5.12.
The previous rates were evaluated for each of the 23 acquisitions performed. It was
thus possible to study the noise equivalent count rate, true, random, scatter and total
event count rate as a function of average eﬀective radioactivity concentration in the
FOV. The activity in the FOV was evaluated with equation 5.7. The concentration
was obtained by dividing AFOV by the volume V of phantom used (see ﬁgure 5.11).
For the cylindrical mouse-like phantom the volume is 34.36 cm3.
98 Chapter 5. Performance evaluation
A wide-open energy window 50-850 keV was used.
Results
Figure 5.14 reports total (RTOT), random (Rr), true (Rt), scatter (Rs) and noise
equivalent count rate (RNEC) as a function of the average eﬀective radioctivity con-
centration in the FOV.
The total, true, scatter and NEC count rate present the same trend for all the
head-to-head distances. An initial approximately linear increase increasing with ac-
tivity that leads to the peak of the count rate and the subsequent slow count rate
decrease for higher activity, when saturation eﬀects occur.
As can clearly be seen from ﬁgure 5.14 (a),(b) and (c), the activity at which true
and NEC count rate reach the peak increases with increasing head-to-head distance.
This eﬀect is mainly determined by the reduced sensitivity due to the reduced solid
angle coverage with raising detectors separation (see section 5.1.2). Table 5.6 reports
the Rt and RNEC peak values and the activity concentration at which they are reached
for 100, 125 and 150 mm head-to-head distance. For both true and NEC count rate,
the peak is higher and is reached at lower activity concentration for closer detectors
conﬁguration. This is in agreement with the increase in sensitivity and coincidence
rate at closer head-to-head distance.
The NEC trend for 100, 125 and 150 mm head-to-head distance is best highlighted
in ﬁgure 5.15. Moving from 100 to 150 mm head-to-head distance the RNEC peak pass
from 38.4 kcps at 370 kBq/ml (∼ 400 µCi or 11 MBq in the phantom) to 39.4 kcps at
730 kBq/ml (∼ 900 µCi or 24 MBq in the phantom). These data are important for
in vivo studies, since the NEC peak gives indication about the maximum injectable
activity for good working conditions.
For each head-to-head distance, the random contribution presents a three phases
trend throughout the activity concentration span. A signiﬁcant increase with increas-
ing activity up to an activity concentration a bit higher that the value at which Rt
and RNEC peaks occur, a sort of plateau and a slow decrease at higher activity due to
saturation eﬀects. For 150 mm head-to-head distance the decrease at higher activity
is slower with respect to 100 mm distance because of a reduced eﬀect of saturation.
For 100 mm head-to-head distance, the scatter peak reaches a higher value (23
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kcps at 370 kBq/ml) with respect to 150 mm (17 kcps at 730 kBq/ml) due the greater
solid angle covered by the detectors.
Head-to-head Peak (kcps) @ activity
distance (mm) concentration (kBq/mL)
100 Rt = 60.5 @ 370RNEC = 38.4 @ 370
125 Rt = 58.8 @ 530RNEC = 39.0 @ 430
150 Rt = 59.0 @ 730RNEC = 39.2 @ 730
Table 5.6: The Rt and RNEC peak values and the activity concentration at which they are
reached for 100, 125 and 150 mm head-to-head distance. A 50-850 keV energy window was
used.
5.1.5 Partial volume eﬀect
One of the main diﬃculties in the ROI (Region Of Interest) or VOI (Volume Of Inter-
est) analysis in in vivo studies 7 is to accurately determine the activity concentration
in regions or volumes of dimensions comparable with the resolution of PET scanner.
This is of particular importance in the quantitative characterization of small lesions
or structures.
Due to PET systems ﬁnite spatial resolution, the radiation emitted from inﬁnitely
small point source will be smeared out and will appear as a ﬁnite-size blob in the
reconstructed image. This is known as the partial volume eﬀect, (PVE) [137].
This eﬀect occurs for structures that have dimensions of about 2 × FWHM the spatial
resolution of the scanner or smaller. Since the spatial resolution of the YAP-(S)PET
scanner is about 2 mm (see section 5.1.1), the radioactivity presents in objects with
dimensions of 4 mm or smaller will be underestimated. The degree of underestimation
is a function of both object size and system reconstructed image resolution, and
is characterized by the recovery coeﬃcient (RC) deﬁned as the ratio between the
measured and the true activity concentration in the ROI:
RC =
Measured peak activity concentration
True activity concentration
(5.14)
If the recovery coeﬃcient can be determined, it is possible to correct reconstructed
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Figure 5.14: Total (RTOT), random (Rr), true (Rt), scatter (Rs) and noise equivalent count
rate (RNEC) as a function of the average eﬀective radioctivity concentration in the FOV.
The measurements are reported for diﬀerent head-to-head distances: (a) 100 mm, (b) 125
mm and (c) 150 mm. A 50-850 keV energy window was used.
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Figure 5.15: The NEC trend measured for the mouse-like phantom at 100, 125 and 150
mm head-to-head distance. A 50-850 keV energy window was used.
images for partial volume eﬀects.
Experimental procedure
To evaluate the RC for diﬀerent dimensions object size, we used the Image Quality
(IQ) phantom described in [126] for image quality evaluations (see section 5.1.7). In
fact, due to the physical limitations in producing hot spheres in non-zero background
with physical walls much smaller than the spatial resolution of the imaging systems,
we used the ﬁllable rods of diﬀerent diameters in cold solid background of the IQ
phantom (see ﬁgure 5.19).
The rods have radii of 1, 2, 3, 4 and 5 mm and were ﬁlled with the same activity
concentration, about 7.5 µCi/mL (0.20 MBq/mL) of 18F. A wide-open energy window
50-850 keV was used and FBP reconstruction with ramp ﬁlter with cut oﬀ at the
Nyquist frequency was used.
Data analysis
The recovery coeﬃcients were calculated by considering, for each rod, the maxi-
mum value or the mean value of a ROI having the same size of the physical dimensions
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of the rod. The RC are then reported as a function of the rod size.
Results
The RC curve for 100 and 125 mm head-to-head distances are reported in ﬁgure
5.16. In panel (b) the recovery coeﬃcient calculated as the maximum value (red
circles) and the mean value of a ROI having the same size of the physical dimensions
of the rod (black squares) are represented.
For 4 mm rod, that is object size about ' 2 × FWHM the spatial resolution of
the scanner, the activity concentration underestimation is about 20% for 100 head-
to-head distances and less than 15% for 125 mm. The better quantiﬁcation at wider
detectors distance is due to lower acceptance angle, thus less parallax error and better
spatial resolution (see section 5.1.1).
The comparison of the RC curves for maximum or mean value of a ROI having the
same size of the physical dimensions of the rod (see panel (b) of ﬁgure 5.16) highlight
that if the size of region is identical to the object size, the underestimation of activity
concentration is increased. Particularly, the rods with diameters of 2, 3 and 4 mm
shows a quantiﬁcation error about 40% greater when considering the mean value of
the ROI.
5.1.6 Attenuation corrections
At 511 keV, a relatively high probability exists that one or both annihilation photons
will interact in the subject, predominantly through Compton interactions. The results
of these interactions are the removal or attenuation of primarly photons from a given
LOR and the potential detection of scattered photons in a diﬀerent LOR.
The erroneous identiﬁcation of the LOR degrades the spatial resolution and makes
more diﬃcult the quantitive evaluation. Thus, attenuation corrections methods have
been developed.
Correction means correcting each LOR for the fraction of events that were atten-
uated from that LOR.
Attenuation of the signal from a given LOR can be corrected either by a direct
measurement or using a mathematical model or a combination of the two.
At present time, no attenuation correction is performed on the YAP-(S)PET data,
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Figure 5.16: (a) Calculated recovery coeﬃcients for the 1, 2, 3, 4 and 5 mm rods of the
NEMA Image Quality phantom [126] and for 100 mm head-to-head distance. (b) Eﬀect of
the region of interest dimensions on Recovery Coeﬃcient calculated for 1, 2, 3 and 4 rods
of the NEMA Image Quality phantom [126], for 125 mm head-to-head distance. A 50-850
keV energy window was used.
but in the multi-Ray 3-D PET reconstruction tool under evaluation (see section 3.3.4)
a mathematical model for the attenutation corrections has been implemented. The
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model assumes that the outline of the object being imaged can be approximated with
a geometrical shape as a cilinder. Furthermore, the attenuation coeﬃcient within this
object is assumed to be constant.
Considering a circular section of the cilinder and a point source located at an
unknown depth x (see ﬁgure 5.17), if D is the diameter, the probability that the
annihilation photon 1 will escape the object is:
p1 =
I(x)
I(0)
= exp(−µ · x) (5.15)
In the same way, the probability that annihilation photon 2 will escape is:
p2 =
I(D− x)
I(0)
= exp(−µ · (D− x)) (5.16)
The probability that both annihilation photons will escape the object is the prod-
uct of the individual probabilities:
p1 · p2 = exp(−µ · x) · exp(−µ · (D− x)) = exp(−µ ·D) (5.17)
The attenuation correction factors, cij, that need to be applied to the emission
data for the LOR joining two coincidence detectors ij is the reciprocal of the combined
probability:
cij = exp(µ ·Dij). (5.18)
The coeﬃcients cij applied in the standard ML-EM algorithm used in the multi-
Ray 3-D PET reconstruction is a moltiplication coeﬃcients in equation 3.7):
ak+1i =
aki∑
j cij ·Mi,j
∑
j
Mi,j · sj∑
iMi,j · aki
(5.19)
The attenuation correction method implemented in the multi-Ray 3-D PET re-
construction can in principle be applied to previous data. It is then necessary to ﬁt a
circle to the outline of the subject imaged on each individual transaxial slice. From
these circle, the attenutation corrections are calcualted and applied to the raw data,
which are reconstructed again. However, due to the approximation of the shape of
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the object and the assumption of a uniform coeﬃcient, the method tends to under-
estimate the attenutation.
In order to estiamte the entity of attenuation inside the rat brain, we have cal-
culated the attenuation correction of photons of 511 keV produced inside a circular
water object with a diameter of 3 cm. The mass attenuation coeﬃcient µ/ρ for 511
keV photons in water is 0.0958 cm2/g, with water density ρ= 1 g/cm3. So the com-
bined probability p1 · p2 is about 0.75, that indicate that attenuation eﬀects decrease
the intensity of emitted radiation of about 25%.
Figure 5.17: Sketch of a transaxial section of the uniform cilinder employed in the mathe-
matical model used for attenuation corrections.
5.1.7 Phantoms studies
Three phantoms were imaged to test the imaging capability of the YAP-(S)PET
scanner in PET modality:
a-) a miniature version of a Derenzo-like phantom ( [138]).
b-) the Image Quality proposed by the Animal PET Scanner Standard Task Force
[124] for image quality evaluations.
c-) the mini Defrise phantom.
a-) The mini Derenzo-like phantom is a hot-rods phantom. It is a solid plexiglas
cylinder 38 mm in diameter and 37 mm in height, divided in sectors of rods with the
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same diameter (see ﬁgure 5.18). The phantom used has 5 sectors with rods diameters
of 3.0, 2.5, 2.0, 1.5 and 1.2 mm, respectively. The center-to-center distance between
adjacent rods is twice the rod diameter.
Figure 5.18: Top and full body photos of the Derenzo-like phantom.
b-) The Image Quality is a plexiglas cylinder (see ﬁgure 5.19). It consists of three
parts:
• a main ﬁllable chamber with 30 mm diameter and 30 mm in length in the
central part.
• a lid that is attached to the large uniform region of the phantom, containing two
cold region chambers. The chambers are composed of hollow ﬁllable cylinders
15 mm in length and 8 mm of internal diameter (10 mm external diameter and
1 mm wall thickness).
• a 20 mm solid ﬁnal part with 5 ﬁllable rods drilled through (at 7 mm from the
center) with radii of 1, 2, 3, 4, and 5 mm.
c-) The Defrise phantom is a hot/cold disks phantom. Is is a hollow plexiglas
cylinder of 38 mm in diameter and 38 mm in height containing 5 plexiglas disk with
3 mm thickness (see ﬁgure 5.20). Once ﬁlled with radioactive solution, it presents
alternate cold (plexiglass disks) and hot regions.
Experimental procedure
All the phantoms were ﬁlled with a solution of 18F.
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Figure 5.19: Sketch and photo of the Image Quality NEMA phantom [126].
Figure 5.20: Sketch and photo of the Defrise phantom.
Since the spatial resolution performance are comparable at 100, 125 and 150 mm
(see section 5.1.1), while the sensitivity decreases with incresing head-to-head distance
(see section 5.1.2), the phantom studies were performed only at 100 and 125 mm.
The evaluation performance results highlighted that the best compromise between
spatial resolution and sensitivity is obtained whit a head-to-head distance of 100
cm. Due to reduced working space at 100, the best compromise between scanner
performance and animal experiments is to ﬁx the head-to-head distance at 100 mm
for mice studies and 125 mm for rats studies.
a-) The Derenzo phantom was ﬁlled with about 8 MBq (∼ 300 µCi) of 18F and
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placed at the center of the FOV with the rods axis parallel to the scanner
axis. A 128 views over 1800 acquisition was performed for 100 and 125 mm
head-to-head distances. About 120 Mevents were acquired.
b-) The Image Quality was ﬁlled with about 16 MBq (∼ 600 µCi) of 18F and placed
in the FOV such that its main axis is aligned with the longitudinal axis of the
tomograph. A preset time acquisition of 40 minutes over 1800 with 128 views
was performed for 100 and 125 mm head-to-head distances.
c-) The mini Defrise phantom was ﬁlled with about 11 MBq (∼ 600 µCi) of 18F,
centered in the transverse FOV and oriented along the body axis of the scanner.
A 128 views over 1800 acquisition was performed for 100 and 125 mm head-to-
head distances. About 1 Gevents were acquired.
Data analysis
The collected data were processed via 3-D MSRB sinograms (see section 3.3.3) and
then reconstructed with FBP algorithm (with ramp ﬁlter with cut oﬀ at the Nyquist
frequency) or EM algorithm. A 128 × 128 reconstructed image matrix was chosen
(pixel dimension 1.5 mm/4, about 0.38 mm). In the axial dimension the sampling
step was 1.5 mm (27 slices) for Derenzo and Image Quality phantom and 0.75 mm
(53 slices) for the Defrise phantom. The thinner sampling in the axial direction for
the Defrise phantom was chosen to better evaluate the YAP-(S)PET axial spatial
resolution. A wide-open energy window 50-850 keV was used.
Results
a-) Figure 5.21 shows the FBP (ramp ﬁlter at the Nyquist frequency) recon-
structed transaxial section of the Derenzo phantom for 100 and 125 head-to-head
distances. The slice thickness is 19.5 mm (13 slices summed). The 1.5 mm hot rods
can be distinguished for both head-to-head distances, while the 1.2 mm rods start to
be resolved only for wider detectors distance.
Figure 5.22 reports the transaxial section of the Derenzo phantom for four central
slices (a) and for 13 summed slices (b) obtained with EM reconstruction algorithm.
The proﬁle of the last series of 1.5 mm and 1.2 mm rods are also reported.
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Figure 5.21: Transaxial sections of the Derenzo-like pahtnom for 100 and 125 mm head-to-
head distances. FBP reconstruction algorithm with ramp ﬁlter with cut oﬀ at the Nyquist
frequency was used.
b-) Figure 5.23 reports the FBP (ramp ﬁlter at the Nyquist frequency) transaxial
section of the 5 ﬁllable rods and the two cold region chambers, in addition to a coronal
section of 4 cm portion centered on the uniform region. Due to partial volume eﬀects
(see section 5.1.5), the 1 mm radii hot rod is not resolvable neither for 100 nor 125 mm
head-to-head distance, and the 3 and 4 mm rods show a lower activity concentration.
In ﬁgure 5.24 coronal and transaxial sections of the Image Quality phantom ac-
quired at 100 head-to-head distance and reconstructed with EM algorithm are re-
ported. The 1 mm radii hot rod is barely distinguishable.
c-) In ﬁgure 5.25 two coronal sections of the Defrise phantom for 100 and 125 mm
head-to-head distance are represented. The slice thickness is about 4 mm (5 slices
summed, 0.75 mm each). Due to the lower axial degradation for wider detectors
distance (5.1.1), the alternate cold and hot regions is better deﬁned for 125 head-to-
head distance.
5.2 SPECT modality performance
5.2.1 Spatial resolution
As for PET systems, the spatial resolution is commonly quantiﬁed from the FWHM
of point or line spread response function. It depends on the intrinsic capabilities of
the scintillation detectors, the geometrical properties of the collimator, the scattered
radiation and the septal penetration [2]. In terms of the FWHM of the point spread
function (PSF) or Line Spread Function(LSF), the most important factors are the
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Figure 5.22: Transaxial section of the Derenzo-like phantom for four central slices (a) and
for 13 summed slices (b) obtained with EM reconstruction algorithm. The proﬁle of the
last series of 1.5 mm and 1.2 mm rods are also reported. The measurements have been
performed at 100 mm head-to-head distance.
intrinsic resolution Rint of the detector and electronics, and the collimator resolution
Rcoll. The combined eﬀect of these two factors is to produce the system resolution
Rsys that is somewhat worse than either one alone. System resolution Rsys (FWHM)
is so determined by the relation:
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Figure 5.23: Transaxial section of the 5 ﬁllable rods and the two cold region chambers, in
addition to a coronal section of 4 cm portion centered on the uniform region of the NEMA
Image Quality phantom. The FBP reconstruction algorithm with ramp ﬁlter with cut oﬀ
at the Nyquist frequency was used. The measurements were performed at 100 and 125
head-to-head distances.
Figure 5.24: Coronal and transaxial sections of the NEMA Image Quality phantom acquired
at 100 head-to-head distance and reconstructed with EM algorithm.
Rsys =
√
(Rint)2 + (Rcoll)2 (5.20)
The spatial resolution of a parallel-hole collimator can be approximated by the
expression [91]:
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Figure 5.25: Coronal sections of the Defrise phantom for 100 and 125 mm head-to-head
distance. The slice thickness is about 4 mm (5 slices summed, 0.75 mm each).
Rcoll = d+D
d
L
(5.21)
where d and L are the diameter and the length of the holes of the collimator,
respectively. D is the object - collimator distance. The parallel-hole collimator of
the YAP-(S)PET scanner has d=0.6 mm and L=20 mm (see section 3.2.4), so Rcoll
will range between 2.1 mm (for 10 mm head-to-head distance and the source placed
at the CFOV) to 2.7 mm (for 150 mm head-to-head distance with the source at the
CFOV).
The procedures followed for the spatial resolution measurement are based on those
deﬁned by the clinical SPECT NEMA reference standards NU1-1994 [116] and on the
report number 52 of American Association of Physicists in Medicine (AAPM) [139].
Experimental procedure
The measurements were performed with a glass capillar with inner and outer
diameter of 0.8 and 1.2 mm, respectively. The capillar was ﬁlled with 111 MBq
(about 3 mCi) of 99mTc and positioned parallel to the FOV longitudinal axis with 1
cm radial oﬀset. The measurements were repeated for 100, 125, 150 mm head-to-head
distances.
The acquisitions were performed over 1800 with 128 views. At least four hundred
thousand counts were acquired for each head-to-head distance.
Data analysis
The collected data were processed via 2-D sinograms (see section 3.3.3) and then
reconstructed with FBP algorithm with ramp ﬁlter with cut oﬀ at the Nyquist fre-
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quency. A 140-250 keV energy window was used.
The radial and tangential spatial resolution components in the transaxial plane
were measured. The spatial resolution was determined by drawing a proﬁle along the
radial and tangential direction through the hottest pixel in the reconstructed image
and calculating the FWHM by linear interpolation.
Since the reconstruction matrix size can aﬀect the spatial resolution, we have
chosen a pixel dimension that could provide a FWHM as accurately as can practically
be achieved. A 128 × 128 pixels matrix have been used for the transaxial cross-
sections.
Results
The radial (RFWHM) and tangential (TFWHM) FWHM resolutions at 1 cm radial
oﬀset and for 100, 125 and 150 mm head-to-head distances are reported in ﬁgure 5.26.
Table 5.7 reports the radial spatial resolution at the diﬀerent head-to-head distances.
Head-to-head RadialFWHM
distance (mm) (mm)
100 2.94
125 3.17
150 3.38
Table 5.7: Radial (RFWHM) FWHM resolutions at the center of the FOV for each head-to-
head distance: 100, 125 and 150 mm.
Since collimator resolution Rcoll depends on source-to-collimator distance (see
equation 5.21), also the system resolution depends on this parameter. This eﬀect
explains the spatial resolution degration at wider detectors distance. Moving from 100
to 150 head-to-head distance RFWHM show a degradation higher than 10%, passing
from 2.94 to 3.38 mm.
5.2.2 Sensitivity
The sensitivity of a SPECT scanner is measured as the number of detected counts
per unit time per unit source activity for a speciﬁed energy window and geometry of
measurement.
Sensitivity(cps/MBq) =
counts
time(sec)× sourceactivity(MBq) (5.22)
114 Chapter 5. Performance evaluation
Figure 5.26: Radial and tangential spatial resolutions at the center of the FOV for each
head-to-head distance: 100, 125 and 150 mm. A 140-250 keV energy window was used.
Experimental procedure
The system sensitivity measurements were performed with the same glass capillar
ﬁlled with 99mTc employed for the spatial resolution measurements. The activity was
measured with a calibrated well-counter. The uncertainity on the activity was about
10%. The activity was low enough so that dead time data loss is negligible.
The acquisitions were performed over 1800 with 128 views. At least four hundred
thousand counts have been acquired. The sensitivity was evaluated only for 100
mm head-to-head distance since the spatial resolution signiﬁcantly degrades as the
head-to-head distance is increased (see section 5.2.1).
Data analysis
The number of counts (C) and the acquisition time (Tacq) registered to obtain
the counting rate (R=C/Tacq) in counts per second (cps), were obtained by the ﬁnal
row of the column Used% and Dt(s) of the YAP-(S)PET log ﬁle, respectively (see
section 3.3.3). A 140-250 keV energy window was used.
Results
In the energy window 140-250 keV, the system sensitivity is 37 cps/MBq (3.7 ×
10−3%).
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5.2.3 Phantoms studies
To test the imaging capability of the YAP-(S)PET scanner in SPECT modality we
performed acquisitions with both Derenzo and Image Quality phantom. These phan-
toms are the same used for phantom studies in PETmodality, and their characteristics
can be found in section 5.1.7.
Experimental procedure
All the phantoms were ﬁlled with a solution of 99mTc.
a-) Derenzo phantom
The Derenzo phantom was ﬁlled with about 150 MBq (∼ 4 mCi) of 99mTc and
placed at the center of the FOV with the rods axis parallel to the scanner axis.
A 128 views over 3600 acquisition was performed for 100 head-to-head distance.
More than 90 Mevents were acquired.
b-) Image quality phantom
The Image Quality was ﬁlled with about 170 MBq (∼ 5 mCi) of 99mTc and
placed in the FOV so that the axis of its main cylindrical compartment is aligned
with the longitudinal axis of the tomograph. A 128 views over 1800 acquisition
was performed for 125 head-to-head distance. To obtain a high statistic image
160 Mevents were acquired in about 4 hours and half acquisition.
Data analysis
The collected data were processed via 2-D sinograms (see section 3.3.3).
Image reconstruction was performed with FBP algorithm with ramp ﬁlter with
cut oﬀ at the Nyquist frequency for Derenzo phantom and with EM with collimator
model [99] and 50 iterations for IQ phantom. A 128 × 128 transaxial image matrix
(pixel dimension about 0.38 mm) with 27 axial slices (1.5 mm) was chosen for both
Derenzo and Image Quality phantom. A 140-250 keV energy window was used.
Results
a-) Figure 5.27 (a) and (b) reports the transaxial section of the Derenzo phantom
for four central slices and for 5 summed slices, respectively, obtained with FBP (ramp
ﬁlter at the Nyquist frequency) algorithm. The proﬁle of the last series of 3.0, 2.5,
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2.0, and 1.5 mm hot rods are reported. The 1.5 mm is barely distinguishable, while
the 1.2 mm is completely unresolved.
Figure 5.27: (a) Transaxial sections of the Derenzo phantom for four central slices. (b)
Transaxial section of the Derenzo phantom for 5 summed slices.
b-) Figure 5.28 (a) shows all the 27 transaxial slices of the IQ phantom recon-
structed with EM algorithm with collimator model and 50 iterations. The transaxial
sections of the uniform hot region show several non-uniformities highlighted by con-
centric ring or bull's eye artifacts [140]. These artifacts are determined by spatial
non-uniformities in the detectors or by local sensitivity variations (see chapter 4).
The radius of the ring artifacts is equal to the distance of non uniform pixels from
the center of rotation of the scanner.
Figure 5.28 (b) reports the summed slices of the transaxial section of the two
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Figure 5.28: (a) All the 27 transaxial slices of the NEMA Image Quality phantom recon-
structed with EM algorithm with collimator model and 50 iterations. (b) Summed slices
of the transaxial section of the two cold region chambers, of the central hot uniform region
and of the 5 ﬁllable rods of the NEMA Image quality phantom.
cold region chambers, of the central hot uniform region and of the 5 ﬁllable rods.
The 1 mm radii hot rod is hardly distinguishable. The proﬁles through the hot
rods are reported in ﬁgure 5.29. Due to partial volume eﬀect (same eﬀect described
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in section 5.1.5 for PET modality), the activity concentration in the center of rod
highly decreases as the source becomes smaller. The activity concentration of 1 mm
hot rod is underestimated by about 95%.
Figure 5.29: The proﬁles through the 1, 2, 3, 4, and 5 hot rods of the NEMA Image Qualuty
phantom.
Chapter 6
Simultaneous PET/SPECT imaging
In the last decade, various research groups have shown a growing interest in developing
PET/SPECT systems able to perform combined PET and SPECT acquisitions in one
single device [76,141144].
Exploiting the YAP-(S)PET scanner intrinsic capability of performing both PET
and SPECT imaging [120], we have implemented the capability of performing simul-
taneous PET/SPECT acquisitions with the new version of the YAP-(S)PET scanner,
the 27 × 27 version (see chapter 3).
6.1 Simultaneous PET/SPECT data imaging archi-
tecture
The peculiar YAP-(S)PET scanner architecture (four detector heads mounted on the
same gantry, see chapter 3) and the use of the same detector for PET and SPECT
modalities (YAP) provide the capability to perform simultaneous PET/SPECT ac-
quisitions.
Referring to ﬁgure 6.1: the opposing heads 1 and 2 are equipped with the collima-
tors and independently acquire single events (SPECT mode), while the other pair 3-4
detects coincident events (PET mode). In order to reduce the background produced
by the Compton scattering of 511 keV gamma rays, each SPECT head (1 and 2) is
set in anticoincidence with the opposing one.
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Figure 6.1: Scheme of the layout used for combined PET/SPECT acquisitions. Head 1
and 2 (red ones) works in SPECT mode, while the couple 3-4 (blue heads) acquires events
in PET modality.
6.2 Data analysis
Data analysis is performed in two steps. In the ﬁrst step, we process the data acquired
in PET mode, then we analyze the SPECT data.
Since the thickness of the collimators (2 cm) is optimized to stop low energy
gamma rays, particularly the 140 keV gamma rays of 99mTc, the high energy radi-
ation (511 keV) passes or scatters through the collimator. The events detected by
the SPECT heads during the simultaneous PET/SPECT acquisition are mainly due
(about 95%) to scattered gamma rays produced by the interaction of 511 keV gamma
rays with the lead collimators. This scattered radiation generates signiﬁcant arti-
facts in the reconstructed images. Hence, it is necessary to perform a subtraction
procedure to clean up the SPECT data.
On the contrary, the events detected by the PET pair (3-4) are only slightly
inﬂuenced by the random coincidences produced by the a 511 keV photons originated
by the positron annihilation and a single gamma emitted by the 99mTc decay (140
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keV). For a 10:1 99mTc/18F activity ratio, the random coincidences are about 5%.
Thus, the data acquired by the PET pair 3-4 do not need heavy clean up procedures
for SPECT heads 1 and 2. Two techniques were adopted to reduce the incidence of
99mTc on PET coincidence imaging:
• an hardware procedure consisting in placing a lead layer of about 2 mm in front
of the scintillator of the heads used for the PET acquisition
• a software procedure based on selecting only the coincidence events registered
in an energy window excluding all the possible contamination from 99mTc. The
energy window used is 200-850 keV. It is worthwhile to note that this energy
window start at a energy higher that the 99mTc photo-peak energy window
(125-180 keV).
Since the two procedures provide comparable results, usually we adopted the soft-
ware procedure. Neverthelss, in animal studies we preferred to adopt the hardware
procedure in order to further reduce the scattered radiation.
The PET data (pair 3-4) are sorted in 3-DMS sinograms, while the SPECT data
(heads 1 and 2) are stored in 2-D sinograms. The reconstruction has been performed
both with FBP or EM algorithms.
The two produced images are then fused using the PMOD image data analysis
software [109]. At the end of the procedure, we obtain an image that correspond to
the simultaneous PET/SPECT acquisition.
6.2.1 Subtraction procedure
The subtraction procedure we have elaborated is based on multi-energy window
method [95] and relies on the following approximation. The background events pro-
duced by the 511 keV gamma rays scattered radiation that are detected in the energy
region of 99mTc photo-peak (140 keV) are a fraction (f) of the events registered in
an energy window close to the photo-peak but containing only scattered events. In
order to determine the fraction f, before the simultaneous PET/SPECT acquisition
we performed an acquisition that provides an evaluation of the background produced
by the scattered 511 keV photons acquired in SPECT mode (see Fig. 6.2).
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We used a cylindrical phantom (2.5 cm in diameter, 5.6 cm in height) ﬁlled with
a known quantity of 18F and acquired data in SPECT mode with the collimators
mounted on the heads 1 and 2. The energy window containing the 99mTc photo-peak
spreads out one σ at left and two σ at the right of the photo-peak (125-180 keV). The
energy window close to the photo-peak but containing only Compton events extends
from 220 to 280 keV. The fraction f is given by the ratio between the SPECT sinogram
produced in the 125-180 keV energy window (SABG of Fig. 6.2) and the sinogram
(still SPECT) generated in the 220-280 keV energy window (SBBG of Fig. 6.2). For
a more accurate evaluation, the SPECT sinograms ratio is performed independently
for each head (1 and 2), slice by slice and pixel by pixel. A better statistics is gained
averaging out on the angular coordinates the pixel by pixel ratio for each slice.
The corrected sinogram (PkSA), used for image reconstruction (in SPECT mode)
of the data acquired in simultaneous PET/SPECT mode, is obtained by subtracting
the scattered background due to 511 keV photons from the image sinogram evaluated
in the same photo-peak energy window (125-180 keV) used to produce SABG.
Referring to ﬁgure 6.2, the corrected sinogram PkSA has the following expression:
PKSA = SA− BGSA = SA− f · SB (6.1)
with
f = SABG/SBBG (6.2)
6.2.2 How simultaneous PET/SPECT aﬀects single mode PET
and SPECT acquisitions
Since the simultaneous PET/SPECT modality is realized by performing the acquisi-
tion with a couple of heads in PET mode and the other two heads in SPECT mode
(see section 6.1), the performance of each single modality are degraded: particularly,
the sensitivity and a little bit the spatial resolution.
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Figure 6.2: Top (blue line): energy spectrum of a simultaneous PET/SPECT acquisition
with 99mTc as SPECT radiotracer and 18F-FDG as PET radiopharmaceutical. Bottom (red
line): energy spectrum of 18F-FDG performed in SPECT mode with the collimators. Both
spectra refer to head 1 of the YAP-(S)PET scanner.
• SENSITIVITY
As a ﬁrst evaluation, the sensitivity of each modality (PET or SPECT) can be
estimated to be about the half of the sensitivity of each single mode. In fact,
in the simultaneous acquisition only half of the scanner detectors are used: one
couple in PET and two heads in SPECT.
PET modality
To evaluate the diﬀerence in sensitivity between the PET mode in the simulta-
neous acquisition (a couple of detector) and the full PET modality (two couples of
detector), we used a glass capillary (inner diameter of 0.8 and outer diameter 1.2
mm) ﬁlled with 177.6 kBq (4.8 µCi) of 18F and placed 10 mm oﬀ-axis. We placed the
capillary not in the CFOV in order to obtain an average value. In fact, in sections
5.1.1 and 5.1.2 it is shown how resolution and sensitivity change with the source
position. Since for animal studies, especially mice, we used a 100 mm head-to-head
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distance, the measurements were performed with the scanner in this conﬁguration.
The acquisitions were performed over 1800 with 128 views and at least one and a
half million counts have been acquired.
The sensitivity was evaluated with the 22Na point source procedure (see section
5.1.2).
Table 6.1 compares the sensitivities among the full PET modality (two couple of
detectors) in the energy window 50-850 keV and the PET mode in the simultaneous
PET/SPECT acquisition. The sensitivities of the two diﬀerent techniques used to
reduce the incidence of 99mTc on PET coincidence (see section 6.2) are reported.
In the hardware procedure the usual 50-850 keV energy window was used. In the
simultaneous PET/SPECT acquisition, the PET sensitivity is reduced of about 76%
using an energy window of 200-850 keV and no lead shields, and more than 80%
using an open energy window (50-850 keV) and 2 mm thick lead layers in front of the
detectors.
The high reduction in sensitivity with the open energy window and the lead shields
leads to prefer the software procedure to clean-up the PET data. We used the lead
shields only for animal studies with high activity concentrantion in the FOV.
Modality Sensitivity (%)
Full PET
2 couples 1.71
50-850 keV
PET/SPECT
1 couple without Pb 0.40
200-850 keV
PET/SPECT
1 couple with Pb 0.33
50-850 keV
Table 6.1: Comparison of the sensitivity for the full PET modality and the PET mode in
simultaneous PET/SPECT acquisition.
SPECT modality
In SPECT mode, the diﬀerence in sensitivity between the simultaneous acquisi-
tion (only two detectors) and the full SPECT modality (all the four detectors),
was evaluated by using a glass capillary (inner diameter of 0.8 and outer diam-
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eter 1.2 mm) ﬁlled with a 20.15 MBq (544 µCi) of 99mTc and placed at 10 mm
from the CFOV.
The acquisitions were performed over 1800 with 128 views and at least one and
half million counts have been acquired.
The sensitivity was evaluated according to the procedure described in section
5.2.2.
The SPECT sensitivity in the simultaneous PET/SPECT acquisition is closely
connected to the 99mTc/18F activity ratios. In fact, the SPECT sensitivity in
the 125-180 keV energy window after the subtraction procedure ranges bewteen
40% and 10% of the sensitivity of the full SPECT sensitivity (four heads and
140-250 keV) by changing the 99mTc/18F activity ratios between 34 to 10.
• SPATIAL RESOLUTION
The spatial resolution would in principle not be aﬀected in similtaneous ac-
quisitions. Nevertheless, the necessity of the subtraction procedure in SPECT
mode and the use of lead shields or a reduced energy window in PET mode
lead to a small degradation of the spatial resolution.
PET modality
The spatial resolution evaluation was deduced by the acquisition used for the
sensitivity evaluation.
Since we used a capillary, we have evaluated just the radial (RFWHM) and tan-
gential (TFWHM) FWHM resolutions.
The obtained value are reported in table 6.2. Both the radial and tangential
spatial resolution of the reduced energy window (200-850 keV) are a little bit
worse than the values obtained for the full PET acquisition (two couples). On
the contrary, the spatial resolution with the lead shield is even slightly better
than the spatial resolution of the full PET acquisition. This eﬀect can be
explained with the removal of scattering due to the attenuation produced by
the 2 mm lead layer in front of the detector. By using the attenutation law
(I(x) = I0 exp(−µ · x)), we obtained an attenuation (1 - I(x)/I0) of about
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25% for 511 keV photons and more tha 50% for photons of 300 keV and lower
energies.
SPECT modality
The spatial resolution evaluation was obtained from the same acquisition used
for the sensitivity evaluation. As in PET modality, we evaluated only the radial
and tangential FWHM resolutions. For both the radial and tangential spatial
resolution we have a degradation of about 20%. This is mainly due to the
subtraction procedure.
Modality RadialFWHM (mm) TangentialFWHM (mm)
Full PET
2 couples 2.62 2.68
50-850 keV
PET/SPECT
1 couple without Pb 2.64 2.72
200-850 keV
PET/SPECT
1 couple with Pb 2.58 2.61
50-850 keV
Table 6.2: Comparison of the radial (RFWHM) and tangential (TFWHM) FWHM resolutions
for the full PET modality and the PET mode in simultaneous PET/SPECT acquisition.
6.3 Phantom imaging
The simultaneous PET/SPECT imaging capabilities were evaluated performing sev-
eral acquisitions with diﬀerent phantoms and various 99mTc/18F activity ratios.
The phantoms employed are:
A-) capillaries.
B-) syringes for insuline (0.5 mm diameter).
C-) Image quality phantom (see section 5.1.7).
The 99mTc/18F activity ratios range between 5 and 50:1.
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All the acquisitions were performed for a 125 mm head-to-head distance, in order
to exploit the best compromise between spatial resolution and sensitivity of both
PET and SPECT modalities (see chapter 5).
A-) Two glass capillaries with inner and outer diameter of 0.8 and 1.2 mm were
used. A capillary was ﬁlled with 370 kBq (10 µCi) of 18F and the other one with
18.5 MBq (about 500 µCi) of 99mTc (99mTc/18F activity ratio 50:1). The capillaries
were placed parallel to the longitudinal YAP-(S)PET scanner axis at about 1 cm far
from the central axis of the scanner. A simultaneous acquisition of about 30 minutes
over 1800 with 128 views was performed. The data were reconstructed with EM
algorithm with 50 iterations. In SPECT mode EM algorithm with collimator model
was used [99]. The transaxial and coronal sections are reported in ﬁgure 6.3.
Figure 6.3: Transaxial (a) and coronal (b) section of a simultaneous PET/SPECT acqui-
sition of two capillaries. The left one was ﬁlled with 18.5 MBq (about 500 µCi) of 99mTc,
while the right with 370 kBq (10 µCi) of 18F (99mTc/18F activity ratio 50:1).
B-) Figure 6.4 shows the simultaneous acquisition of two syringes for insulin (5
mm inner diameter). The syringes were placed parallel to the longitudinal axis of the
scanner. The syringe on the left was ﬁlled with 16.3 MBq (70 µCi) of 99mTc, while
the syringe on the right was ﬁlled with 630 kBq (about 17 µCi) of 18F (SPECT/PET
radiotracers ratio 10:1).
In order to evaluate the more appropriate 99mTc/18F activity ratio, various PET/SPECT
simultaneous syringes acquisition were performed. The SPECT/PET radiotracers ra-
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Figure 6.4: Transaxial image of a simultaneous PET/SPECT acquisition of two syringes
for insulin: the left one ﬁlled 16.3 MBq (70 µCi) of 99mTc and the right one with 630 kBq
(about 17 µCi) of 18F (SPECT/PET radiotracers ratio 10:1).
tio ranged between 5:1 to 50:1. Four diﬀerent acquisitions were performed. Referring
to ﬁgure 6.5, the syringe on the right was ﬁlled with 99mTc, while the one on the left
with 18F, and the activity ratio are as follow:
(a) 141 MBq (3.80 µCi) of 99mTc and with 30 MBq (about 800 µCi) of 18F, for a
SPECT/PET radiotracers ratio 5:1.
(b) 100 MBq (2.70 µCi) of 99mTc and 10 MBq (about 260 µCi) of 18F: SPECT/PET
radiotracers ratio 10:1.
(c) 63 MBq (1.70 µCi) of 99mTc and 2.10 MBq (about 60 µCi) of 18F, for a
SPECT/PET radiotracers ratio ∼ 30:1.
(d) 51 MBq (1.30 µCi) of 99mTc and 0.96 MBq (about 26 µCi) of 18F, for a
SPECT/PET radiotracers ratio 50:1.
Figure 6.5 reports the transaxial slices of three central sections of the two sy-
ringes. A qualitatively evaluation shows that the 50:1 99mTc/18F supplies the best
results. The activity ratio more suitable for animal studies in order to maintain the
tracer principle [145] is of the order of 30:1. Since the images quality of SPET/CT
radiotracers 30:1 is acceptable, we assumed that 30:1 is the best compromise between
image quality and tracer principle.
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Figure 6.5: Transaxial images of a simultaneous PET/SPECT acquisition of two syringes
for insulin. the syringe on the right was ﬁlled with 99mTc, while the one on the left with
18F, and the activity ratio are as follow: (a) 141 MBq (3.80 µCi) of 99mTc and with 30
MBq (about 800 µCi) of 18F, for a SPECT/PET radiotracers ratio 5:1. (b)100 MBq (2.70
µCi) of 99mTc and 10 MBq (about 260 µCi) of 18F: SPECT/PET radiotracers ratio 10:1.
(c) 63 MBq (1.70 µCi) of 99mTc and 2.10 MBq (about 60 µCi) of 18F, for a SPECT/PET
radiotracers ratio ∼ 30:1. (d) 51 MBq (1.30 µCi) of 99mTc and 0.96 MBq (about 26 µCi) of
18F, for a SPECT/PET radiotracers ratio 50:1.
C-) The NEMA Image Quality (IQ) phantom (see section 5.1.7) was used to ex-
ploit the simultaneous PET/SPECT imaging capabilities of objects having shape and
dimensions comparable with small animal used for preclinical experiments, particu-
larly mice. The whole IQ phantom, except the two 8 mm diameter hollow chambers,
was ﬁlled with 133 MBq (about 3.6 mCi) of 99mTc. The hollow chambers were ﬁlled
with 6.6 MBq (∼ about 180 µ Ci) of 18F. The SPECT/PET radiotracers ratio was
28:1, quite close to the best compromise between image quality and tracer princi-
ple (see syringes experiments reported in B-)). The IQ is placed in the FOV such
that the axis of its main cylindrical compartment is aligned with the longitudinal
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axis of the tomograph. The SPECT data were reconstructed with EM algorithm
with collimator model [99], while PET data were reconstructed with FBP algorithm
with ramp ﬁlter with cut oﬀ at the Nyquist frequency. Figure 6.6 represents all the
transaxial sections of the IQ for both PET and SPECT tracers of the PET/SPECT
simultaneous acquisitions.
Figure 6.6: Transaxial sections of a simultaneous PET/SPECT acquisition of the NEMA
Image Quality phantom. (a) SPECT image obtained ﬁlling the whole IQ phantom, except
the two 8 mm diameter hollow chambers, was ﬁlled with 133 MBq (about 3.6 mCi) of 99mTc.
Top: all 27 transaxial sections. Bottom: summed slices of the uniform region conatining
the hollow chambers ﬁlled with 18F and of the rods regions of the IQ. (b) PET images
obtained ﬁlling the hollow chambers with 6.6 MBq (∼ about 180 µ Ci) of 18F. Top: all the
transaxial slices containg the hollow chambers. Bottom: sum of all the slices containg the
hollow chambers.
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6.4 Animal imaging
In order to evaluate the feasibility of simultaneous PET/SPECT acquisition on living
subject injected with SPECT and PET tracers at the same time, we performed a
study in a male healthy mouse. The aim of the study was to investigate the system
capability to image the mouse heart.
260 MBq (about 7 mCi) of 99mTc-sestamibi (see section 7.4) and 12.70 (∼ 340 µCi)
of 18F-FDG were injected via tail vein. Before the tracers injection, the mouse was
injected with 5 ml of glucosate at 5% 10-15 in order to have a better 18F-FDG uptake.
After an uptake time of 45 minutes, the mouse was anesthetized with intraperitoneal
injection of a mix of ketamine (60 mg/kg and 4.4 mg/kg) and fenobarbital (50 mg/kg)
and placed on the ﬂat bed. About one and half hour of simultaneous acquisition was
performed. In order to reduce the random 511 -140 keV random coincidences (see
section 6.2), a lead layer of about 2 mm was placed in contact of the heads used
for the PET acquisition. The data were reconstructed with EM algorithm with 50
iterations. In SPECT mode EM algorithm with collimator model was used [99].
Figure 6.7 shows the transaxial, coronal and sagittal sections of the images obtained
by the SPECT heads 1 and 2 (ﬁrst row), the PET pair 3-4 (central row) and the
fusion (ﬁnal row) realized by the fusion of the two images. The PMOD software [109]
was used for fusion.
The images is quite blurred and diﬃcult to understand. It is due to the very small
dimensions of mouse heart (some millimeters) and to heavy eﬀect of partial volume
and spillover.
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Figure 6.7: Transaxial (left column), sagittal (central column) and coronal (right column)
of the simultaneous PET/SPECT acquisition of a male healthy mouse. Top row: SPECT
images. 260 MBq (about 7 mCi) of 99mTc-sestamibi injected. Central row: PET images.
12.70 (∼ 340 µCi) of 18F-FDG were injected via tail vein. Bottom row: Fusion of the two
previous images realized with Pmod software [109]. The uptake time before the simultaneous
acquisition was 45 minutes and the acquisition time one and half hour. Both PET and
SPECT images were obtained with a EM reconstruction algorithm with 10 iterations.
Chapter 7
YAP-(S)PET small animal studies
Since the new version of the YAP-(S)PET scanner (the 27 × 27 version) with
improvements in both hardware and software (see chapter 3) has been completed
during the ﬁrst half of 2006, the majority part of the animal studies reported in this
thesis were performed with the ﬁrst 20 × 20 version of the YAP-(S)PET scanner.
Diﬀerent animal models and various isotopes and tracers have been used in the
experiments performed in collaborations with the diﬀerent research groups. In these
thesis only some of these studies are reported in order to point out the YAP-(S)PET
imaging capabilities, particularly in neuropharmacology, psychiatry and oncology.
Other studies performed in collaboration with various European research groups can
be found in [146,147].
Recently, a collaboration projection aimed to evaluate a rat model of ischemia
and reperfusion has been started. Preliminary results of this studies performed with
the new 27 × 27 version of the YAP-(S)PET scanner are reported.
7.1 Brain's glucose metabolism
The brain is metabolically one of the most active organs in the body. In adult humans,
for example, in whom the brain comprises only 2% of body weight, the brain alone
accounts for approximately 20% of the total body basal oxygen consumption and
maintains a steady rate of energy expenditure of at least 20 watts [148].
Brain's glucose metabolism is one of the most powerful tools to investigate tumors
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and brain disorders such as Alzheimer or Parkinson.
The study presented here was performed in collaboration with the Endocrinology
and Metabolic Disease Department of the University of Pisa using the YAP-(S)PET
scanner installed at the IFC institute of the CNR in Pisa. The aim of the collab-
oration project is to understand the relation between hypothyroidism and cognitive
or psychiatric disturbance. Up to now, the experimental results are under study by
medical doctors. In this thesis, an image regarding healthy male rat is reported in
order to show the capability of the YAP-(S)PET scanner to visualize the diﬀerent
brain structures. (see ﬁgure 7.1).
Figure 7.1: Transaxial (coronal) section (0.5× 0.5× 2 mm voxel size), of a rat brain injected
with 37 MBq of 18F-FDG and acquired for 45 minutes, after 30 minutes of uptake. The
images are arranged from rostral (upper left) to caudal (lower right). The right hemisphere
of the animal is represented on the right hand side of the ﬁgure, and the dorsal aspect
corresponds to the top of the ﬁgure. EM algorithm with 30 iterations was used for image
reconstruction.
The rat was injected with 37 MBq (∼ 1 mCi) of 18F-FDG and acquired for 45
minutes after 30 minutes of uptake. Figure 7.1 shows how cerebral activity can be
clearly distinguished from extracerebral activity. More speciﬁcally, activity in the
Harderian glands is clearly distinct from brain activity. Within the brain, principal
brain structures such as cortex, thalamus and striatum are well resolved [149].
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7.2 Receptors studies
Dopamine neurotransmitters aﬀects brain processes that control movement, emo-
tional response, and ability to experience pleasure and pain. Regulation of dopamine
plays a crucial role in certain brain diseases, e.g. Parkinson's disease and schizophre-
nia. Some drugs are known as dopamine agonists. These drugs bind to dopamine
receptors in place of dopamine and directly stimulate those receptors. Some dopamine
agonists are currently used to treat Parkinson's disease. In contrast to dopamine ag-
onists, dopamine antagonists are drugs that bind but do not stimulate dopamine
receptors. Antagonists can prevent or reverse the actions of dopamine by keeping
dopamine away from attaching to receptors. Dopamine antagonists are traditionally
used to treat schizophrenia and related mental disorders. A person with schizophrenia
may have an overactive dopamine system. Dopamine antagonists can help regulate
this system by turning down dopamine activity [150].
Studies on the binding of various radiolabeled dopamine neurotransmitter ana-
logues in order to visualize dopamine D2/D3 receptor availabilities were performed
in both PET and SPECT modality using rats and mice.
The PET studies were performed within a collaboration project with the Vita-
Salute San Raﬀaele University, Milan, group leader Dr. R. M. Moresco.
The SPECT studies were realized in collaborations with the University of Pisa,
Nuclear Medicine Department, group leader Prof. G. Mariani.
7.2.1 PET studies: 11C-Raclopride, rat model of Huntington's
disease
Huntington's disease (HD) results from genetically programmed degeneration of neu-
rons in certain areas of the brain. This degeneration causes uncontrolled movements,
loss of intellectual faculties, and emotional disturbance. HD is a familial disease,
passed from parent to child through a mutation in the normal gene. HD can be
identiﬁed in individuals by genetic testing and, when present, is associated with a
phenotypic penetrance of nearly 100 % (i.e., if you have the mutate gene, you get the
disease) by the time the patient's ﬁfth decade is reached [95]. The presymptomatic
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detection of metabolic abnormalities has speciﬁcally been shown for HD disease using
PET. Abnormalities are identiﬁed by PET with FDG about 7 years before symptoms
emerge [151]. In contrast, there are generally no structural abnormalities evident on
CT on MRI scan preclinically or even during the symptomatic stages. PET scan-
ning thus oﬀers a non-invasive yet sensitive method to detect the disease when actual
pathologic changes in the brain become functionally manifest at the neuronal level.
A preclinical model of Huntington's disease was studied within a collaboration
project with the Vita-Salute San Raﬀaele University, Milan, group leader Dr. R. M.
Moresco.
This model which consists in the intrastriatal administration of an excitotoxin, the
quinolinic acid (QA), produces neurochemical changes that approximate Huntington's
disease including the degenerations of intrinsic striatal neurons, reactive gliosis and
microglia activation [152155].
The aim of the experiment is the quantitative evaluation of the neuronal loss in
lesioned and unlesioned striatum [156]. Male albino CD rats (225-250 g; Charles
River, Italy) were used for the study. QA solution was prepared dissolving 50.2 mg
of acid (Sigma-Aldrich, Milan, Italy) in 0.6 ml of 1 M sodium hydroxide and 0.4
ml of PBS solution (0.1 M, pH 7.4) to obtain a ﬁnal concentration of 300 nmol/µl.
Rats were anesthetized by intraperitoneal injection (50 mg/kg) of pentobarbital and
placed on a stereotaxic frame (Narashige, Japan). The scalp was cleaned with an
iodine solution, incised on the midline and two holes were made in the skull at the
appropriate stereotaxic location using a micro-drill. Unilateral intrastriatal admin-
istration (left side) of 0.7 µl of QA solution (210 nmol) was performed using a 5
µl Hamilton syringe; contralateral injection (right side) of 0.7 µl of PBS 0.1 M was
used as internal control. Either QA or solvent were infused into striatum at a rate
of approximately 0.5 µl/min. The stereotaxic coordinates of the target site were AP
= +1.5, L = +2.6, V = -7.0mm from the Bregma, according to the atlas of [157].
After the injection, the needle was left in place for additional 5 min, and then slowly
withdrawn. At the end of the surgery, the wound was closed with metallic clips, and
the rats were located in their cage [158].
The PET studies were performed 11C-Raclopride and repeated at diﬀerent times
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from the striatum lesion induction. Since 11C-Raclopride is a radiotracer that selec-
tively binds to D2 receptors presents on the intrastriatal GABA neurons, it is suitable
to provide information about neuronal losses in the lesioned striatum. The rats were
injected with no more than 7.4 MBq (∼ 200 µCi) of 11C-Raclopride and acquired
for 10 minutes after 30 minutes of uptake. The acquisitions were performed over 900
with 64 views. A wide-open energy window 50-850 keV was used and images were
reconstructed with EM algorithm.
Figure 7.2 shows the transaxial sections of the PET acquisition at diﬀerent times
after striatum lesion induction. It is evident how the 11C-Raclopride radiotracer
selectively binds to D2 receptors accumulating in the striata. It is interesting to note
that the bind is maximum in the unlesioned striatum and progressively gets lower
in the lesioned striatum (left side). As described in [159, 160], the neuronal loss in
lesioned striatum is already signiﬁcant within 8 days from QA injection and increases
when time from lesion increases.
Quantitative analysis can be found in [156].
7.2.2 SPECT studies: 123I-FP-CIT, binding in a new model
for Parkinson's disease
The dopamine D2 receptors have been evaluated on mice with the 123I-DaTSCAN
tracer. 123I-DaTSCAN is a radiotracer commonly used in clinical trial. It is indicated
for detecting loss of functional dopaminergic neuron terminals in the striatum of pa-
tients with clinically uncertain Parkinsonian Syndromes, in order to help diﬀerentiate
Essential Tremor from Parkinsonian Syndromes.
We have performed static acquisitions of healthy male mice in order to determine
the YAP-(S)PET capability to resolve the mouse striatum. The mice striata are, in
fact, tiny brain region with less than 20 mm3 in volume.
The mice were intravenously injected with 11 MBq (∼ 300 µCi) of 123I-DaTSCAN
and scanned for six hours, after an uptake time of 6 hours. Figure 7.3 shows transaxial
sections of the SPECT acquisition of a mouse injected with 123I-DaTSCAN. The
striata are the two hot spots in the seventh image starting from upper left and going
from left to right. The image is not very clear and there is a rough ring corresponding
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Figure 7.2: Transaxial sections of the 11C-Raclopride PET acquisitions of a rat model of
Huntington's disease at diﬀerent times after striatum lesion induction (0, 8, 30 and 60 days).
It is evident how the 11C-Raclopride radiotracer selectively binds to D2 receptors accumu-
lating in the striata. The bind is maximum in the unlesioned striatum and progressively
gets lower in the lesioned striatum (left side).
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to the FOV edge. This is due to the thickness of YAP-(S)PET scanner collimators.
In contrast to 99mTc imaging, the thickness of the collimators (2 cm, see section 3.1)
is not enough to stop the small percent (1-2%) of high energy radiation (around 520
keV) emitted by 123I, whose Compton interaction in the crystals produces a nearly
uniform background below the photopeak region of the 159 keV gamma-lines. It was
therefore necessary to elaborate a subtraction procedure [146].
Figure 7.3: Transaxial (coronal) section (0.5 × 0.5 × 2 mm voxel size), of a mouse brain
injected with 11 MBq of 123I-DaTSCAN and acquired for 6 hours, after 6 hours of uptake.
The images are arranged from rostral (upper left) to caudal (lower right). The right hemi-
sphere of the animal is represented on the right hand side of the ﬁgure, and the dorsal aspect
corresponds to the top of the ﬁgure. EM algorithm with 30 iterations was used for image
reconstruction.
7.3 Oncologic studies
The biological alterations of tumor cells goes back to more than 80 years ago, when the
German biochemist Otto Warburg and colleagues published their observations on the
metabolism of cancer cells [161]. A decade before, Flexner and Jobling [162] studied
the metabolism of tumor cells in a rat model and have found that the glycolitic
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rates of tumors were 124 times greater than the glycolitic action of blood. From
these and other observations, they concluded that the metabolism of rat tumor cells
is predominantly one of glicolysis. They subsequently conﬁrmed these ﬁnding in
a variety of human cancer cells and uncovered that benign tumors also exhibited
increased glycolitic activity but to a much smaller degree than malignant tumors.
Traditionally, the diagnostic tools for diagnosing, staging and restaging of patients
with cancer relied on anatomic imaging with computed tomography, magnetic reso-
nance and ultrasound. Nevertheless, these techniques can not reliably discriminate
between benign and malignant tumors. Since their introduction, emission computed
tomography, and particularly PET have been used to investigate oncologic diseases.
The most extensively used positron-emitting tracer in oncological evaluation has been
FDG (glucose analogue 2-deoxy-2-[18F]ﬂuoro-D-glucose) [163].
Studies on rats and mice models of tumors were performed in both PET and
SPECT modalities.
The PET studies were performed within a collaboration project with the C.N.R.
(Centro Nazionale delle Ricerche) Institute of Clinical Physiology, Pisa, group leader
Dr. Piero Salvadori.
The SPECT studies were realized in collaboration with the University of Pisa,
Nuclear Medicine Department, group leader Prof. G. Mariani.
7.3.1 PET studies: 18F-FDG, human glioma implantation in
rat brain
Gliomas are the most common of primary human brain tumors [164]. About 50% of
gliomas and 20% of all brain tumors are glioblastomas. They represent the second
death cause among cerebral disease after stroke. Diﬀuse gliomas are therapeutically
vexing: their inﬁltrative (diﬀuse) growth pattern essentially prevents surgical cure,
and the majority of these gliomas are resistant to standard chemotherapeutic and
radiotherapeutic approaches.
In 1951, Sweet [165] ﬁrst suggested that Neutron Capture Therapy (NCT) might
be useful for the treatment of brain tumors, and in particular, the treatment of the
most highly malignant and therapeutically persistent of all brain tumors, glioblastoma
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multiforme (GBM). Boron neutron capture therapy (BNCT) is based on the nuclear
reaction that occurs when 10B, a nonradioactive constituent of natural elemental
boron, absorbs thermal neutrons (<0.025 eV) and undergoes instantaneous nuclear
ﬁssion to produce high energy alpha particles and recoiling 10Li nuclei (see equation
7.2).
10B +1 nthermal(0.025 eV)→7 Li3+ +4 He2+ + 2.79 MeV (kinetic E) (6%)
10B +1 nthermal(0.025 eV)→7 Li3+ +4 He2+ + γ (0.48 MeV)+ (7.1)
+2.79 MeV (kinetic E) (94%)
These heavy particles have pathlengths of approximately 5-9 µm and deposit
their energy within cells 10B containing. If a suﬃcient amount of 10B (20-40 parts
per million or ppm) can be delivered, and enough thermal neutrons (ﬂuence @ 1013
n. cm−2) reach the treatment volume, then selective destruction of tumor cells can
occur as a result of the 10B (n,α) 10Li capture reaction. Clinical failures of BNCT
for patients with brain tumors in the United States in the 1950's [166,167] and early
1960's [168] were due to a lack of boron compounds with the requisite selectivity, as
well as thermal neutron beams that were incapable of depositing adequate ﬂuence at
depths greater than a few centimeters. As a result of this, eﬀorts have been made
to synthesize boron compounds that had more desirable biological and biochemical
properties, and to develop higher energy epithermal neutron beams that had greater
tissue penetrating properties. After the promising results obtained in 1991 by the
Japanese research group leaded by Hatanaka [169], new BNCT therapy clinical trials
started again in USA [170], Japan [171] and Europe [172174].
A preclinical model for BNCT therapy has been realized within the collaboration
project with Institute of Clinical Physiology of the C.N.R. in Pisa. F98 glioma
cells [175] were intracerebral implanted in a Wistar male rats. F98 glioma tumor has
an inﬁltrative pattern of growth within the brain, is very weakly immunogenic, and
an intracerebral inoculum of as few as ten cells invariably killed all animals. These
characteristics closely resemble those of human glioblastoma, and for this reason we
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have found it to be a particularly good tumor model for our studies on BNCT [175].
The implantation methodology and the tumor-neuronal tissue ratio were evaluated
through YAP-(S)PET acquisitions performed with 18F-FDG.
A group of 7 rats (male Wistar, 190-250 g) composed of 4 implanted rats and 3 con-
trol animals has been evaluated. The control animals have been exposed to the same
implantation methodology without F98 glioma cells inoculation. The animals were
anesthetized with intraperitoneal injection of chloral hydrate (400 mg/kg), placed on
hollow bed (see section 3.1) and positioned with the brain in the FOV. The 18F-FDG
was introduced with a bolus injection in the femoral vein. The mean injected dose
was 54 MBq (about 1.5 mCi). The uptake time was 45 minutes and the acquisi-
tion time 60 minutes. The acquisitions were performed over 1800 with 128 views. A
wide-open energy window 50-850 keV was used and images were reconstructed with
EM algorithm. After the YAP-(S)PET acquisition, the animals were euthanized with
anesthetic overdose and the brain was extracted. Tumors and surrounding normal
brain tissues were treated following conventional preparative histological protocols
to ﬁxation and subsequent criosectioning. Coloration with hematoxylin/eosin was
performed.
Figure 7.4 (a) shows the transaxial section of one the rat bearing F98 glioma: the
tumor is the blacker spot clearly visible in the central line. Figure 7.4 (b) reports the
comparison with an istological section. The agreement is quiet good.
Table 7.1 reports the tumor-neuronal tissue ratio for three of F98 glioma implanted
rats. The tumor captation ratio ranges between 1.5 and 2.
Further details can be found in [176].
F98 glioma Transaxial Tumor-neuronal
bearing rat section tissue ratio
Ratto291004
Slice 11 1.973
Slice 12 2.096
Slice 13 1.943
Mean ± σ 2.00 ± 0.08
Ratto251004
Slice 11 1.652
Slice 12 1.494
Slice 13 1.319
Mean ± σ 1.49 ± 0.17
Table 7.1: Tumor-neuronal tissue ratio for three of F98 glioma implanted rats.
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Figure 7.4: (a) The transaxial section of one the rat bearing F98 glioma: the tumor is the
blacker spot clearly visible in the central line. (b) Comparison between a transaxial image
of the rat bearing F98 glioma obtained with the YAP-(S)PET scanner and an istological
section.
7.3.2 SPECT studies: 99mTc-Annexin V mice model of breast
cancer
Breast cancer represents the most common tumor in women with the highest inci-
dence being recorded in western Europe and the USA. During the last two decades,
several favorable factors have considerably decreased breast cancer mortality. These
factors include early diagnosis, development of new therapeutic strategies, and more
reliable monitoring after primary treatment. In general, early disease management
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includes surgery and adjuvant therapy, combining hormonal therapy, chemotherapy
and radiotherapy. Chemotherapy is associated with side eﬀects: nausea, vomiting,
alopecia, and hematologic toxicity with the risk of subsequent infections, neurotox-
icity (e.g., taxanes), or cardiotoxicity (e.g., anthracyclines). Therefore, in order to
avoid ineﬀective treatment together with unnecessary side eﬀects, a molecular tool to
assess the early response to treatment would be very helpful. This line of thought is
the basis for the experiments performed in collaboration with the Nuclear Medicine
Department of the University of Pisa. These experiments aim at evaluating the degree
of apoptosis occurring in tumor tissue as the result of anti-cancer treatment.
Programmed cell death or apoptosis is an essential process for normal develop-
ment and function of tissue. Tissue homeostasis is achieved by a tight regulation
of proliferation, diﬀerentiation, and apoptosis. Dysregulation of apoptosis is associ-
ated with a variety of diseases, either leading to excessive cell proliferation, e.g., in
malignancies, or increased cell death as found in neurodegeneration, tissue ischemia,
immunological disorders (e.g., transplant rejection), and autoimmune diseases [5].
The apoptotic signaling cascade is schematically depicted in ﬁgure 7.5.
Figure 7.5: Apoptosis Expression of the phosphatidylserine. On the left: normal mem-
brane translocase and ﬂoppase activity. On the right: translocase and ﬂoppase inactivated,
scramblase activated. .
Apoptosis induces characteristic histomorphological changes including cell shrink-
age, DNA fragmentation (laddering), nuclear condensation, and membrane-enclosed
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apoptotic body formation. However, histological analyses require sampling of biopsy
material, a severe limitation for a method to be used for clinical diagnosis. Hence,
noninvasive methods to assess apoptosis are highly desired and several approaches
are currently under development.
Cells undergoing apoptosis redistribute aminophospholipidis that normally are
localized at the cytoplasmatic leaﬂet of the cell membrane to the outer (extracellular)
leaﬂet [177]. These extracellular aminophospholipidis, primarily phosphatidylserine
are recognized by phagocytotic cell prompting a signal for cell removal [177179]. The
presence of apoptotic cells is a transient event with a limited time window between
the induction of the apoptotic cascade and cell death/removal.
Externalized phosphatidyl-serine moieties are recognized by annexin-V [180,181],
a human protein of molecular weight 36 kDa, to which it binds with high aﬃnity (pKd
= 8.15-10). Labeling of the macromolecule Annexin V with radioligands, MRI con-
trast agents, or ﬂuorescent dyes constitutes an attractive approach for in vivo imaging
of apoptotic cells. A distinct advantage of using annexin-V as targeting moiety is the
fact that its molecular target is located at the extracellular membrane leaﬂet; hence,
no cell penetrating reporter constructs are required. An additional features of An-
nexin V is its rapid clearance from circulation by the renal system providing a high
contrast between the target-speciﬁc signal and the nonspeciﬁc background.
Blankenberg and co-workers [182] have used the bifunctional linker hydrazinoni-
cotinamide (HYNIC) that forms stable bounds to lysine residues of polypeptides/proteins
and conjugates metallic centers such as 99mTc.
The aim of the experiments was to evaluate drug-induced apoptosis signal after a
single dose of chemotherapy. For this purpose, we used mice with spontaneous breast
cancer and studied the accumulation pattern of 99mTc-Annexin V over time after
the administration of Paclitaxel (Taxol r©). This chemotherapy agent was selected
because it is eﬀective in this mouse model used and is often used in patients with
breast cancer.
The RIII female mouse represents a model of genetically modiﬁed breast cancer
induced by a virus (RIII virus, murine mammary tumor virus, MuMTV) which is
transmitted from mother to daughter through breast feeding. The eﬀect of Taxol
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was evaluated at diﬀerent time points after the drug administration (1, 3, 6 and
24 hours), trying to understand when the highest uptake of 99mTc-Annexin V, as
indicator of Taxol induced apoptosis, occurs.
Human Annexin V, provided by Theseus Imaging Corporation (Boston USA),
was produced by expression in Escherichia coli [183]. The recombinant protein was
radiolabeled with 740-1110 MBq (about 20-30 mCi) of freshly eluted 99mTc from a
6 Gb generator (Amersham GE HealthCare, UK) after derivatization with hydrazi-
nonicotinamide (HYNIC) (99mTc-Annexin V; speciﬁc activity, 3.0 MBq/µg protein).
Speciﬁc activity was 10 to 15 MBq/µg protein (depending on desired activity) with
a radiopurity of 85-90 % determined with Sephadex G25 column chromatography
instant thin layer chromatography using saline solution as a solvent.
The animals were treated with a single dose of Taxol (0.02 mg/g, about 6mg/animal)
administered through intravenous (i.v.) injection in one of the caudal veins. After 1,
3, 6 and 24 hours from Taxol administration, the radioligand was injected i.v. (via
tail vein), at the dose of about 37-55 MBq (∼ 1, 1.5 mCi) of 99mTc-Annexin V (cor-
responding to about 3.5 µg protein) per mouse. One hour after radiotracer injection
the animals were anaesthetized with intraperitoneal injection of a mix of ketamine
(60 mg/kg and 4.4 mg/kg) and fenobarbital (50 mg/kg). Once placed on the ﬂat bed
(see section 3.1), multiple bed positions were acquired in order to perform a whole
body scan. Figure 7.6 and 7.7 highlight 99mTc-Annexin V uptake in breast cancer
sites. The images are visualized with Pmod software [109] and the blue cross-axises
are positioned on the tumor signal. These results have been conﬁrmed by phosphor
image system (Cyclone Storage Phosphor System, Packard). The maximum uptake
has been registered at 3 hours from Taxol administration [184].
7.4 Cardiology studies of a rat model of ischemia
and reperfusion
Ischemia is the condition suﬀered by tissues and organs when deprived of blood ﬂow,
mostly the eﬀects of inadequate nutrient and oxygen. Reperfusion injury refers to the
tissue damage inﬂicted when blood ﬂow is restored after an ischemic period. Ischemia
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Figure 7.6: Transaxial (top left), coronal (bottom left) and sagittal (top right) section
of RIII female mouse PET scans performed with 99mTc-Annexin V. The uptake in breast
cancer sites is highlighted by the blue cross-axises. The images are visualized with Pmod
software [109].
and reperfusion can cause serious brain damage in stroke or cardiac arrest.
There is increasing evidence that cell death after myocardial ischemia and reper-
fusion may begin as apoptosis rather than necrosis [185,186].
Investigation of the biodistribution and dosimetry of various forms of radiolabeled
annexin in humans [187,188] has demonstrated the safety of this agent and the eﬃcacy
of imaging for the detection of cardiac transplant rejection and acute myocardial
infarction [189,190].
Among patients with myocardial infarction, there is intense localization in the
infarct region both in those with and in those without reperfusion [191]. These data
suggest that a considerable number of cells in the infarct zone die by apoptosis. Al-
though the most eﬀective method to limit the zone of injury in areas of markedly
decreased perfusion is restoration of blood ﬂow, studies have demonstrated that reper-
fusion is a major stimulus for apoptosis in previously ischemic tissue, especially in
nonsalvageable cells [185,186]. A current concept is that apoptotic cell death occurs
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Figure 7.7: Transaxial (top left), coronal (bottom left) and sagittal (top right) section
of RIII female mouse PET scans performed with 99mTc-Annexin V. The uptake in breast
cancer sites highlighted by the blue cross-axises is located at the edge of the FOV. The
images are displayed with Pmod software [109].
primarily at the periphery of the lesion, rather than in the center. However, the non-
salvageable cells should be most abundant at the center of the lesion, where oxygen
deprivation should be most prevalent [192].
Cardiovascular research in animals increasingly relies on small animals like rats
and mice.
Phenotypic consequences on myocardial function, perfusion, and substrate metabolism
in small animals can be evaluated with dedicated MR imaging, CT scan and radionu-
clide imaging systems.
Small animal emission tomography imaging systems allow noninvasive approach
and provide high spatial resolution.
Examination of the heart remains challenging because of its small size, its thin
wall, and motion and activity cross-contamination between blood and myocardium
[193].
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To determine the distribution of apoptosis in myocardial infarction, we performed
PET and SPECT studies on rats using the tracer 99mTc-annexin V as a marker of
apoptosis. These experiments were performed in collaboration with with the Univer-
sity of Pisa, Nuclear Medicine Department, group leader Prof. G. Mariani and with
Scuola Superiore Sant'Anna, Institute of Clinical Physiology, C.N.R., Pisa, group
leader F. Recchia. The evaluation of regional myocardial blood ﬂow was performed
with diﬀerent tracers: 99mTc-Myoview, 99mTc-Sestamibi, 99mTc-Tetrofosmin or 13N-
Ammonia.
The ischemia reperfusion heart model was realized on male Sprague Dawley rats
(10-12 weeks old). The animals were anesthetized with intraperitoneal injection of
50 mg/kg of sodium pentobarbital and artiﬁcially ventilated with room air by an
animal respirator. Left thoracotomy at the ﬁfth intercostal space and pericardiotomy
were performed. A 6/0 braided silk suture was placed around the proximal portion
of the left anterior descending coronary artery, and the coronary artery was occluded
for 30 minutes by pulling on the suture. At 30 min after occlusion, the heart was
reperfused by releasing the ligature, and the thoracotomy was closed. One hour later,
the rats were injected via tail vein with a myocardial blood ﬂow tracer and acquired
in PET or SPECT modality according to the used tracer. Immediately after the
perfusion acquisition, a tail vein injection of 300 MBq (∼ 8 mCi) of 99mTc-Annexin
V was performed. An acquisition of 1 hour and half was performed after 90 minutes
of uptake. The images of blood ﬂow and apoptsosis tracer were reconstructed and
then fused in order to rightly localize the apoptosis signal.
Figures 7.8, 7.9, 7.10 show the three main heart axis images as obtained with
blood ﬂow tracer (99mTc-Myoview, 13N-Ammonia or 99mTc-Tetrofosmin) and apopto-
sis tracer (ﬁrst two rows) and the fusion (last row). The fused image allow to exactly
localize the apoptosis signal on heart anatomy.
Other studies were performed on the same animal models. Glucose metabolism
was evaluated with 18F (see ﬁgure 7.11), while 99mTc-Glucarate was used to asses the
presence of necrosis (see ﬁgure 7.12). As expected in the ischemia reperfusion model
used no necrosis signal is present.
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Figure 7.8: Short axis (left column), vertical long axis (center column) and horizontal long
axis (right column) of the heart of a male Sprague Dawley rat. Top row: 300 MBq (8 mCi)
of 99mTc-Myoview, uptake time time 180 minutes, acquisition 48 minutes, EM recostruction
algorithm with 20 iterations. Central row: 300 MBq (8 mCi) of 99mTc-Annexin, uptake
time 90 minutes, acquisition 1 hour and half, EM recostruction algorithm 20 iterationas.
Bottom row: Fusion of the two previous images realized with Pmod software [109].
Figure 7.9: Short axis (left column), vertical long axis (center column) and horizontal long
axis (right column) of the heart of a male Sprague Dawley rat. Top row: 111 MBq (3
mCi) of 13N-Ammonia, no uptake time, acquisition 20 minutes, EM recostruction algorithm
with 20 iterations. Central row: 300 MBq (8 mCi) of 99mTc-Annexin, uptake time 90 min,
acquisition 1 hour and half, EM recostruction algorithm 20 iterationas. Bottom row: Fusion
of the two previous images realized with Pmod software [109].
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Figure 7.10: Short axis (left column), vertical long axis (center column) and horizontal long
axis (right column) of the heart of a male Sprague Dawley rat. Top row: 300 MBq (8 mCi) of
99mTc-Tetrofosmin, uptake time time 180 minutes, acquisition 48 minutes, EM recostruction
algorithm with 20 iterations. Central row: 300 MBq (8 mCi) of 99mTc-Annexin, uptake time
90 minutes, acquisition 1 hour and half, EM recostruction algorithm 20 iterationas. Bottom
row: Fusion of the two previous images realized with Pmod software [109].
Figure 7.11: Short axis (top left), vertical long axis (bottom left) and horizontal long axis
(top right) of the heart of a male Sprague Dawley rat. The uptake of 18F-FDG is highlighted
by the blue cross-axises. The images are visualized with Pmod software [109].
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Figure 7.12: Short axis (top left), vertical long axis (bottom left) and horizontal long axis
(top right) of the heart of a male Sprague Dawley rat. The uptake of 99mTc-Glucarate is the
rat heart is nearly negligible (blue cross-axises). Clearly appreciable uptake comes from the
kidneys, i. e., the execration organs. The images are visualized with Pmod software [109].
Chapter 8
Conclusion
The YAP-(S)PET is a small animal scanner that provide the capability of performing
simultaneous PET and SPECT acquisitions on a single gantry [194,195].
A new version of the scanner has been realized in the ﬁrst half of 2006 within a
collaboration between the Department of Physics of the University of Pisa and the
small italian company I.S.E. Ingegneria dei Sistemi Elettronici s.r.l., Pisa, Italy [77].
The following improvements are included in this new version (in the thesis named
27 × 27 version):
• reduction of the YAP crystal pitch down from 2.0 to 1.5 mm to improve both
PET and SPECT spatial resolution.
• faster ADCs in order to improve the count rate capabilities;
• a novel electronic pile-up rejection circuitry that allow to improve the image
quality. (An application for patent has been ﬁlled for this circuit).
• more on-line counters in order to have a complete control of what is going on
during the acquisition.
At present, there are only two 27 × 27 version units of the YAP-(S)PET scanner.
The research unit is installed at the Institute of Clinical Physiology (IFC) of the
National Research Council (C.N.R.) within a cooperative research agreement with
the Center of Excellence AmbiSEN of the University of Pisa; while the commercial
version has been delivered at the Scientiﬁc Institute H S. Raﬀaele in Milan, Italy, on
July 2006.
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During this thesis work, the research unit has been calibrated and the performance
evaluation in both PET and SPECT modalities were evaluated at diﬀerent head-to-
head distances (100, 125 and 150 mm).
In PET mode the performance has been evaluated following the standards pro-
posed by the PET NEMA task force for small animal scanners [124]. The performance
evaluation regards spatial resolution, sensitivity, scatter fraction and count rate.
The spatial resolution was evaluated using a 22Na point source positioned in dif-
ferent radial and axial positions within the FOV. Three components of the spatial
resolution (FWHM) were measured for each position: the radial and tangential in the
transaxial plane, and the axial component along the axis of the scanner. The radial
spatial resolution shows a little improvement as the radial oﬀset increases, while the
tangential spatial resolution increases slowly approaching the edge of the FOV. The
axial resolution degrades as the source radial oﬀset exceeds 5 mm. The best volume
resolution was obtained for 100 mm head-to-head distance and is about 8 µl. The
The maximum sensitivity was registered at the center of the FOV with a 50-850
keV energy window and with a 22Na point source. As expected, the highest valued
is reached at 100 mm head-to-head distance, about 3%. The system sensitivity was
measured with a linear source of 18F placed inside a metal tubes. The measurement
was repeated ﬁve times with increasing wall thickness. This measurement conﬁrmed
that the sensitivity increases as the head-to-head distance is reduced.
The scatter fraction and NEC curve were evaluated using a mouse-like phantom
ﬁlled with 18F. Due to greater solid angle covered by the detectors, the scatter fraction
is higher for closer head-to-head conﬁguration (100 mm). The activity at which true
and NEC count rate reach the peak increases with increasing head-to-head distance.
This eﬀect is mainly determined by the reduced sensitivity due to the reduced solid
angle coverage with raising detectors separation. The peak NEC rate is about 38
kcps at an activity concentration in the FOV of about 370 kBq/ml. Derenzo, NEMA
Image Quality and Defrise phantom were also performed. The NEMA Image Quality
phantom was also used to evaluate partial volume eﬀects. For a 4 mm rod, that is
object size about ' 2 × FWHM the spatial resolution of the scanner, the activity
concentration underestimation is about 20% for 100 head-to-head distances and less
155
than 15% for 125 mm. The better quantiﬁcation at wider detectors distance is due
to lower acceptance angle, thus less parallax error and better spatial resolution.
The evaluation performance results and phantoms studies highlighted that the
best compromise between spatial resolution and sensitivity is obtained whit a head-
to-head distance of 100 cm.
Since the lack of small animal SPECT performance standardization, the SPECT
performance of YAP-(S)PET scanner has been evaluated by rescaling the clinical
SPECT NEMA reference standards NU1-1994 [116].
The spatial resolution and sensitivity measurements were evaluated with a glass
capillar ﬁlled with 99mTc and positioned parallel to the FOV longitudinal axis with
1 cm radial oﬀset. The radial and tangential resolutions highlighted the system
performance degradation for wider detectors distances. This eﬀect is due to collimator
resolution Rcoll dependence on source-to-collimator distance. The spatial resolution
is about 2.8 mm at CFOV at 100 mm. The sensitivity is 3.7×10−3% for 140-250 keV
energy window.
Also in SPECT modality the best results are obtained for 100 mm head-to-head
distance. Due to reduced working space at 100 mm, particularly highlighted in rats
experiments, the best compromise between scanner performance and animal experi-
ments is 125 mm for both PET and SPECT modality. On the contrary, mice exper-
iments can better performed at 100 mm head-to-head distance.
Exploiting the YAP-(S)PET scanner intrinsic capability of both PET and SPECT
imaging, we have implemented the simultaneous PET/SPECT dual imaging modal-
ity. The simultaneous PET/SPECT imaging modality was arranged by equipping
two opposing heads the opposing heads 1 and 2 are equipped with the collimators
and independently acquire single events (SPECT mode), while the other pair 3-4
detects coincident events (PET mode). In order to reduce the background produced
by the Compton scattering of 511 keV gamma rays, each SPECT head (1 and 2) is
set in anticoincidence with the opposing one. Since the thickness of the collimator is
optimized to stop low energy photons, the crosstalk from 511 keV photons seriously
impairs the single photon acquisition. The subtraction procedure we performed was
based on a multi-energy window method. The phantoms and animal studies per-
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formed open the way to new and interesting protocols for the investigation of many
biological phenomena, more eﬀectively than with PET or SPECT modalities alone.
Diﬀerent animal models and various isotopes and tracers have been used in the
experiments performed in collaborations with the diﬀerent research groups. The main
medicine branch we investigated are: oncology, cardiology and neuroscience. PET
receptors studies performed in collaborations with Vita-Salute San Raﬀaele Univer-
sity, Milan, group leader Dr. R. M. Moresco, was related to evaluation of certain
areas of the brain degeneration as a consequence of Huntington's disease. The used
radiotracer was 11C-Raclopride and male rats were investigated at diﬀerent time from
disease starting.
The SPECT studies concerned the evaluation of Parkinson disease in a new mice
model developed by a gene mutation. The 123I-DaTSCAN was the used tracer, and
the experiments were performed in collaboration with the Nuclear Medicine Depart-
ment of the University of Pisa, group leader Prof. G. Mariani.
PET oncologic studies regarded a preclinical model for BNCT therapy and were
realized within the collaboration project with Institute of Clinical Physiology of the
C.N.R. in Pisa. F98 glioma cells were intracerebral implanted in Wistar male rats
than were then subjected to 18F-FDG scanner.
SPECT studies were performed on RIII female mice the represent a model of genet-
ically induced breast cancer. The animals acquisistions were performed with 99mTc-
Annexin V within a collaboration project with the Nuclear Medicine Department of
the University of Pisa.
Cardiologic studies was related to a rat model of ischemia and reperfusion. To
determine the distribution of apoptosis in myocardial infarction, we performed PET
and SPECT studies on rats using the tracer 99mTc-annexin V as a marker of apop-
tosis. The evaluation of regional myocardial blood ﬂow was performed with diﬀerent
tracers: 99mTc-Myoview, 99mTc-Sestamibi, 99mTc-Tetrofosmin or 13N-Ammonia. The
experiments were performed in collaboration with with the University of Pisa, Nu-
clear Medicine Department, group leader Prof. G. Mariani and with Scuola Superiore
Sant'Anna, Institute of Clinical Physiology, C.N.R., Pisa, group leader F. Recchia.
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8.1.1 Multimodality imaging
PET technology is rapidly advancing Among the most exciting developments is the
emergence of combined PET and CT imaging devices The combination of molecular
and anatomic imaging has several advantages.
• biologic and anatomic whole-body staging can be performed in one examination.
• because of limited patient motion due to the near simultaneous acquisition of
PET and CT images, near ideal fusion of biologic and anatomic images can be
achieved.
• anatomic landmarks provided by CT will greatly facilitate the assignment of
biological abnormalities to anatomical structures in which disease exists.
• diﬃcult-to-image regions of the body such as head and neck, mediastinum, and
the postsurgical abdomen will be evaluated with a high diagnostic accuracy due
to improved anatomical assignment of biologically identiﬁed disease.
The ﬁrst commercial PET/CT devices became available for clinical testing in the later
part of 2001 ( [196]) and small animal imaging systems are now available [197,198].
A prototype of a high resolution CT scanner for small animals was built and tested
in our laboratory, and it will be integrated in the YAP-(S)PET in order to realize
a multimodal scanner [199]. In the current conﬁguration, the main components of
the prototype are: an X-ray source (Hamamatsu 60KVMFX) with tungsten anode,
a peak voltage up to 60 kV with maximum power of 10 W, and a focal spot size of
20 µm, a ﬂat panel detector (Radicon Rad-Eye 4) composed of a Ga2O2S:Tb layer
directly coupled to a CMOS sensor. The active area of the detector is 10 ×5 cm2.
The obtained Field of View (FoV) is a cylinder of diameter 5 cm and height 4 cm,
with a geometrical magniﬁcation varying in the range 1.2-2. Several phantoms and
specimen of small animals were acquired in tomographic acquisition and the we are
almost ready for the implentantion in the YAP-(S)PET scanner. In the meanwhile,
we have performed a proof of principle of the fusion of the images, by acquiring a
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mice in both PET and CT modalities. The PET acquisition was performed by 30
minutes acquisitions of a healthly mouse inject with 4.6 MBq (about 125 µCi of 18F
realized wiht the YAP-(S)PET scanner. The The fusion realized with the PMOD
software [109] is represented in ﬁgure 8.1.
Figure 8.1: Transaxial (left column), sagittal (right column) and coronal (central column)
section of a healthly mouse. Top row: CT study performed with a clinical PET/CT scanner
(Gemini GXL, Philips). Acquisition time about 30 seconds. Central row: PET acquisition
realized wiht the YAP-(S)PET scanner. 30 minutes acquisitions after an uptake time of 45
minutes by the injection of 4.6 MBq (about 125 µCi) of 18F. EM reconstruction algorithm
with 50 iterations. Bottom row: Fusion of the two previous images realized with Pmod
software [109].
8.1.2 New photomultipliers
The development of novel photodetectors has a fundamental role for the future of
nuclear imaging. The possible solutions proposed by various research groups have a
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two fold approach. On the one hand, systems overcoming the coding limitation have
been introduced through APD based solutions (one-to-one coupling) [200]. On the
other, detectors based on a scintillator block coupled to high granularity position-
sensitive photodetectors (Anger camera principle) are under development [201]. In
the latter case, the limitation introduced by the ﬁnite size of the crystal elements
could be overcome by measuring, with high precision, the center of gravity of the
light spot.
The Silicon Photomultiplier (SiPM) we are developing is a silicon diode detector
that shows great promise as a photodetector for scintillators for both one-to-one or
Anger camera approaches. The development of these devices started about 15 years
ago at MEPHI (Moscow, Russia) [202] and has seen signiﬁcant technological progress,
in particularly in recent years. In summary, the SiPM is a densely packed matrix
of small, Geiger-mode avalanche photodiode (GAPD) cells (typically 40 ×40 mm2),
with individual quenching resistances for each cell. The Geiger-mode operation of
each cell produces a large gain (of the order of 5 ×105) at low bias voltage (50 V). All
the cell outputs are then connected in parallel to produce the summed signal. This
microcell structure of the SiPM gives a proportional output for moderate photon ﬂux.
The performance is in many ways comparable to that of a conventional PMT, but
with the compactness and other beneﬁts of a semiconductor detector. Such a compact
silicon detector is well disposed for being developed into a close-packed array in order
to have a position-sensitive detection surface, and this justiﬁes the wide interest and
the great eﬀorts dedicated to the SiPM development. For example, a new camera
design has been proposed by the Department of Physics, University of Pisa [203] .
The proposed camera consists of a stack of three modular layers, each being relatively
thin, continuous slab of LSO (or LYSO) scintillator viewed by an array of compact
of 1mm2 active area SiPM detector elements on a 1.5mm pitch. To provide suﬃcient
detection eﬃciency as well as intrinsic DOI information, three of these modular layers
are stacked together to form a single detector head. From Monte Carlo simulations
the new detector heads is expected to show excellent performance in intrinsic spatial
resolution (down to 0.5mm FWHM) [203].
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3-DMS 3-D Multi Slice
3-DRP 3-D Reprojection
ABL Abelson
ADC Analog to Digital Converter
Ambisen Ambiente e Sistema Endocrino e Nervoso
AMIDE Amide's a Medical Imaging Data Examiner
BCR Breakpoint Cluster Region
BGO Bismuth Ortho-Germanate
BNCT Boron Neutron Capture Therapy
CCD Charge Coupled Device
CFD Constant Fraction Discriminator
CFOV Center of the Field Of View
CNR National Research Council
COR Center of Rotation
CT Computed Tomography
DICOM Digital Imaging and Communication in Medicine
EM Expectation Maximization
FAB Fast Acquisition Board
FBP Filtered Back Projection
FORE Fourier Rebinning
FOV Field Of View
FWHM Full Width at Half Maximum
GBM Glioblastoma Multiforme
GFP Green Fluorescent Protein
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